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Objective: To assess the need for an adolescent cancer unit to serve the
population in Yorkshire.
Design: An epidemiological review of the data from two sources in the Northern
and Yorkshire Region. A qualitative methodology was employed to assess the
views of patients, healthy adolescents and staff on a unit away from the centre
dealing with adolescents, on the benefits of a centralised adolescent unit.
Interventions: None
Results: Routine cancer registration data on 2411 adolescents registered with
cancer between 1985 and 1994 were collected from the Northern and Yorkshire
Cancer Registry and the Northern Children's Tumour Registry. The data related
to 1375 patients in the former Yorkshire Region and 1036 patients in the former
Northern Region. Incidence data are presented for the two regions. Survival
differed significantly between parts of Yorkshire but this did not appear to relate
to place of treatment or social class. In the former Northern Region some
differences were also apparent in survival, but the content of the data did not
allow analysis by social class. However, in both instances survival appeared to
be better in areas close to the cancer centre which was counter-intuitive to the
expectations based on the known social class gradients in the former Yorkshire
and Northern Regions. The qualitative studies discovered the specific needs of
adolescents with cancer (e.g. the importance of peer group support and
maintaining their education) and suggested that there could be benefit from
centralised, specialised management. However, there were considerable
potential flaws in the data which may render such a conclusion as debatable.
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Conclusions: This study adds weight to the proposal for the development of an
adolescent cancer unit in Yorkshire, however, this study is by no means
conclusive because of the absence of available data to answer this question.
The reasons why, overall support should be given to create an adolescent unit
fall into four categories: philosophical (the need to provide services which
recognise the specific needs of adolescents), qualitative (the ability of specialist
units to provide a higher quality of care), pragmatic (the ability to concentrate
specialist skills in one location), and improved outcome, this study suggests
that outcome, and survival in particular differs may differ significantly according
to where people live, and that this may be related to the type of care they
receive. Further studies are needed to explain the apparent survival differences
in the region.
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2. Background and Introduction
2.1 The proposal to establish an Adolescent Cancer Unit
This piece of work originated from a proposal from the paediatric and medical
oncologists at St. James' Hospital in Leeds to establish an Adolescent Cancer
Unit. Such units have been established in other parts of the country. Their
creation has been encouraged by grants from the Teenage Cancer Trust1.
Such grants have been made available for the capital costs associated with
such developments and have therefore covered the costs of buildings and
equipment. In some instances, running costs have been provided for a limited
number of years. The Teenage Cancer Trust suggests in their publicity material
that "treating young people with cancer in specialist Teenage Cancer Trust
Units can improve recovery rates by 15%". The units themselves are designed
to provide an environment appealing to teenagers as well as full emotional,
social, psychological, educational and recreational support. They are also
designed to support parents, relatives and friends as well as the patients
themselves.
The Teenage Cancer Trust estimates that the average annual running costs of
a specialist cancer unit for teenagers is likely to be £500,000, The trust
estimates that 20 such units are required in the U.K. A business case from the
1
Teenage Cancer Trust, Kirkham House, Kirkham Place, 54a Tottenham Court Road, London.
W1P9RF
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Leeds Teaching Hospitals Trust states that the cost in the first year will be
£1.09 Million2. The details of this proposal are considered further in chapter 9.
The Teenage Cancer Trust has pointed out the difficulties of the management
of teenagers with cancer. Unless they are managed in special units, they are
likely to be managed either in a children's ward ("with bunnies decorated on the
walls") or alongside the elderly - isolated from people of their own age.
The proposal from the Leeds Trust only includes a small start up cost, the bulk
of which, it is anticipated will be met from charitable sources. Whilst not
decrying the proposal to develop special units for teenagers with cancer, it is a
stark fact of life that if the National Health Service invests in these
developments, this will occur at the expense of other developments. It is
therefore essential to be clear what benefits will accrue from this type of
development, in order that investment decisions can be taken to ensure that the
limited funds available to the NHS are spent to the best effect.
2.2 The Role of a public health physician
This work has been undertaken from the perspective of a public health
physician working in a health authority (the role and function of health
authorities is discussed in the following section). Public health physicians are
trained to be able to give advice and to make decisions on such questions.(1).
Their skills in epidemiology, management, economics are particularly relevant
in this area. Public health physicians are also unique in bringing these skills
2
Leeds Teaching Hospitals Trust. The Business Case for Adolescent Cancer Services. 1999
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together with a background of medical training which enables them to
understand and relate directly to some of the complex clinical issues involved in
such an area as teenage cancer.
Most public health physicians work in health authorities, although some work in
specialist academic units, and some in the Regional Offices and in the National
Health Service Executive of the Department of Health. This places the public
health physician in a position of responsibility working in situations, where
decisions about major new investments such as the management of teenage
cancer are currently made and are likely to be made in the foreseeable future.
2.3 Role and functions of health authorities
Under the 1992 NHS Act, Health Authorities had the following responsibilities:
• To assess the health needs of their populations
• To commission services to meet the needs of those individuals in those
populations
At the outset of the National Health Service in England, Regional Hospital
Boards were created in 1948 around the major teaching centres. Therefore in
1948, the Leeds and Newcastle Regional Hospital Boards were created. In
1974, these became Regional Health Authorities. Between 1974 and 1990,
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Regional Health Authorities were responsible for the planning and provision of
specialist services such as specialist cancer services. In 1990 the then
Conservative Government, in an attempt to stem health service expenditure,
created what was to become the internal market. NHS Trusts were formed
which became responsible for the delivery of services (providers) and health
authorities became responsible for commissioning of those services. Money
flowed between the health authorities and trusts by means of 'contracts'.
There are approximately 100 health authorities in England. Health Authorities
serve populations between 250,000 and 1 million and are responsible for
primary, secondary and tertiary health services.
Gradually, the Regional Health Authorities were also required to divest
themselves of their purchasing function to health authorities. This in itself
created difficulties because there was suddenly no regional strategic body, nor
the wherewithal to ensure that a common approach was taken to the
purchasing of specialist services. Regional Health Authorities existed until 1994.
After the abolition of regional health authorities in 1994, it became very difficult
to co-ordinate the development of regional specialist services. No individual
health authority had the lead, not all health authorities had the same priorities,
and some health authorities were intent on dis-investing in what they saw as
large greedy teaching hospitals.
This led to great dissatisfaction amongst those working in large teaching
centres who depended on a number of health authorities for their funding.
Consequently, regional specialist services in the early 1990s suffered under
investment, and at best, fragmented development. It was not clear how
developments occurred, who would take responsibility for planning them and
perhaps most importantly, how they would be funded.
In Yorkshire, the chief executives of health authorities decided to join together
to commission these specialist services (under what was to become the M6
arrangements - there were six health authorities in Yorkshire). This
arrangement had a shaky start while chief executives gained confidence in one
another for an arrangement where to all intents and purposes, they were
allowing their colleagues to commit resources on their behalf. Each health
authority in Yorkshire took on responsibility for one or more regional specialist
services. North Yorkshire Health Authority had already developed a degree of
expertise in cancer, and it was therefore not surprising when North Yorkshire
health Authority was asked to take on the commissioning of specialist cancer
services.
Subsequent to the defeat of the Conservative Government in 1997, the Labour
Government announced that the role of health authorities was to change (2).
This is largely because of the creation of primary care groups which are taking
over the responsibility of commissioning health services from health authorities.
However, as far as specialist cancer services are concerned, it is likely that
these will continue to be commissioned by health authorities working on behalf
of other health authorities in the role of specialist commissioner.
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2.4 The role ofNorth Yorkshire Health Authority
North Yorkshire Health Authority is a health district in the Northern and
Yorkshire Region, sited in the North of England. It is one of thirteen health
authorities in the Northern and Yorkshire Region (see maps). It was only in
1994, that the Northern and Yorkshire Region was created from parts of the
former Northern and Yorkshire Regions. This was done at a time when the
former Regional Health Authorities were abolished and Regional Offices of the
NHS Executive were created.
North Yorkshire Health Authority, by which the author is employed, acts in the
role of specialist commissioner for cancer services in Yorkshire. It is likely, that
in at least the short term to medium term, these arrangements will continue.
2.5 The aims of this project and the hypotheses
2.5.1 Aims of the project
The development of cancer services for adolescents quickly emerged as a
proposal for further funding. The clinicians in the cancer centre in Leeds were
keen to develop a cancer unit for adolescents. There were similar moves in
Newcastle. Clinicians in both Leeds and Newcastle were receiving considerable
support and encouragement from the Teenage Cancer Trust. This trust was
keen to provided capital funds for the provision of cancer centres for
adolescents. The problem for the health authorities was that these centres have
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Yorkshire, it was agreed that further investigation should be carried out. This
study formed the basis of this work.
The purpose of this piece of work was, therefore to contribute to the debate on
the future of cancer services for adolescents in Yorkshire.
A small unit had been established based in an existing ward at St James
Hospital in Leeds, for young people with cancer, but this did not have all the
features of an adolescent cancer unit which would be provided from a fully-
fledged unit
At the same time, it became apparent in the early stages of the work, that
comparisons between the situation in the former Northern and Yorkshire
Regions might also be of value, with the recent creation of an adolescent
cancer unit in Newcastle.
As adolescent cancer is relatively rare it was decided that the needs of Young
People with cancer should be assessed across the whole of the new Northern
and Yorkshire Region.
The work therefore, contains two main components:
1. A needs assessment of young people with cancer using standard descriptive
epidemiological techniques. The study will describe in detail, the incidence of
cancer in young people across the region. Data will be presented showing the
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incidence by geographical location, by cancer type. Survival data for the both
Northern and Yorkshire part regions will be presented.
2. A qualitative piece of work examining the needs of young people with cancer.
The aim of this part of the work is to delineate the features of cancer care in
adolescents, which is deemed to be important.
2.5.2 Hypotheses
In summary this study aims to test a number of hypotheses. These are as
follows:
1. That place of treatment results in improved survival
2. That the incidence of cancer in 10-24 year olds does not differ across the
Northern and Yorkshire Region
3. That the quality of care which can be offered by specialist teenage units is
no better than that offered by smaller, local hospitals.
2.6 Treatment of adolescents with cancer in the Northern and Yorkshire
Region
Compared with the United States, there is very little attention paid to the use of
health services by adolescents (3). In a survey carried out in 1998 in a selection .
of English, Scottish and Welsh Health Authorities and Boards, it was found that
adolescents aged 12 to 19 occupied an average of 18 inpatient beds and 2.2
day case beds in a district general hospital serving a population of 250,000.
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The current pattern of treatment of adolescents in Yorkshire and the Northern
region is described below (personal communication Professor Kevin
Windebank, Dr. Ian Lewis).
Certain cases tend to be managed at national centres. This applies most
specifically to malignant bone tumours which are almost exclusively referred to
Birmingham. Choriocarcinoma is managed at a specialist unit in London. Brain
tumours are managed in the neurosurgical departments in the region based in
Middlesbrough, Newcastle, Leeds and Hull.
There is some variation in how young people with lymphomas and leukaemias
are managed. Almost all leukaemias are referred to haematologists in the major
centres of the region (Middlesbrough, Newcastle, Leeds and Hull), and
managed according to British Committee for Standards in Haematology (4).
However, the management of lymphomas is more variable with some patients
being managed in local district hospitals by haematologists. Currently the newly
established networks of clinicians are setting up systematic methods of
collecting these data, but currently more systematic information is not available.
Routinely collected hospital statistics are currently inadequate to provide insight
into the management patterns of cancer in adolescents in the region - the main
deficiency being the variability in completeness of clinical coding.
At St James' Hospital in Leeds, which acts (in Yorkshire) as the regional centre
for the management of childhood malignancy, a small 4-bedded bay for
adolescents has been created in the children's ward act as a focus for the
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treatment of adolescents. At the Royal Victoria Infirmary in Newcastle, a
specialist adolescent unit has been established with the capital cost provided
by the Teenage Cancer Trust.
Radiotherapy for adolescents with cancer is provided at radiotherapy centres in
Leeds, Newcastle, Hull and Middlesbrough. In all instances, radiotherapy is
provided in a separate hospital from where other treatment is carried out.
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3. The Health of Adolescents
3.1 The concept of adolescence
The Oxford English Dictionary defines adolescent as: (someone) between
childhood and adulthood (5).
Although adolescence was not recognised historically, characteristics of today's
teenagers can be identified in the writings of the ancient Greeks (6):
Our youth love luxury; they have bad manners, contempt for authority, they
show disrespect for elders and love chatter in place of exercise.
When Keats was twenty-three, he wrote in Endymion(7):
' The soul is in ferment, the character undecided, the way of life uncertain, the
ambition thickest'
In lay terms, adolescence(8) is described as a stage of maturation between
childhood and adulthood. The term denotes the period from the beginning of
puberty to maturity; it usually starts at about age 14 in males and age 12 in
females. The transition to adulthood varies among cultures, but it is generally
defined as the time when individuals begin to function independently of their
parents.
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Not all writers have always accepted that there is such a period of time in life. In
the nineteenth century, children were treated as adults as soon as they were
old enough to work or leave school. John Locke (9) wrote The sooner you treat
him as a man, the sooner he will be one'. In 1939 the headmaster of Rugby
School was reported as saying 'the change from childhood to manhood....
ought to be hastened; and it is a sin not to hasten it (10).
There are other factors which have lead to an increased recognition of the
period of adolescence since that date. These are set out in box 1.1.
22
Box 1.1 Social Changes leading to the developing concept of adolescence
• The state school system from the 1880s,
• The demands of modern industrial society for workers who have been
educated
• The gradual rise in the school leaving age
• Increasing national concern about managing the health of young people and
their future reproductive health
• Rising unemployment rates among adults, who prefer young people to be at
college and not competing for real jobs
• The growth of commercially driven youth cultures
• Recent reductions in benefits for people under 25, housing shortages
delaying move away from the parental home
Source: Alderson (11)
3.1.1 Physical Development
Changes in physical appearance are very noticeable at this period of life.
Many of the changes are due to hormonal activity. The pituitary gland begins
to secrete an increased level of follicle stimulating hormone and lutenising
hormone. These two hormones have a direct effect on the gonads and have a
secondary effect throughout the body and lead to the development of
secondary sexual characteristics. There is also increased secretion of growth
hormone at this time resulting in rapid growth. This results in the body
becoming close to its adult height and weight in about two years. This growth
spurt occurs earlier among females than males, also indicating that females
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mature sexually earlier than males. The production of androgens in boys and
oestrogens in girls leads to the onset of menstruation in girls and in boys, the
production of semen. These hormones also lead to the development of
secondary sexual characteristics including facial, bodily, and pubic hair and a
deepening voice among males; pubic and bodily hair, enlarged breasts, and
broader hips among females.
3.1.2 Intellectual development
Adolescents are developing fast at this time in their lives, though intellectual
development is thought to be closely associated with educational input rather
than due to physical, including hormonal changes.
3.1.3 Emotional Development
The American psychologist G. Stanley Hall (12) asserted that adolescence is
a period of emotional stress, resulting from the rapid and extensive
physiological changes occurring at pubescence. Studies by the American
anthropologist Margaret Mead (13) however, showed that emotional stress is
not inevitable, but culturally determined; she found that difficulties in the
transition from childhood to adulthood varied from one culture to another. The
German-born American psychologist Erik Erikson (14) sees development as a
psychosocial process going on through life.
The psychosocial task of adolescence is to develop from a dependent to an
independent person, whose identity allows the person to relate to others in an




Adolescence is inevitably an indistinct concept and will vary from individual to
individual. There is no universally accepted age limit for adolescents. Most
would agree that no individuals could be considered adolescents outwith the
age of 10 to 25, but within that age range, many different age criteria are used.
The World Health Organisation defines adolescents as being aged between 10
and 19 (15)
Other studies on adolescents, some of which will be described later, consider a
different age range for adolescents. Jamison (16) in his study of the
psychological impact of cancer in 1985, used the age range 12-18. Enskar K
and colleagues (17) in a study which looked at ten adolescents with cancer
used the age range 13-20. Lewis(18) describes adolescence as a flexible
concept that encompasses most individuals in the age range of 14 - 22, but
can stretch several years in each direction. "Adolescents are both adults and
children".
Kuykendall describes the inconsistency of the concept of adulthood. He points
out that in England, 16 year olds are allowed to leave school, marry (with
parental consent) and legally have sex. They can ride a motorbike, but have to
wait until they are 17 to drive a car and 18 to vote and legally drink alcohol. He
suggests that the only logical way to describe adolescence is using a
developmental approach dividing adolescence into early middle and late
stages, and concentrate on what is happening socially, intellectually,
emotionally, physically, sexually, and psychologically. Kuykendall describes the
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interaction between acute and chronic illness, hospitalisation and terminal
admission and adolescence, and states that care givers must be clear about
these interactions. (19)
3.1.5 Does it matter?
Probably no one would argue with the extremes, i.e. no one could be
considered adolescent outwith the age range 10-25. So far as the health
service is concerned; age ranges have been used in a range of specialties and
continue to be used. In some areas the use of strict age related criteria has
been abandoned. Only a few years ago there were strict age related criteria for
admission to coronary care units. In some cases patients were denied
admission if they were over the age of 65 years. These policies are gradually
changing; this has partly come about with the increasing confidence in the
specialism of elderly medicine. However, it is generally recognised that patients
should be managed according to needs, rather than to strict age bands.
Similarly in the past, prejudices have been exercised against other groupings in
society. For many years, patients with learning disabilities were managed solely
by consultants in this speciality. This extended to the management of physical
conditions. So for example, a healthy adult patient, with problems of epilepsy
would be managed by a neurologist. This would not be the case for a patient
with a learning disability. It could therefore be argued that these patients did not
receive optimal care.
The parallels to be drawn from this, and lessons to be learnt, must be that rigid
age criteria are generally inappropriate and the patient should be catered for in
an environment which meets their needs. This must include both physical and
psychosocial needs as well as being best able to meet the needs the individual
has as a patient.
3.1.6 Conclusions
Adolescence cannot effectively be described solely by chronological age. It
must take account of stages of development. However teenage units probably
need to have broad, but flexible, age limits which probably start no earlier than
10 years, but are very dependent on the maturity of the child. At the older end,
again, a degree of flexibility needs to be exercised. For some 20-24 year old
with recurrence, it might indeed be appropriate for these to be managed by the
adolescent team, but for others it may not be appropriate. Individual
judgements by the clinicians responsible for the care of these patients will need
to be exercised. For the purposes of this study, data will be examined in relation
to cancer in three distinct age bands 10 -14, 15-19, 20 -24. Some data will also
be presented by single years, but by and large complex data analysis is not
practical at this level because of relatively small numbers.
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3.2 The health and health needs ofadolescents and young adults
3.2.1 Causes ofDeath in Adolescents
Adolescence is characterised by good health. In 1993 there were 3985 deaths
in the age range 10 -24 in England and Wales. Table 3.2.1 shows the major
causes of death in this age group (in five-year age bands). This shows that
when both sexes are taken together, the overwhelming cause of death in this
age group is from injury and poisoning. Furthermore, it should be noted that
there are around five times as many deaths in males compared to females in
the 20-24 year age band and three and twice as many in the 15-19 and 10-14
respectively. This excess is largely accounted for by injuries and poisoning,
although when figures for these causes are removed, there is still an excess of
death in males compared to females of between 1.23 and 1.63 to one. (table
3.2.2)
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Table 3.2.1 Numbers of deaths from all causes in 10-24 year olds - England
and Wales 1993




I Infections M 16 22 19
(001-139) F 12 18 19
II Neoplasms M 61 89 139
(140-239) F 52 48 99
III Endocrine, nutritional and metabolic M 13 20 30
(240-279) F 11 29 22
IV Blood and blood forming organs M 6 5 9
(280-289) F 6 4 3
V Mental Disorders M 6 33 46
(290-319) F 1 6 12
VI Nervous system and sense organs M 48 81 87
(320-389) F 26 44 30
VII Circulatory system M 15 41 84
(390-459) F 17 21 58
VIII Respiratory system M 17 41 36
(460-519) F 28 18 32
IX Digestive system M 4 12 14
(520-579) F 2 4 15
X Genito-urinary system M 1 5 6
(580-629) F 2 0 7
XI Complication of pregnancy M
(630-676) F 0 1 1
XII Skin and subcutaneous tissue M 1 0 6
(680-709) F 0 2 1
XIII Musculoskeletal system M 1 3 3
(710-739) F 2 5 3
XIV Congenital abnormalities M 23 21 25
(740-759) F 20 19 25
XV Conditions in antenatal period M 0 0 1
(760-779) F 0 0 0
XVI Signs, symptoms and ill defined M 2 2 11
(780-799) F 1 4 3
EXVII External causes of injury and poisoning M 121 527 1058
(E800-E999) F 66 159 227
All causes M 333 902 1569
F 237 382 562
Source: Office of National Statistics. DVS3.L 1993
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Table 3.2.2 Numbers of deaths from all causes in 10 - 24 year olds
demonstrating the effect of removing deaths from injuries and poisoning




All causes excluding injuries M 212 375 511
and poisoning
F 171 223 335
Ratio of Males to Females* 1.23 1.68 1.53
"Unadjusted for population at risk
Source: Office of National Statistics. DVS3.L 1993
A further breakdown of the nature of the injury classification is shown in tables
3.2.3 which illustrates that most of the deaths in these age groups are taking
place amongst young men from motor vehicle accidents. However, the level of
suicides in young men between 20 and 24 is the greatest single cause of death
in the 20 - 24 year old category.
Table 3.2.3 Numbers of deaths from External Causes in 10 -24 year olds -
England and Wales 1993
External Cause (ICD 9) Sex
Age range
10-14 15-19 20-24
Motor vehicle accidents M 55 256 355
(E819-819) F 43 86 74
Accidental poisoning M 2 43 84
(E850-869) F 5 7 27
Accidental falls M 4 19 26
(E880-888) F 1 4 3
Accidental cause by fire M 33 46 84
(E890-929-173) F 7 5 9
Suicide and self inflicted M 19 130 444
(E950-959) F 6 33 90
Homicide M 4 22 49
(E960-969) F 3 21 21
Others M 4 11 16
Others F 1 3 3
Total M 121 527 1058
(E800-999) F 66 159 227
Source: Office of National Statistics. DVS3.L 1993
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The number of suicides in young men is a well-recognised phenomenon which
successive governments have attempted to address through National
Strategies. (20) (21)
3.2.2 Deaths from cancer in adolescents
Data have been obtained on deaths from neoplasms for the age group 10-24
from ONS. Data were only made available for the first time in 1993 in 5-year
age bands and therefore these data has been shown.
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Table 3.2.4 Numbers of deaths from neoplasms in 10-24 year olds - England
and Wales 1992




Lip, oral cavity and pharynx M 0 1 2
(140-149) F 1 2 0
Digestive Organs M 3 1 8
(150-159) F 0 3 10
Respiratory Tract M 0 1 3
(160-165) F 0 0 1
Bone M 7 7 10
(170) F 9 18 10
Skin M 0 5 5
(172-173) F 1 2 7
Female Breast (174) F 0 0 3
GU Organs M 2 1 11
(179-189) F 1 0 13
Cervix (180) F 0 0 2
Testis (186) M 1 1 8
Brain M 17 19 20
(191) F 8 5 12
Lymphatic and Haemopoietic M 28 48 61
(200-208) F 10 24 42
Lymphoid leukaemia M 14 27 24
(204) F 4 10 12
Myeloid leukaemia M 4 9 9
(205) F 5 6 13
Benign and other unspecified M 0 4 1
(210-229) F 0 1 2
Total M 70 95 141
F 36 62 116
Source: Office of Population Censuses and Surveys (22)
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Table 3.2.4 shows the number of deaths from neoplasms in each age group in
England and Wales in 1992. The data which are presented later in this study
relate to incidence of disease, rather than death. This table illustrates the
mortality from cancer in these age groups.
The table illustrates that the predominance of deaths is from lymphatic and
haemopoietic causes, a further breakdown of these data can be seen in table
3.2.5. This table illustrates the larger number of deaths from Hodgkin's disease
in older age groups (reflecting the incidence) together with a greater number of
deaths from myeloid leukaemia as the teenagers and young adults get older.
Table 3.2.5 Numbers of deaths from neoplasms of the lymphatic and
haematopoietic tissues in 10 -24 year old - England and Wales 1992




Lymphosarcoma and M 1 1 2
Reticulosarcoma (200) F 0 1 0
Hodgkin's Disease M 0 5 13
(201) F 0 3 9
Non Hodgkin's
Lymphoma
M 7 6 12
(202) F 1 3 7
Myeloid leukaemia M 4 9 9
(205) F 5 6 13
Lymphoid Leukaemia M 14 27 24
(204-) F 4 10 12
Total (200-208) M 28 48 61
F 10 24 42
Source: Office of Population Censuses and Surveys (22)
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3.2.3 Incidence of cancer in adolescents
Of course, the burden of disease cannot be solely represented by examining
mortality statistics. As will be discussed in chapter 5, cancer is unique in the UK
in having a well established registration system. It is therefore possible in
cancer to examine well established data which do not exist in other areas of
health and disease
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Table 3.2.6 Registrations of newly diagnosed cases of cancer 1992 - England
and Wales




Lip, oral cavity and pharynx M 4 4 7
(140-149) F 3 9 7
Digestive Organs M 1 4 11
(150- 154, 157) F 2 4 9
Respiratory Tract M 1 3 1
(161,162) F 0 2 4
Bone M 14 29 19
(170) F 15 16 14
Melanoma of Skin M 2 5 27
(172) F 5 18 71
Female Breast (174) F 1 6 29
GU Organs M 3 34 155
(180-189) F 4 19 82
Cervix (180) F 0 3 34
Ovary (183) F 1 11 35
Testis (186) M 2 30 144
Brain M 44 40 45
(191) F 34 23 24
Non Hodgkin's Lymphoma M 22 30 35
(200 & 202) F 11 19 23
Hodgkin's Disease M 24 43 86
(201) F 12 47 78
Leukaemias M 40 49 60
(204 - 208) F 21 38 36
Lymphoid leukaemia M 24 27 19
(204) F 11 15 9
Myeloid Leukaemia M 16 19 40
(205) F 9 21 24
Carcinoma in situ cervix F 0 291 2728
(233.1)
Total (excluding 173 non
melanoma skin cancer)
M 186 277 503
Total (excluding 173 non F 120 243 457
melanoma skin cancer and in
situ carcinoma of the cervix)
Source: Office of National Statistics. (23)
This table illustrates the importance of tumours of the testis in men, and of brain
tumours. It also shows the importance of malignant melanoma in women aged
20-24. The following table combines males and females and shows a
percentage for each malignancy.
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Table 3.2.7 Registrations of newly diagnosed cases of cancer 1992 - England
and Wales showing the burden of each disease
Cancer site (ICD 9) Number %
Age band 10-14 15-19 20-24 10-24 10-14 15-19 20-24 10-24
Lip, oral cavity and pharynx
(140-149)
7 13 14 34 2.29 2.50 1.46 1.90
Digestive Organs (150 - 154,
157)
3 8 20 31 0.98 1.54 2.08 1.74
Respiratory Tract 162 1 5 5 11 0.33 0.96 0.52 0.62
Bone (170) 29 45 33 107 9.48 8.65 3.44 5.99
Melanoma of Skin (172) 7 23 98 128 2.29 4.42 10.21 7.17
Female Breast (174) 1 6 29 36 0.33 1.15 3.02 2.02
GU Organs (180-189) 7 53 237 297 2.29 10.19 24.69 16.63
Cervix (180) 0 3 34 37 0.00 0.58 3.54 2.07
Ovary (183) 1 11 35 47 0.33 2.12 3.65 2.63
Testis (186) 2 30 144 176 0.65 5.77 15.00 9.85
Brain (191) 78 63 69 210 25.49 12.12 7.19 11.76
Non Hodgkin's Lymphoma
(220 & 202)
33 49 58 140 10.78 9.42 6.04 7.84
Hodgkin's Disease (201) 36 90 164 290 11.76 17.31 17.08 16.24
Leukaemias (204-208) 61 87 96 244 19.93 16.73 10.00 13.66
Lymphoid leukaemia (204) 35 42 28 105 11.44 8.08 2.92 5.88
Myeloid Leukaemia (205) 25 40 64 129 8.17 7.69 6.67 7.22
Total 306 520 960 1786 100.00 100.00 100.00 100.00
Much of the routinely available data is inadequate to provide a comprehensive
picture of adolescent cancer both regionally, nationally and internationally. As
Viner (3) pointed out as far as the UK is concerned, the standard approach to
presenting data divides adolescents as the usual groups are 0-14 and 15-44.
This also applies to much internationally compiled data, where again standard
age breakdowns covering these areas of interest are 0-14 and 15-44 (24) (25)
However, some data are presented below (tables 3.2.8 - 3.2.9) from published
sources, but it is clear that illustrates the difficulty of examining cancer in this
age group because of the inconsistencies in describing data in young people
and its completeness. In addition discussion on the appropriateness of the
classification used is discussed further in chapter 6. These tables of limited
data, suggest that the incidence and survival in the Northern and Yorkshire
region is broadly similar to England and the registries involved in the SEER
programme in the United States. Table 3.2.10 shows the incidence of selected
cancers from selected registers in comparison to the incidence reported by the
Yorkshire Cancer Registry as published in Cancer in Five Continents (26) (the
Northern Registry did not submit data in this period). These data would suggest
that the incidence of cancer in Yorkshire is well within the range experienced
elsewhere in the world.
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Table 3.2.8 Incidence of selected cancers per 100,000 in young people from published sources
Geography Period Sex Age band
10-14 15-19 20-24
All cancers SEERJ 1986-1995 M - 20.4 -
F - 19.9 -
England4 1995 M 12.20 16.60 26.40
F 9.80 13.60 25.90
Yorkshire3 1989-1993 M 11.70 15.60 22.10
F 8.60 13.00 21.90
Northern4 1989-1993 M 10.40 17.50 21.70
F 7.90 9.60 19.20
Leukaemias SEER 1986-1995 M - 2.6 -
F - 1.6 -
England 1995 M 3.70 3.10 1.90
F 1.60 1.30 1.50
Yorkshire 1989-1993 M 2.70 1.90 1.20
F 2.70 1.70 1.60
Northern 1989-1993 M 2.10 3.10 2.00
F 2.00 2.20 1.70
NHL SEER 1986-1995 M - 1.9 -
F - 1.1 -
England 1995 M 1.60 1.60 2.50
F 0.50 0.70 1.50
Yorkshire 1989-1993 M 1.00 1.80 1.20
F 0.40 0.50 1.00
Northern 1989-1993 M 0.90 1.00 1.50
F 0.50 0.20 1.10
Hodgkins SEER 1986-1995 M - 2.9 -
F - 3.6 -
England 1995 M
F
Yorkshire 1989-1993 M 1.50 3.00 4.00
F 0.50 3.90 3.80
Northern 1989-1993 M 1.30 4.60 4.20
F 0.20 1.50 3.70
CNS tumours SEER 1986-1995 M - 2.3 -
F - 1.7 -
England 1995 M 1.70 1.20 2.10
F 2.00 1.40 0.90
Yorkshire 1989-1993 M 2.60 1.80 1.60
F 1.60 1.30 1.00
Northern 1989-1993 M 1.90 2.10 2.40
F 1.40 1.10 0.70
3 SEER http://www-seer.ims.nci.nih.gov/Publications/ (see Annex 2 for explanation of SEER)
4 Office for National Statistics. Statbase. Http:/www.statistics.gov.uk/statbase
5 Northern and Yorkshire Cancer Registry. Quickdata. Version 2 1999
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Table 3.2.9 Survival from selected causes from published data sources
Geography Period Sex Age band
10-14 15-19 20-24
All cancers SEER2 1986-1995 Both - 77 -
England01 1995 M
F
Yorkshire 1989-1993 M 67.8 73.5 75.9
F 66.0 80.6 70.4
Northern4 1989-1993 M 69.5 68.2 73.4
F 58.9 66.0 75.6
Leukaemias SEER 1986-1995 Both - 46.5
England 1995 M
F
Yorkshire 1989-1993 M * k k
F * k *
Northern 1989-1993 M * k k
F * * k
NHL SEER 1986-1995 Both - 69
England 1995 M
F
Yorkshire 1989-1993 M * * k
F •k k k
Northern 1989-1993 M k k k
F
Hodgkins SEER 1986-1995 Both - 90
England 1995 M
F
Yorkshire 1989-1993 M * k 93.7
F k 87.1 77.9
Northern 1989-1993 M k 91.3 83.0
F * * 90.1
CNS SEER 1986-1995 Both - 75
England 1995 M
F
Yorkshire 1989-1993 M * * k
F * ★ k
Northern 1989-1993 M k * k
F k k k
• less than 20 observations
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Table 3.2.10 Incidence rates for selected cancers from published cancer registry data world-wide b
Australia - New South Wales
1988-1992 10-14 15-19 20-24
Disease Males females males females Males females
Acute lymphoid
lymphoma
2.0 2.2 2.2 0.9 0.9 0.6
Hodgkin's Disease 1.1 0.6 2.6 1.7 2.9 3.0
Non Hodgkin's
Lymphoma
1.5 0.3 1.6 0.9 2.3 1.1
CNS Tumours 2.6 2.9 2.3 2.4 2.8 2.0
Bone tumours 1.0 0.7 2.4 1.1 0.6 0.6
All malignancies 11.9 10.6 24.4 18.6 34.8 34.4
Canada - British Columbia
1988-1992 10-14 15-19 20-24
Disease Males females males females Males females
Acute lymphoid
lymphoma
2.8 1.7 1.1 0.9 1.0 0.7
Hodgkin's Disease 2.0 - 3.8 0.2 2.6 -
Non Hodgkin's
Lymphoma
0.7 0.8 1.1 1.3 2.0 2.2
CNS Tumours 3.1 2.3 1.6 1.5 2.3 2.0
Bone tumours 1.1 1.9 1.1 1.3 0.8 0.3
All malignancies 12.3 11.4 15.8 18.7 24.8 28.7
Switzerland - (Geneva)
1988-1992 10-14 15-19 20-24
Disease Males females males females Males females
Acute lymphoid
lymphoma
4.0 - 5.2 - 1.5 -
Hodgkin's Disease - - 3.5 3.5 1.5 4.1
Non Hodgkin's
Lymphoma
2.0 4.2 5.2 - 10.3 1.4
CNS Tumours - - 1.7 - 2.9 1.4
Bone tumours - - 3.5 - 4.4 1.4
All malignancies 9.9 8.3 28.0 15.9 42.6 27.6
Yorkshire
1987-1992 10-14 15-19 20-24
Disease Males females males females Males females
Acute lymphoid
lymphoma
1.6 1.3 1.4 0.8 0.3 0.1
Hodgkin's Disease 1.4 0.6 2.7 3.9 3.8 4.0
Non Hodgkin's
Lymphoma
2.1 1.1 2.2 0.3 1.2 1.0
CNS Tumours 2.1 1.9 1.9 1.1 1.5 1.0
Bone tumours 1.2 1.1 0.9 1.6 0.7 0.4
All malignancies 11.0 8.5 15.3 13.3 19.6 20.6
Source: Cancer Incidence in Five Continents Vol. VII. Eds. D.M.Parkin. S.L.Whelan, J.Ferlay, C.
Raymond, J.Young. IARC Scientific Publication 143. Lyon 1997 (26)
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Finland
1987-1992 10-14 15-19 20-24
Disease Males females males females Males females
Acute lymphoid
lymphoma
2.2 1.6 2.1 1.1 0.8 0.4
Hodgkin's Disease 0.9 1.4 2.3 3.5 3.2 1.9
Non Hodgkin's
Lymphoma
0.8 0.8 2.1 0.4 1.9 1.5
CNS Tumours 3.6 3.0 2.6 2.6 3.3 3.3
Bone tumours 1.1 0.6 1.6 0.9 0.5 1.3
All malignancies 11.6 12.3 18.4 18.4 23.2 27.9
UK Scotland
1988-1992 10-14 15-19 20-24
Disease Males females males females males females
Acute lymphoid 1.7 1.6 2.5 1.1 0.5 0.2
lymphoma
Hodgkin's Disease 1.4 1.8 2.1 3.2 5.1 3.5
Non Hodgkin's 1.7 0.4 1.2 0.8 1.8 1.9
Lymphoma
CNS Tumours 3.1 2.8 2.4 1.7 2.3 1.1
Bone tumours 1.4 0.8 1.9 0.9 0.7 0.4
All malignancies 11.5 10.9 18.2 15.9 28.0 22.2
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4 Literature review
4.1 Sources and Methods
4.1.1 Medline
There is an extensive literature on cancer in adolescents. The American
National Library of Medicine makes available an on-line Medline service. (27)
The NLM's search service has access to nine million citations in Medline and
other related databases. Entering the terms 'adolescent' and 'cancer' revealed
116,868 references - 42,148 related to the previous ten years. In the past year
alone 3,930 articles met the stated criteria. In order to restrict the number of
articles to a manageable level the search was repeated on titles and text words
(tw - neoplasms, cancer, adolescent). At this stage searches were also
restricted to articles published in English. No specific quality criteria were used
in the initial search.
Table 4.1 Results of Medline search
Year Neoplasms Adolescent Number of Articles
(tw) Adolescent (tw) and
Neoplasms
1999- 1996 16171 4924 49
1995-1991 20367 ' 5183 /00•sr
1990-1985 21640 4901 55
1984- 1976 25451 3933 22
1975- 1966 18219 1648 3
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Abstracts for all the identified articles were obtained and scanned for relevance.
A significant number of articles related to the adjustment of children and
adolescents to parental cancer. As this is not the subject of this investigation
these articles were excluded. For the purposes of this investigation the
literature was classified into following groups.
• Epidemiology of cancer in adolescents
• Specific cancers of adolescents
• The psychological impact of cancer in adolescents
• The evidence for the creation of centralised services for patients with cancer
4.1.2 Nursing Literature (CINAHL)
The nursing literature of 1982 - December 1999 was searched using textword
adolescent and neoplasm. The results were:
Table 4.2 Results of Nursing Literature Search
Adolescent Neoplasm Adolescent and Neoplasms
2787 4112 40
4.1.3 Review of Psychology Literature
Psychology literature is held on a specialist database called Psyclit. In the same
way as previous searches were carried out, the terms adolescent and cancer or
neoplasm were used. The database was searched between 1991 and
September 1998. The results of the search were as shown in the cable below:
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Table 4.3 Results of psychological literature search
Adolescent Neoplasm Adolescent and Neoplasms
5971 2814 32
Thirty-two articles were identified in the time period 1991 to 1998 (September).
4.1.4 Review of Sociology Literature
Sociofile is a tool for accessing the literature in applied sociology, social and
policy science. The database contains abstracts from 2300 journals published
since 1974. Twenty three articles were identified using the search terms cancer
and adolescent (or young adults) since 1990.
Some overlap of articles was noted, this was particularly evident with psyclit
and medline.
4.2 Epidemiology of cancer in adolescents
A considerable number of studies exist for cancer in children (aged 0-14
years) (28) (29) (30). Fewer studies present data for children and adolescents
above 14 years of age. A study published by Fritschi (31), which looked at the
incidence of cancer amongst New South Wales adolescents concentrated
principally on the appropriate classification scheme in a study of adolescents
aged 10-19 with cancer between 1972 and 1991 in New South Wales. 2,620
cases of cancer were diagnosed, the average (crude) incidence rate for all
cancers combined was 158 and 140 per million in males and females,
respectively. The authors concluded that the childhood classification scheme is
an appropriate scheme to describe cancer incidence in adolescent age groups
but perhaps requires minor modifications. A striking finding of the New South
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Wales study was the high level of incidence of malignant melanoma. Australian
adults have the highest incidence rates of melanoma in the world (32) and the
rate in New South Wales' children is also much higher than in any other country
(33)
A population based study was carried out on 3,988 tumours in teenagers (aged
10 - 19) in Denmark, and published in 1993 (34). The average incidence rates
for all histological types were found to be 136 per million for boys and 108 per
million for girls. Like most studies, an overall excess of cancer in boys was
mainly due to the frequency of leukaemias, malignant lymphomas, carcinomas
and germ cell tumours. This study suggested that, with the exception of
increasing trends in malignant lymphoma and in non-seminoma germ cell
tumours amongst boys aged 15 - 19, the rates have remained largely
unchanged. The authors draw the conclusion from their study that
environmental factors associated with modern society therefore play a small
role in the causation of cancer among teenagers.
Broadly similar (standardised incidence) findings were reported in a study
published by Van Hoff in 1988 (35) of the trends in the incidence of childhood
and adolescent cancer in Connecticut between 1935 and 1979. However, this
study looked at the incidence of specific cancers in children in 5-year age
bands between 0 and 19, and found significant increases in incidence overtime
*
in Hodgkin's disease in males aged 15-19 and in females aged 10-19.
Pollan et al. (36) published a report on the trends in mortality in the under 20
year olds in the population of Spain between 1956 and 1990. They looked at
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the mortality from seven sites and reported that overall mortality had declined
over this period. This decline had begun to occur at the beginning of the 1970s.
The decline was not apparent in malignant renal tumours in males and
malignant bone tumours and non-Hodgkin's lymphoma in both sexes. As the
incidence of malignancy in this age group was reported as not changing, the
authors concluded that the decline (where it could be demonstrated) was due to
better treatment and improved facilities.
In 1992, Adami et al (37) reported trends in survival in adolescent cancer in
Sweden between 1960 and 1984, however, this study did not report incidence
(standardised or crude) data for the respective age bands studied.
In 1996 Weiss et al (38) published a study of 788 malignancies in Texas
residents under the age of 20 and found that the incidence of cancer in
Hispanics was significantly lower than that seen in other racial and ethnic
groups. In particular, they found a lower incidence of total cancers, non-
Hodgkins lymphoma, lymphoma, neuroblastoma and CNS neoplasms in
Hispanics compared to other young Texans. However the overall incidence of
leukaemia and acute non-lymphocytic leukaemia in particular, was highest
among the Hispanics.
In the Northern and Yorkshire Region there are significant ethnic minorities
from South Asia. 1979 Children (aged up to 14 years) with cancer were studied
between 1974 and 1995. It is known that cancer incidence in the UK does vary
by ethnic origin, with a notable excess of lymphomas in children of Asian ethnic
origin. (39). McKinney et al found that survival did not differ in any ethnic group.
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Risk of death was higher for children in most deprived areas though these
differences did not reach statistical significance (40).
Unlike in children where leukaemias are the commonest form of cancer,
lymphomas are more common in adolescents. Leukaemia and brain tumours
are also very common. When looking at the differences in distribution between
the sexes in a study carried out in Canada, it is notable that there were around
a forty percent excess of cancer reported in males (41), with a 70% excess in
non Hodgkin's lymphoma, whereas there was almost no difference between the
sexes in the incidence of Hodgkin's disease (though this may be partly
explained by the fact that the female group was slightly older than the male
group). Similarly it has been reported that there is a three to four fold excess of
thyroid cancer in females and a fifty percent excess in malignant melanoma.
Similar patterns were seen in the SEER programme in the United States (where
only the white population was used for comparative purposes), but an even
greater excess of non-Hodgkin's disease was seen there.
In childhood, leukaemias account for almost a third of cancers, whereas in
adolescents this falls to about one seventh, with the lymphomas becoming
much more prominent (accounting for one in four cancers in the 10-19-age
range). Embryonal tumours such as Wilm's tumour (nephroblastoma),
retinoblastoma and hepatoblastoma are hardly ever seen in the older age
groups.
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4.3 Specific cancers in adolescents and risk factors
In this section, cancers that affect young people will be considered individually.
4.3.1 Hydatidiform Moles
A hydatidiform mole is a rare mass or growth that may form inside the uterus at
the beginning of a pregnancy. Only 20% of hydatidiform moles care malignant.
Hydatidiform moles arise from foetal tissue and, therefore can only occur in
conjunction with the early stages of pregnancy. The mass is usually placental
material that grows uncontrolled. Frequently there is no foetus at all. The cause
of this developmental disorder is not completely understood. Potential causes
may include defects of the ovum (egg), abnormalities within the uterus, and/or
nutritional deficiencies. The incidence in the U.S. is 1 out of 1500 pregnancies;
however, it occurs in up to 1 out of 125 pregnancies in Mexico and some Asian
countries. Women under 20 or over 40 years old have an increased incidence.
Risk factors include low socio-economic status and diets low in protein, folic
acid and carotene. (42) (43)
An hydatidiform mole is treated by therapeutic abortion, if spontaneous abortion
does not occur.
The prognosis is mainly good. More than 80% of hydatidiform moles are benign
and the outcome after treatment is usually excellent. Close follow-up is
essential. Highly effective means of contraception are recommended to avoid
pregnancy for at least 1 year.
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In 10 to 15% of cases, hydatidiform moles may develop into invasive moles.
Invasive moles, however, may intrude so far into the uterine wall that
haemorrhage or other complications develop.
in 2 to 3% of cases, hydatidiform moles may develop into choriocarcinoma
which is malignant. Despite these factors, the rate of cure is high. Over 90% of
women with malignant, non-spreading (non-metastatic) disease are able to
preserve reproductive abilities. In those with metastatic disease, remission
remains at 75 to 85%.
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4.3.2 Cervical Cancer and CIN III
Risk factors for cervical cancer are shown in the box below.
Box 4.1 Risk factors for cervical cancer (44)
• Early first intercourse (coitus below 17 doubles risk) (45)
• Women with multiple sexual partners (45)
• Promiscuous male partners (more than 15 partners - 8 times risk) (45)
• Smoking (doubles risk) (46)
• cervical trauma during childbirth (46)
• Sexually transmitted viral infection (especially HPV16 - present in 93% of
cervical cancer (45)
• Genetic susceptibility (a variation in p53 tumour suppresser gene may
increase risk 7 times (47)
In numeric terms the numbers of CIN III form the largest number of new
cancers in the 10 -24 year old age group compared with any other site. One of
the principal differences between the Yorkshire Cancer Registry and the
Northern Children's' Tumour Registry was found to be that the Yorkshire
Registry recorded CIN Ills. CIN Ills are carcinoma in-situ of cervix. There is
evidence to show that there has been a real increase in incidence of these
cancers, particularly in the younger age groups.
Doll (48) reports a 10% increase in cervical cancer in the 20 - 24-year-old age
group. It is now widely accepted that that this is due to increased infection with
carcinogenic types of human papilloma virus (49) (50) (51). One of the
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dilemmas facing the gynaecologists who are responsible for managing young
women with cervical abnormalities is the natural history of cervical displasia and
CIN I. To what extent these conditions progress to invasive cervical carcinoma
is unclear. In this study CIN III will not be considered, but this does not mean
that the discovery of this potentially serious abnormality in young women does
not have a profound effect on the well being of the patient concerned. There
are significant issues about how this condition should be managed from a
psychological perspective in young women and there are implications for health
promotion and the screening services (including those in primary care) in
providing full information for young women being screened.
4.3.3 Leukaemias
Most of the published material on leukaemias relates to childhood leukaemia
and to a lesser extent adult leukaemia. As Cartwright suggests (52) there are
virtually no epidemiological studies which target adolescents. The aetiology of
cancer in adolescents cannot be assumed to be similar to that of children.
Nationally between 1983 and 1987 leukaemias were reported to constitute
around one fifth of new cases of malignancy in males in the 10-19 year old age
group and slightly less in females (41)
It is thought that ALL (acute lymphoblastic leukaemia) in adolescents is likely to
have a similar epidemiological picture to that in children (52). Table 4.4. shows
the distribution of AML, CML and ALL in 15-24 year olds. This table
emphasises the excess of ALL, especially seen in boys between the ages of 15
and 19 years of age.
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Acute myeloid leukaemia M 0.5 1.0
F 0.7 0.6
Chronic myeloid leukaemia M 0.2 0.1
F 0.2 0.1
Acute lymphoblastic leukaemia M 1.7 0.7
F 0.8 0.3
Source: Cartwright (52)
Risk factors are virtually unknown with some studies now being undertaken.
Little is known about AML (acute myeloid leukaemia) in adolescents.
4.3.4 Non Hodgkins Lymphoma (NHL)
Cartwright (52) suggests that NHL in adolescents is likely to be similar in its
aetiology to that in children with the exception of the viral causes. There are
some inherited impaired immune system conditions which give rise to NHL in
adolescence (53). There are links between NHL and certain other chronic
diseases for example glomerulonephritis. NHL is increasing in incidence in
adults in the US and many other countries, but there is no evidence that this
increase extends to adolescents.(54) (55)
4.3.5 Hodgkin's Disease
This disease appears to be increasing in incidence, there is good evidence from
North America that there has been a marked increase in incidence since the
eariy 1970s which was not due to better diagnostic capabilities (56).
Hodgkin's disease peaks in incidence at in the early 20s and 30s, then in the
early part of the peak, there is no difference between the sexes, but at other
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ages there is a male excess. A number of studies have suggested that there is
an excess of this disease in 'upper social' classes, but this may be more due to
where they live than their socioeconomic status (57).
Gutensohn and Cole (58) have suggested that a number of features of
Hodgkin's disease suggest that it has an infectious aetiology. They suggest that
Hodgkin's disease may be a late manifestation of a common infection with the
probability of disease increasing as age at infection is delayed. This hypothesis
is supported by the reports that the risk of Hodgkin's disease is increased in
those who had a low frequency of childhood infectious disease. In a study of
225 cases and 447 controls, they showed that the risk of disease decreased
with five or more siblings, living in multiple family homes. Cases had fewer
playmates and better educated mothers than the controls. They concluded that
this study added weight to their earlier hypothesis that risk of Hodgkin's disease
is associated with a decrease or delay in exposure to infections of childhood
(59).
Clustering is a feature of Hodgkin's disease, most especially in isolated rural
populations. In a study by Alexander almost 1 in 3 cases could be spatially
linked to another (60).
Familial studies suggest that Hodgkin's disease has a genetic basis. It is
thought that the disease may occur more commonly in genetically susceptible
individuals with perhaps some infective agent being involved in the late stage of
the pathogenesis. Viruses that have been suggested include the Epstein Barr
virus (61), although the extent to which this virus is involved in young people
with Hodgkin's disease is thought to be small (62) and the herpes virus (HHV6)
(63). There have also been some suggestions that Hodgkin's disease is linked
to skin conditions (64) and inherited conditions (53) giving rise to immune
deficiency. Other associations with tonsillectomy and appendicectomy appear
to have now been refuted (65).
4.3.6 Brain and CNS Tumours
About half CNS tumours in adolescents and children occur in the posterior
fossa. Boyle concluded that despite the many suggested factors proposed for
cancer of the brain and the CNS, there is little which can be suggested that may
increase the prospects of preventing brain and CNS tumours in adolescents at
the present time. (41)
4.3.7 Bone Cancer
Approximately 10% of all malignant neoplasms in children and adolescents are
due to bone cancer (66). 95% of these are either osteo-sarcoma or Ewing's
sarcoma. Osteo-sarcomas are twice as common as Ewing's sarcoma.
Approximately 60% of patients with this tumour are affected during the second
decade of life, with a predominance of males. There is a suggestion that this
neoplasm is related to rapid bone growth (67). There is a suggestion that
osteo-sarcoma may be genetically pre-determined. The main evidence for this
comes from observations of excess osteosarcoma as a second malignancy in¬
patients with hereditary retinoblastoma (68).
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Ewing's-sarcoma occurs mainly between the ages of 5 and 30, with a peak
incidence of between 10 and 15 years. More boys than girls are affected, and
this tumour is rare in black and Chinese populations.
4.3.8 Testicular cancer
Cancer of the testis has been increasing since the 1930s in this country. In
Scandinavia where the rates are double that in the UK the increase is most
marked in the 15-19 age group. In contrast to the increase in incidence is the
decline in mortality, which is associated with effective treatment. The reasons
for the increase in incidence are unclear, and cannot be satisfactorily
accounted for by factors which are known to cause an increase (earlier sexual
maturity and undescended testis). (69) (70)
4.3.9 Skin Cancers
Significant increases have occurred in melanoma and non-melanoma of the
skin (48). There is a striking increase in melanoma and non-melanoma skin
cancer. In the United States, Kaposi's-sarcoma associated with AIDS has been
an important factor in the increase of non-melanoma skin cancer in young men
(71). However, it is unlikely that this condition has played a significant part in
the United Kingdom. The only other risk factor known to cause skin cancer is
exposure to ultra-violet radiation (72), but it has been questioned whether such
an increase in exposure since the 1960s can account for a 56% and 28%
increase in male and female melanomas, and the 22% and 29% increase in
non-melanoma skin cancer, respectively (73).
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4.3.10 Drugs as causative factors
Two instances of drugs causing cancer in adolescents have been described.
Cyclophosphamide is associated with carcinoma of the bladder (74) and
diethylstiboestrol treatment of pregnant mothers has led to clear cell carcinoma
of the vagina in their daughters (75).
4.4 The psychological and sociological impacts of cancer in adolescents
4.4.1 The psychological literature
Stevens and Dunsmore provide a useful overview of the issues facing the
adolescent with cancer (76). Their review provides an analysis of the situation
of adolescents who are living with life-threatening illnesses, and provides strong
evidence for the need to handle adolescents with cancer differently to adults or
children. For example, they describe some of the features of how adolescents
react to a crisis and point out that "their response is typically that they want to
be loved and supported but not wrapped in cotton wool." They point out that
rather than confide in parents , they may prefer to confide in their peer group,
particularly with peers who are in a similar situation. In addition to coping with
what is already a stressful part of life, adolescents with cancer are having to
cope with the stresses associated with the illness, its treatment and side effects
of therapy. They point out the resilience and soundness of mind of the affected
young people, and emphasise that most young people want to be actively
involved with understanding their illness and take an active part in the treatment
decisions associated with it. The authors draw interesting distinctions between
the needs of adolescents at various ages and group these into early, middle
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and late adolescence. Thus, for example they describe the major concerns of
early adolescents as those which revolve around body image and mobility. Mid
adolescents are concerned about how their illness will affect their ability to form
relationships, particularly with the opposite sex, and late adolescents (17 - 24)
with forming permanent relationships and their careers.
Bradlyn (77) points out the difficulty of assessing quality of life in special
populations, especially children and adolescents. He points out that little
research has been done in these groups, and suggests that there are a number
of conceptual and technical difficulties related to the assessment of the quality
of life in children and adolescents. He points out that a wide range of
differences need to be taken into account in studies which cover ages which
encompass infancy to adulthood. He also pointed out the importance of
assessing secular changes as children move from one developmental stage to
the next. He also highlights the difficulties of using proxy informants (e.g.
parents in children and adolescents). In a study of quality of life in AIDS, Testa
and Simonson concluded that it was necessary to use three different quality of
life instruments corresponding to developmental age (6 months to 4 years, 5 to
11 years and 12 to 20 years). Furthermore, for children under the age of 12, the
respondent was the child's carer rather than the child. (78)
Eiser and Havermans, (79) on the other hand looked at the mothers and fathers
from 245 families with a child (ages 4-14 years) with a severe life limiting
condition, including leukaemia. Their study particularly examined coping
patterns. These varied according to age and gender of the child, and, more
significantly, in relation to the disease and length time to since the diagnosis
was made. Mothers reported that social support and information was felt to be
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less helpful the longer the time since diagnosis, and this was particularly the
case with leukaemia and epilepsy. On the other hand the fathers who
perceived more difficulties found autonomy more helpful and medical care less
helpful compared with fathers who perceived fewer difficulties. In a later study
Eiser (80) also considered the long term effects of childhood cancer, and
suggested that for these children, consideration should be given to the long
term care in order to (a) establish more accurately the incidence of social and
psychological late effects and (b) offer advice to the individual about the
possible long-term effects of cancer treatment on future health, social and
employment prospects.
The follow up of children with cancer is one possible role for an adolescent
cancer unit and is a distinct function which does not appear to have received
much attention in either the literature or in the provision of services.
Alice Friedman (81) undertook a study on the psychological functioning of
children with cancer. She identified the most critical issues relevant to children
diagnosed under fifteen years, and also illustrated the range of demands which
confront children and their families after receiving a diagnosis of cancer. She
also described how behavioural research has contributed to the overall care
and adjustment.
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Glazer (82) describes the psychiatric aspects of cancer in childhood and
adolescence from the first time from which the child is diagnosed through
treatment and other longer-term situations. In this review, he does begin to
explore the differences between the experiences of young children compared to
adolescents. He reviews some specific clinical problems. These include school
phobia7 and regressive symbiosis8, non compliance9, distress10 related to
medical procedures and chemotherapy, cranial irradiation in ALL and bone
marrow transplantation. Non compliance with the taking of medication was seen
more commonly in older age groups, the mean age of patients who had never
missed any doses was 9.5 years compared to 17.4 years for those who had
frequently missed doses. In terms of distress, he reported that adolescents
exhibited a higher rate of symptomatology especially nausea and vomiting
when compared with younger patients. This chapter, therefore is beginning to
suggest that differences do exist between the needs of adolescents and
younger children.
Grootenhuis (83) described the parents' emotional reactions to a child (between
eight and eighteen years) with cancer. Perhaps not surprisingly, she found that
mothers and fathers of children who had relapsed reported more feelings of
helplessness and uncertainty compared with the parents of children not
suffering a relapse. Mothers of children with a relapse also were found to
demonstrate more depression and anxiety. The problems of fathers with
children with cancer were more difficult to identify and were only revealed with
an illness-related questionnaire. The time since diagnosis did not change the
occurs when a child refuses to attend school
8
regressive symbiosis - patients exhioit a group of profoundly regressed behaviours, which include a resumption of
bottle feeding, loss of speech milestones, and assumption of foetal positions.
9
Non compliance was seen particularly in the refusal to take medication
10
Distress particularly involving repeated bone marrow aspirations and therapeutic lumbar punctures. It has been
suggested that the distress caused by these procedures is in effect much worse than the distress caused by the illness
itself.
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emotional reactions of any parent. The author also went on to conclude that
the parents of children whose cancer had relapsed may require considerable
support and should be monitored. Unfortunately in this study there is little
consideration of the age of the patient, and a serious weakness of the work
would appear to be assuming that reactions across the large age range under
consideration were homogeneous.
Hanna (84) reviewed health behaviour among adolescents with cancer. She
pointed out the paucity of studies on health promoting and health risking
behaviour (e.g. use of alcohol and marijuana) on adolescents with cancer. She
concluded the majority of adolescents with cancer engage in the health
promoting behaviour of adhering to their treatment, although a considerable
proportion were non adherent. A small proportion engaged in drug and alcohol
use. She reported that the health behaviour of adolescents with cancer might
be influenced by their development. This study again reinforces the need to
give special consideration to the care of adolescents in that their needs are
different to both adults and children.
Carr-Gregg and Hampson (85) indicate that adolescents suffering from
malignancies experience particularly severe psychological distress which in turn
distresses medical staff and parents. This again supports the suggestion that
the needs of adolescents with malignancies are different to those of young
children.
Schowalter J.E., Fernholt J.B., et al (86) presented a particular example of a
patient with terminal renal disease in an adolescent who had made a decision
that she wanted to die. They point out that it is almost unique for patients who
have not reached adolescence to decide to die. This again reinforces the
difference between the needs of adolescents and children.
Hoekstra-Weebers (87) and colleagues went on to investigate distress in
parents of adolescents further and used the general health questionnaire to
compare 15 parents who had lost younger children (3 - 9 years) with cancer
compared to 14 parents who had lost older children (13-19 years). They were
unable to find any difference in mental health problems between the parents of
younger children and those of adolescents. When mental health problems
occurred they were reported by father and mother. Their research suggests that
special concern should be given to parents of adolescent boys. Parents of
adolescents were also less likely to use problem focussing as a method of
dealing with their bereavement than the parents of younger children. Again, this
may suggest that the needs of parents of adolescents are different if not greater
than those of younger children.
Kazak and her colleagues (88) looked at child and parent distress in relation to
lumbar puncture and bone marrow aspiration in children with leukaemia. The
aim of their study was to develop a valid parent report measure which was
aimed to provide parental reports of their child's distress and their own distress.
Parents of 144 children and adolescents were involved. Special factor analysis
yielded a number of factors which were important:
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1. The satisfaction of the parents with the way in which the procedure was
handled
2. The distress shown by the child during the procedure
3. The distress of the parents before the procedure
4. The involvement of parents in the procedure
There is little information in the paper about the ages of the patients, although
the range (1 month to 17.5 years), mean age (5.8 years) and standard deviation
are quoted (S.D. = 4.3). However, from this one can surmise that few older
patients were involved in this study. The authors do conclude that there is an
inverse relationship between the child's age and the amount of distress
measured. This implies that adolescents may require more support before
procedures, and again emphasises the need to take a different approach to the
management of adolescents compared with children.
Koch (89) looked at parents and their children's (including adolescents) reaction
to their child's cancer. The parents main concerns were education and
professional development (schooling and absences). This differed from the
children and adolescents who were concerned about time pressures, long
periods of inpatient treatment, frequent relapses and complications, absence
from school and having to repeat school years. Parents were more concerned
about the high weekly time burden and unexpected financial pressures. At the
same time many parents reported a reorientation of life's priorities which was
seen as positive. The analysis was based on 473 mothers and 326 fathers from
504 families. Unfortunately in this study, no distinction was made between the
reactions in families with younger and those with older children, although the
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study did cover patients up to the age of 18 years. They concluded that
financial problems need to be addressed, time needs to be made available by
employers to allow them to support their children, and assistance given to
mothers in re-entering employment if their child's illness necessitates them
leaving their employment for a while. They also suggested that the needs of
single mothers in particular need to be addressed, and that specific advice
needs to be made available for the children and adolescents themselves and
their fathers. In the longer term they suggest that greater and more equitable
participation by fathers in the care of their children and adolescents needs to be
encouraged.
In a study which included children and adolescents between the ages of 0 and
20 years, Lozowski (90) found that some parents are able to deal with the
medical and psychosocial challenges of childhood and adolescent cancer by
playing an active and assertive role in the medical treatment process. In her
study, 56% reported intervening at some point in the treatment process to
prevent or correct a medical mistake. The nature of these interventions
included (1) the prevention of erroneous administration of drugs, (2) a need to
remind the staff of correct or incorrect procedures, (3) alter intravenous
procedures, and (4) mediate the staff's style of interacting with ill children.
Parents with high levels of income and education were found to intervene more.
From the adolescent perspective, only 20% of those studied were over 11 years
old, and of those, only 5% were in the 16-20 age group. However, although
the numbers were small, the study suggested that parents of older children and
adolescents were less likely to intervene, although the authors failed to
comment on this finding reported in the results. Again this reinforces the
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hypothesis that the needs of adolescents and older children differ in important
ways with those of young children.
O'Malley (91) looked at the psychotherapeutic consultation process on the
cancer in-patient ward of a hospital in Harvard Medical School, and looked at
children in adolescence, aged 8 to 17. He identified some of the obstacles to
psychological consultation and reported that the process of such a consultation
may in itself lead to obstacles preventing effective intervention. He suggested
that there must be willingness on the part of the consultant to alter some of the
working practices if effective services to hospitalised children are to be
provided.
Ostroff and Steinglass (92) looked at the major issues faced by childhood
cancer survivors and described potential parent and medical team factors which
were associated with differential adequacy of psycho-social adaptation to
childhood cancer survival. They pointed out in work undertaken by Koocher et
al. (93) that it had been shown that adolescents report more psychological
difficulties than younger children and hypothesised that this may be due to the
features of adolescence which feature establishing independence and having to
cope with demands and restrictions imposed because of their cancer. Ostroff
and Steinglass also introduced a concept of multiple family discussion groups,
which were designed to help facilitate more successful transition of adolescent
cancer patients and their families from the active treatment to the 'off treatment'
phase. They reported this approach as being very promising cost effective
approach to long term follow up in adolescents with families welcoming an
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opportunity to tell their story and to better understand the impact of cancer on
the life of their family.
van Veldhuizen (94) described over-protection as a child rearing attitude in
parents of children (aged 9 to 15 years) with life-threatening diseases, and
some found that over-protection was used as a coping strategy in such
children.
Eiser et al. (95), looked at the impact of limb salvage in-patients with a primary
bone tumour. She suggested that the evaluations of patients in this situation
should not just be confined to functional measures alone, but extend to the
perceived impact of treatment. Her series had a mean age of 17 years (range 8
- 25 years).
4.4.2 Conclusions from the psychological literature:
A number of conclusions can be drawn from this review of the psychological
literature, these are as follows:
1. The literature on the psychological impact of cancer in adolescents is thin.
At best the needs of adolescents are considered within research or reviews
which mainly deal with younger children. Some of the age ranges which are
considered are very large. There is therefore a need for specific research to *
be undertaken looking at the needs of adolescents as a group.
2. Where differences between children and adolescents are described, there
do indeed appear to be important differences. These have been described
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in the preceding paragraphs and would tend to lend weight to the need to
create separate facilities and support for adolescents.
3. The needs of children diagnosed with cancer, as they grow up into
adolescents does not seem to be described in any detail within the literature
at all. This would appear to be an important area of research which is
highlighted by the increased survival of children with cancer.
4.4.3 The Sociological literature
The sociological literature reveals some interesting insights into the experiences
of young adolescents with cancer and how their management might be
improved. Roberts (96) undertook a study based on the postal questionnaire of
46 adults who had completed, or were still receiving, outpatient treatment for
cancer. He found that their concerns were in relation to recurrence, their
children's future, potential financial uncertainty, and relationships. He argued
that additional psycho-social intervention was required to confront these
concerns, and that focus groups in themselves may provide support to young
people with cancer. In a second study undertaken by Roberts, (97) he went on
to conclude that such groups can help psychological well-being but was unable
to demonstrate any change in coping mechanisms or in quality of life.
Pendley (98) looked at the importance of body-image and psycho-social
adjustments. She found that concerns about body-image and social anxiety
may not develop until several years after treatment. Albaret (99) looked at the
differences between males and females and found that girls were less likely to
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use coping strategies and confirmed the importance for girls of external family
support in contrast to boys use of internal resources.
Dunsmore and Quine (100), in an Australian study, looked at 51 young people
aged 12 to 24 with cancer to identify their information support and decision
making needs and preferences. They found that the participants in their study
wished to be more informed and involved in treatment decisions, particularly in
the case of bad news. They also reported the qualities of health professionals
that facilitated communications. These included the ability to listen, the ability
to express genuine concern, professional expertise, and honesty. In contrast
an impersonal manner, the excessive use of technical jargon, haste and the
generation gap impaired communication.
Varni (101) in a study of 39 patients with cancer (mean age 17) found that
stress management interventions could enhance the quality of life in this group.
Stern (102) in a study comparing 48 adolescents with cancer to 40 healthy
adolescents from local schools, found that adolescents with cancer are
relatively well adjusted but exhibited less positive social sexual self-image than
did their healthy peers.
Lynam (103) interviewed 12 young adults with cancer to determine how their
illnesses affected relationships with others. They found that maintaining
relationships was a priority and this helped them to cope more effectively with
their illness, however, they also pointed out that whilst relationships with others
were at many times supportive, they could also be stressful.
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4.4.4 Conclusions from the sociological literature
The sociological literature provides valuable insights into how effective
management may be undertaken in adolescents with cancer:-
1. The principle concerns of adolescents with cancer have been documented
and priority could be given to address these in the clinical situation.
2. Support groups are of value improving psychological well-being but that is
not necessarily reflected in formal assessments of the quality of life.
3. Differences between males and females may be important
4. The information given to young people should be considered, and how it is
delivered and by whom
Stress management techniques may have a role in helping young people to
cope with cancer.
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4.5 Evidence for the centralised management of cancer
Perhaps the most significant piece of work which has been published recently
which has stimulated discussion about the need for centralisation of cancer
services was the publication, in April 1995, of the report by the Expert Advisory
Group on Cancer to the Chief Medical Officers of England and Wales (the
Calman-Hine Report) (104).
This report has been adopted as formal policy by the Secretary of State for
England and Wales, and is now one of the key driving forces for implementing
change in cancer care at the present time.
One of the principal themes of the Calman-Hine report was the creation of a
network of expertise in cancer care, extending from primary care to cancer units
in district hospitals to cancer centres. The report also emphasised the centrality
of primary care with a patient-centred approach. The Calman-Hine report
specifically recommends that cancer centres should undertake the
management of rare tumours including those of children and adolescents.
This model of care was a significant development of the pre-existing situation
where most cancer management would be undertaken in a district hospital and
in relatively few circumstances referrals would be made outwith that unit, with
perhaps the exception of patients requiring treatments which were not widely
available, e.g. radiotherapy. However, even within the existing framework the
access to even basic treatment such as radiotherapy was highly variable (105).
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It was envisaged that the Calman-Hine report would lead to a model of care
whereby the patient was managed at the most appropriate point within the
cancer network, and this would enable the patient to have the best quality of
care as close to home as possible.
The Calman-Hine report's philosophy was that the cancer network thus formed
should be based on proficiency and not buildings. The Calman-Hine report also
emphasised that "services should be planned to minimise travelling times whilst
maintaining higher standards of specialist care, using local expertise and
agreed protocols ... this network is one of proficiency and not buildings. It may
however be appropriate in some areas to relocate or rebuild some facilities to
create effective cancer services."
It is important to stress that specialisation is not the same as centralisation.
One of the key messages of the Caiman Hine report was to stress that clinical
teams should allow specialist care to be provided locally.
The issues set out in the Caiman Hine Report are clearly highly relevant to
providing services for adolescents with cancer. The rarity of adolescent
cancers inevitably attracts the proposal that their management should be
centralised. However, centralisation potentially can be very disruptive to a
young person, particularly in their formative years where contact with friends,
education and social networks are highly important. Thus, the purpose of this
report is to consider the benefits and disbenefits of centralised model care.
One of the key points illustrated by Ferguson (106) was that if centralisation
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significantly compromises accessibility then a priori outcomes will be worse for
the population.
Stiller (107) found that children (defined as under 15 years of age) with certain
types of cancer, namely acute non-lymphoblastic leukaemia, non-Hodgkin's
lymphoma, Ewing's tumour, Rhabdomyosarcoma, and between 1981 and 1984
osteosarcoma, treated at paediatric oncology centres had significantly higher
survival rates than those treated elsewhere. He concluded that children with
cancer should be referred to specialist treatment. Further evidence came from
a paper published by Pritchard (108) which demonstrated that children with
Wilm's tumours who were treated outside paediatric oncology services were
subject to over-treatment. Selby et al (109) produced evidence to further
support the benefits from specialised cancer care in adults and children, but
with no reference to adolescents. They concluded that evidence existed to
support the various aspects of specialisation (e.g. training, caseload and the
formation of multi-disciplinary teams) were strongest for breast cancer, ovarian
cancer and some haematological malignancies. They also concluded that there
was some evidence to support the conclusion that specialised care can
successfully be delivered by a network of district hospitals and main general or
teaching hospitals, and does not always require referral to a cancer centre.
In 1994 Stiller (110), published a paper suggesting that survival rates for cancer
in relation to patterns of organisation of medical care, specifically treatment at
specialist centres or at hospitals treating larger numbers of patients and
treatment by protocol (usually within the context of a clinical trial) provided
better outcomes. Centralised referral or entry to trials was frequently
associated with a higher survival rate, especially in the less common cancer,
and was never found to be associated with lower survival rates. An interesting
additional twist to this was found in a study by Sandra Rousch which showed
that in Florida socio-demographic factors were associated with the type of
facility where a child with cancer was treated (111). Nineteen percent of
children in their study were never seen at a cancer centre. These children were
likely to be older, with Hodgkin's disease or a brain tumour, reside in a county
without a cancer centre or have a higher median income. This latter
observation drew the conclusion that in the United States private insurance may
be a barrier to referral and protocol-based treatment.
In 1999, Stiller and colleagues (112) published the first evidence about the
effectiveness (in terms of survival) or otherwise of centralised management of
adolescent cancer. He and his colleagues looked specifically at 879
adolescents and young adults with leukaemias (417 with acute lymphoblastic
leukaemia and 462 with acute myeloid leukaemia aged from 15 to 29 years old)
and concluded that survival did not vary with the category of hospital, although
improvement was shown to have been made over time (from 1984-88, and
1989-94).
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4.5.1 Conclusions on the benefits of centralisation for services for
adolescents with cancer
The evidence of benefit for the centralisation of care of adolescents with cancer
is limited. However, the clear evidence from the management of other cancers
is strongly suggestive that the management of rare conditions benefits from
centralisation. Furthermore, we do know that many of the features associated
with centralised management (e.g. entry into trials) are more prevalent in larger
centres. As Stiller has stated, no disadvantage of centralisation has ever been
shown.
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5. Sources and weaknesses of the data used in the study
5.1 Cancer Registry Data
Cancer has been the subject of a registration system for many years. This
means that there is a comprehensive national database on all new cases of
cancer. For the purposes of this study data were requested from the Northern
and Yorkshire Cancer Registry and Information Service (NYCRIS), based at
Arthington House, Leeds.
NYCRIS was formed in April 1997 from the former Yorkshire Cancer
Organisation. It brought together the former registries of the Northern and
Yorkshire Regions which had hitherto been separate. However, currently the
registry only holds accurate data for the former Yorkshire Region. Although,
basic registration was carried out in the former Northern Region, the level of
investment meant that only a limited amount of information was recorded and
that latterly there was a considerable backlog in the registration process at the
time of this study. Data were only available up to 1992 for the former Northern
Region. Furthermore, the methods of data extraction differed considerably
between the registries in the north and south of the region. Yorkshire employed
a system using peripatetic clerks, who were directly responsible to the Cancer
Registry, whereas in the North, data were recorded by members of the various
medical records departments. This inevitably meant that there was a lower level
of commitment to cancer registry data recording, and a lower level of expertise
in the North compared to Yorkshire.
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It was therefore decided not to use the Northern Cancer Registry data because
of the weaknesses in the data and due to the unavailability of large amounts of
data. However, it has been possible to use another significant source of data
which covers the former Northern Region, namely the Northern Region Young
Persons' Malignant Disease Registry, based in Newcastle.
5.2 Northern Region Young Persons' Malignant Disease Registry
This registry was established in 1968 in the then Newcastle Region. (113). All
consultants were asked to notify the secretary of the Malignant Disease Co¬
ordinating Committee about all children under their care who were diagnosed
as having cancer before their fifteenth birthday. All cases of malignant disease,
including neoplasms of uncertain behaviour e.g. histiocytosis X have been
included. To ensure completeness, cross-checks are made with hospital-based
data (hospital activity analysis, and more recently Korner data set) and the
cancer registry, in the early 1980s the data collection was extended to cancers
diagnosed up to 25 year olds.
5.3 Differences between the data collection systems in the former
Northern and Yorkshire Regions.
There are demonstrable differences between the data collection systems
employed in the former Northern Region and the former Yorkshire Region.
Although similar data sets have been utilised from both parts of the former
region, the data have been kept separate and analysed separately. However, in
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the presentation of results some data has been brought together as it could be
demonstrated that there were no systematic differences between the Northern
and Yorkshire datasets with perhaps one exception, namely the ascertainment
of data on epithelial cancer.
The methods of initiation of a cancer registry record in Yorkshire are based on
the receipt of a pathology record or in the case of leukaemia a copy report from
a haematologist. This means that ascertainment is comprehensive. The
pathology report initiates the creation of a data collection form (shown in the
appendix) which is then used by the peripatetic clerk to collect additional details
from the case records. Pathologists and haematologists are subject to
extensive internal and external quality control procedures which provides a
considerable degree of confidence that cases of malignancy are not being
missed in the cancer registration system.
5.4 Other potential differences in the dataset and possible weaknesses
In the Northern Region the absence of certain routine notification pathways
means that the data may be incomplete in certain areas, for example unlike
cancer registries, the specialised tumour registry does not receive routine death
certificate notification. Although the number of malignancies diagnosed in this
way is likely to be extremely low, inevitably some cases will be missed. In
Yorkshire during the study period there was only a single case registered solely
from a death certificate. In Yorkshire, as well as peripatetic clerks who extract
the data from case notes, systems are in place to derive direct notifications
from pathology records. Furthermore, cancer registries receive death certificate
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notifications from ONS (Office of National Statistics - formerly Office of
Population Censuses and Surveys [OPCS]). Data are also (rarely) obtained
from direct notifications from general practitioners and other clinicians directly.
It may also be possible that ascertainment in the Northern Region is more
complete than the Yorkshire Registry data, given the singular purpose of the
registration staff and their accumulated experience.
The existing Yorkshire Children's Tumour Registry based in Leeds (114)
already has a system whereby data is exchanged between itself and the cancer
registry to ensure completeness. However, currently the data collection for the
Children's registry only extends to the age of 15. There are proposals to extend
the age range to 25 years.
The following data were requested from both NYCRIS and from the Northern
Region Young Persons' Malignant Disease Registry, for the period 1985-1994,











Treatment modalities (present or absent)
Date of death
Cause of Death
The responses to the requests were different and demonstrated the differences
in the available datasets and approach. Before any data were released, the
author was required to satisfy both NYCRIS and the Northern Tumour Registry
of the validity of the proposed study and agree to standard confidentiality
clauses.
Occupational data would have been of interest but was not available from either
data source. In examining the relationship with disadvantage, proxy measures
of social class have been utilised in the Yorkshire data derived from postcodes.
This approach will be discussed in greater detail later.
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Table 5.4 shows the differences in the available data from the two sources.
Table 5.4 Difference between datasets from Northern and Yorkshire Sources
Data Requested NYCRIS Northern Children's
Tumour
Registry
Patient Identifier Available Available
Postcode of residence Not available due to Not available due to
confidentiality - electoral confidentiality - data only
ward data available provided by county
district
Sex Available Available
Age at diagnosis Not produced directly but Not produced directly but
calculated from other calculated from other
fields fields
Consultant in charge of Not available due to Not available due to
case consultant confidentiality confidentiality
- a list of consultants was
made available
Clinical diagnosis Available - all as ICD 9 Available ICD 9 until
1990, ICD 10 thereafter
Histological diagnosis Available Available
(M codes)
Date of diagnosis Available Available
Place of treatment Classification of Named hospital data
hospitals into three produced
groups
Treatment modalities Available for first 8 Not included on
weeks of care database
Date and cause of death Collected systematically Not collected - but the
and made available date of death can be
deduced from the data
by combining a status of
death - with the date of
the last known follow up.
Cause of death is not
*
recorded but a death is





The differences between the two sources of data did not produce a major
difficulty with the study.
The absence of occupational data meant that it was impossible to directly
examine the relationship between occupational class and the incidence of
malignant disease. Similarly the absence of treatment data held on the
Northern Tumour registry was a limiting factor in performing a regionwide
analysis. In the Northern data, geographical location was limited to local
authority district of residence, therefore analysis by social class and population
density, though technically possible was not undertaken because the results




Epidemiology is concerned with the distribution and determinants of disease.
Hennekens and Buring (115) have attempted to provide an overview of the
types of designs that may be used in epidemiological research. This is shown in
Table 6.1 below:
Table 6.1 Overview of Epidemiological Studies
Descriptive Studies Analytic studies
Population (correlational studies) Observational studies
Individual Case control studies
Case reports Cohort studies - retrospective and
prospective
Case series Intervention studies (clinical trials)
Cross sectional surveys
This classification only provided limited insight into the choice of methodology in
order to test the hypotheses set out in section 2.5.2. However, some
methodologies to test these hypotheses were clearly impractical e.g. case
control study, because of the small numbers involved and the difficulty in being
clear about the intervention. The study carried out here is basically a descriptive
epidemiological study with an analytic component (the survival analysis).
Nested within the study is a qualitative study.
Investigators in the field of cancer have the advantage in the UK (and indeed
many other parts of the world) of a long-standing registration system. This
system provides comprehensive data on individuals with cancer. Often this rich
source of data is under-utilised.
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Attempts have been used in this study to utilise health services data. However,
it will be seen that this has only been possible to a limited degree. The reasons
for this are mainly due to the poor quality of clinical coding data in England.
Hospital data in England have mainly been collected for administrative (rather
than epidemiological purposes). The introduction of the internal market in
England put great focus on data particularly costs. However during this period
clinical coding of data remained poor (116). Unlike Scotland, where record
linkage has been in place for some time, there is no such linkage between
clinical records and death certificates. Again this presents difficulties when
undertaking epidemiological research in England. This situation is likely to
become worse over the next few years with the new procedures recommended
by the General Medical Council to protect confidentiality. The principle being
introduced may limit the effectiveness of cancer registration, as it is now
required that consent is given by patients to include their data in the cancer
registry. However, the Health and Social care modernisation Bill contains a
clause (clause 65) which will act as a transitional clause allowing the collection
of data by registries without explicit consent for a limited period (personal
communication Professor D. Forman).
It was decided for the purposes of this study to make use of cancer registry
data. The limitations of this data are considered in this thesis, but it does need
to be remembered that registry data of the nature of cancer registries is the
envy of those working in many other health fields.
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6.2 Classification of Diseases
In any epidemiological study it is essential that in order to allow comparability
between different geographical areas and time periods that a standard
classification system is used. The standard classification for disease in the
world is the International Classification of Diseases, now in its 10th revision
(117).
It was Francoise Bossier de Lacroix (1706-1777) who first attempted to classify
diseases systematically. William Cullan (1710-1790) from Edinburgh produced
a classification of disease which was in common usage at the beginning of the
19-century which was published in 1785 under the title of Synopsis Nosologiae
Methodicae. However, it was probably the work of John Graunt on the London
Bills of Mortality whose work had taken place over one hundred years
beforehand which began the statistical study of disease. Despite his somewhat
crude methods, he was able to estimate a mortality rate of 36% in children
under the age of six years.
William Farr was appointed to the General Register Office at is inception in
1837, and it was he who made an extremely important contribution to the
development of a uniform international classification system. Farr, regularly
published his thoughts in the Annual Reports of the Registrar General. Because
of his interest, he was asked to prepare proposals for the first international
statistical congress, held in Brussels in 1853.(118) Farr's classification was
arranged in five groups: epidemic diseases, constitutional (general) diseases,
local diseases (according to anatomical site), developmental diseases and
83
diseases that are a direct result of violence. The congress adopted a
compromise list of 138 rubrics. This list was subsequently regularly revised in
1864, 1874, 1880, and 1886.
In 1891 the International Statistical Congress meeting in Vienna commissioned
Jacques Bertillon (1851-1922) to prepare a classification of causes of death.
The report of Bertillon's Committee was presented to a meeting of the
International Statistical Institute in Chicago in 1893. The classification itself was
based on earlier classifications of death used in the city of Paris which had
been derived from classifications from England, Germany and Switzerland.
The Bertillon classification of causes of death was subsequently used widely. In
1898 the American Public Health Association meeting in Ottawa decided to
adopt this classification for wide usage in Canada, Mexico and the United
States of America.
In August 1900 the French Government held the first International Conference
for the revision of the Bertillon or International Classification of Causes of
Death. Twenty-six countries were represented at this conference. It was
recognised that it was important to revise the classification every ten years, and
the French government was therefore requested to call a second meeting in
1910. Revisions were carried out in 1900, 1910 and 1920, under the leadership
of Bertillon. He died in 1922.
*
In 1928 the Health Organisation of The League of Nations published a study
(119) which listed the necessary changes to the 1920 International List of
Causes of Death that it felt would be required if the classification was to be
used in the tabulation of statistics and morbidity. This lead to the formation of a
"Mixed Commission" which had an equal number of representatives from the
International Statistical Institute and The Health Organisation of The League of
Nations. It was this commission that went on to draft proposals for the fourth
(1929), fifth (1938) revisions. Subsequently, sixth, seventh and eighth revisions
were published.
In 1975 the Intentional Conference for the ninth revision was convened, which
was attended by delegates from forty-six member states. This led to the
production of the ninth revision of the International Classification of Disease
(120; 121). This classification continues to be in use until the present date.
The data collected in this study was initially collected in ICD Version 9. The
subsequent publication of ICD 10 in 1990 has led to further improvements and
changes in classification of diseases internationally. The changes introduced by
ICD 10 are significant, and are discussed in some detail below.
6.3 International Classification ofDiseases for Oncology (ICD-O)
The first edition of ICD-0 (The International Classification of Diseases
Oncology)11 was published in 1976 (121), with a second edition being published
in 1990 (122)
11 t
This is International Classification of Diseases for Oncology, 1s edition Geneva, World Health
Organisation 1976. This classification represents an extension of the Chapter.2 of ICD 9 and
permits the coding of all neoplasms by topography, histology, morphology and behaviour
(malignant, benign, in situ of uncertain behaviour or metastatic).
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Since the sixth revision in 1948, neoplasms have been classified in chapter two
of the International Classification of Diseases, which was largely based on the
topographic sites of tumours, whether they were benign or malignant.
Except for a relatively small number of cancers, including lymphatic and
haemopoietic cancers, choriocarcinoma, malignant melanoma and certain
benign neoplasms there has been no coded nomenclature for histological
types.
In 1968, the International Agency for Research on cancer (IARC) was
requested by the WHO to make recommendations about the structure and
content of chapter 2 of ICD-9. This resulted in the recognition of the need for a
uniform histological classification of neoplasms. The MOTNAC coding scheme
(Manual of Tumour Nomenclature and Coding) was recommended, which had
itself been based on the Systematised Nomenclature of Pathology (SNOP).
The successor to MOTNAC became ICD-O.
6.4. Differences in ICD 10 compared to ICD 9 (for malignancies)
ICD 10 for the first time introduced an alphanumeric coding scheme. In ICD 10
the first character in the code is a letter, which is taken from the ICD chapter
heading. Thus in ICD 10, the first chapter, chapter A, is certain infectious and
parasitic diseases. The letter "C" has been assigned to malignant neoplasms
and "D" to benign neoplasms. In the second edition of ICDO the topography
section runs from "COO" to "C80".
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ICDO 2 is essentially the same as ICDO first edition. However, several new
histological types have been introduced and have been coded appropriately,
e.g. non-Hodgkin's Lymphoma takes account of the entities recognised in the
working formulation published in 1982 (123)
6.5 Differences between ICD-0 and ICD 10
Chapter 2 of the ICD is basically a topographical coding system which takes
into account the behaviour of the neoplasm. ICD-0 has one set of four
characters for topography, based on the malignant neoplasm section of ICD 10,
and the behaviour code.
There are some important differences between the structure of ICDO and ICD
10. Chapter two of the International Classification of Diseases is essentially a
topographical coding system taking into account the behaviour of the neoplasm
(malignant, benign or in situ). ICDO has one set of four characters for
topography, based on the malignant neoplasm section of ICD10, and the
behaviour code, incorporating the morphological field.
Thus, if one considers the coding for lung cancer, in ICD 10 it is possible to use
five different categories of four characters to describe all the various lung
cancer. In ICD-0 there is only one topography code for lung (C34.9). The
behaviour code is taken into account in the morphology code denoted by the
letter "M" which then also changes according to the nature of the tumour, thus
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for example in ICDO malignant neoplasm of the lung is coded 34.9, M-8010/3.
For a benign neoplasm e.g. adenoma, the code in ICD-0 would be C34.9, M-
8140/0. In ICD 10 the benign neoplasm would be coded as D40.3.
Only a small number of histological types are identified in ICD. It is therefore
impossible to distinguish between an adenocarcinoma of the lung and
squamous cell carcinoma of the lung. Both will be coded to C34.9 in ICD 10. In
ICDO, adenocarcinoma of the lung would be coded to C34.9, M-8140/3,
whereas squamous cell carcinoma would be coded C34.9, M-8070/3.
There are further differences in ICD-0 compared to ICD 10. The C81 to C96
session of ICD 10 covers malignant neoplasms relating to lymphoid
haemopoietic and related tissues. In ICD-0 these are assigned specific
morphological codes with behaviour/3 combined with the appropriate
topography code in the range COO to C80. C42 is an unused category in ICD
10 which is used in ICD-0 to designate several topographical sites within
haemopoietic and reticuloendothelial systems. Therefore this category is used
principally as topography site for most leukaemias, C42.1 (bone marrow).
These are coded C90 - 95 in ICD 10.
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6.6 Behaviour Classification
The behaviour code in ICDO 2 is similar to that in the first edition
Behaviour Code Category Term
/O D10-D36 Benign neoplasms









or presumed to be
primary
/6 C77 - C79 Malignant
neoplasms stated
or presumed to be
secondary
6.7 International Classification of Childhood Cancer (ICCC)
It is well argued that for children the classification of cancer should be based on
morphology rather than in the case of adults. Various systems for the
classification of childhood tumours have been used in the past, but Birch
Marsden (124) was used for the presentation of data in the International
Incidence of Childhood Cancer (125) been widely accepted as standard.
The revised classification for The International Classification of Childhood
Cancer was published by the International Agency Research on Cancer (IARC),
The International Association of Cancer Registries (IACR), and the International
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Society of Paediatric Oncology (SIOP). (126) This classification has been used
in this study.
The revised International Classification of Childhood Cancer (ICCC) is based
on the ICD-0 second edition.
6.8 Method of data analysis
A computerised programme is published in conjunction with the ICCC which
allows conversion of data held in ICD 9 to ICD 10, and subsequently to ICCC
classification. The data were processed using this computer programme. The
results obtained from this process are found in paragraph 2.3 and in figures 7.1
and 7.2. Some of the data necessitated hand coding. Some of the data from
Yorkshire included non-malignant codes and these were excluded (for example
certain carcinoid tumours). Similarly all CIN III were removed from the data to a
separate file, as were data on hydatidiform moles. A brief consideration of
these conditions is given in the results section. The Northern Tumour registry
did not collect data on these conditions (personal communication - L. More
Data manager, Northern Children's' Tumour Registry).
Rates were calculated using the revised population estimates from the 1991
census (127) together with mid year population estimates at district level (Office
for National Statistics, unpublished data). The census occurred in the middle of
the study period and therefore is likely to provide the most accurate source of
population data. Some rates will be shown which have been standardised to
World Standard Populations. These data have limitations because World
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Standard Populations are not available for the different sexes. However,
standardisation to the World Standard Populations (32) is undertaken to
provide a broad comparison with studies elsewhere.
Datasets were analysed using a number of software packages. These included
Microsoft Excel", Microsoft Access", and Stata"
Stata" allows Poisson exact confidence intervals to be calculated during the
standardisation process, and these results are presented. Comparisons are
described between the Northern and Yorkshire Region, but analysis has not
been undertaken below county district level. Routinely available population
statistics were used in calculating incidence and mortality rates.
6.9 Survival Analysis
J.M. Bland and D. Altman reviewed the standard method for calculating survival
(128) As they pointed out, analysis of survival data requires special techniques
to take account of the fact that 'the event of interest' i.e. death has not occurred
in all patients (censoring). Thus for example as in the adolescent cancer data
used in this study, where patients were recruited over a ten year period, one
patient who-was recruited at the beginning of the study might have died after
five years, but one recruited two years before the end of the study may be still
alive. Thus, because of censoring, the Kaplein Meier method uses a technique,
which estimates the probability of being alive at any given time. For example,
the chance of remaining alive for two months is the probability of surviving the
first month times the probability of surviving the second month, providing that
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the first month was survived. The calculations continue until the last event is
reached.
A computer is used to calculate these results. There are three assumptions in
using this method:
1. The patients that are censored have the same survival prospects of those
who continue to be followed.
2. The survival probabilities are the same for subjects recruited early and late
in the study. Thus there is a need to guard against changes in case mix over
long times periods.
3. It is assumed that the event happens at the time specified. This is not a
problem with such a definite event as death, but could be a problem if the
event were tumour recurrence. Any delay in identifying this time would bias
the survival probabilities upwards.
Normally survival probabilities are presented as a survival curve. The curve is a
step function with changes in the estimated probability corresponding to times
at which an event (in this case death) occurred. Standard errors and confidence
intervals are calculated using Greenwood's method (129).
For the Yorkshire data, survival was calculated for all cases of cancer in 10-24
year olds and the results are shown in section 7.4. A detailed description of the
analysis of survival in the Northern Region is contained in Appendix. This has
been included in the appendix, as the extent of the analysis was limited
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because of the content of the data, and also that the focus of this study was on
the experience of adolescents and young people in Yorkshire. Cross references
to the findings will be found in the main body of the text.
Survival analysis was performed on 1330 cases of adolescent cancer, aged 10
- 25, occurring in the Yorkshire region between 1985 and 1994. The data set of
1375 cases of cancer was analysed by year, and is shown in the following
table. The data suggests that there may have been under-reporting of deaths
in 1996 and 1997. The data relating to these last two years was excluded, thus
reducing the total number of subjects to 1330. The only point of interest was
deaths from any cause with a date of diagnosis acting as the time origin. For
each diagnostic group/sub-group the following variables were investigated.
• Sex (male or female), age at diagnosis (10 - 14, 15 - 19, 20 - 24).
• Period of diagnosis 1985 - 1989, or 1990 to 1994.
• Socio-economic status (Carstairs12 index based on address at diagnosis).
• County of residence (West Yorkshire, Humberside, North Yorkshire).
• Hospital of treatment (centralised or not).
• Treatment modalities (chemotherapy, radiotherapy, operative treatment,
hormone treatment).
• Place of treatment was classified as teaching, non-teaching, non-Yorkshire,
or private/GP/death certificate only registration.
Individual young people were assigned an area of residence deprivation score
as a proxy for their own or their family's socio-economic status based on the
See Annex 1 for a full discussion of the Carstairs index
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validated post code of their address at diagnosis, using the following census
variables to calculate the Carstair's index (130) These variables include:
• percentage of unemployed male residents over 16
• residents in social class 4 and 5
• non-car ownership
• over-crowding
Each address was linked to its census electoral ward by the central postcode
directory. Carstair's index was then calculated for each electoral ward (n= 536)
with data derived from the 1991 census. The Carstair's index was then
characterised into fifths into the entire study population, with scores ranging
from minus 5.69 (most affluent) to 17.63 (least affluent). Survival rates (in
years) were calculated using Kaplan-Meier methods (131)). Carstairs analyses
were not performed below county level due to the small numbers of deaths at
that level. Data were modelled using Cox's proportional hazard techniques
(132). Hazard ratios (HR) and levels of significance were then reported. Hazard
ratios are the ratio of the hazards (probability of dying at time't', having survived
at that time) for two different values of a co-variate, and can be interpreted in a
similar way to relative risks. In order to retain power, the data was grouped into
the following groupings:
all cancers
• germ cell tumours (due to the small numbers it was not possible to split these
categories to any useful effect)
• carcinomas
• leukaemias
> acute myeloid leukaemia (AML)
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Level of significance was set at 5%, with key value of 0.05 or less, indicating a
statistically significant effect. Statistical analyses were performed using
STATA.(133)
Survival curves were tested for significance using a log rank technique.(134)
Counties were used as the level of geographical analysis.
The choices which were considered for the analysis of location were as follows:
• Postcode sector
• Electoral ward
• Local authority district
• Health Authority area
• County
• Other non administrative boundary
After consideration, counties were selected as the geographical basis for
analysis. The reasons for this are considered below:
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Postcode sector: Postcoded data were not supplied as it was deemed to be
'identifiable data' and therefore because of the registries' protocols for release
of data, could not be provided. Although analysis at postcode sector would
have not been sensible due to small numbers, postcoded data would have
allowed a number of more sophisticated geographical analyses - for example it
would have enabled precise distances between residences and cancer centres
to be calculated. (N.B. the transformation of postcoded data to electoral wards
referred to in the methods section was carried out by the cancer registry).
Enumeration districts/ local authority wards/ local authority districts
The problem with these geographical areas relates to the small numbers. In the
Northern and Yorkshire Region some of the local authority districts are as small
as 40,000. This size of population is likely to yield only six cases per year
(based on an assumed incidence of 150 per million per year).
Health Authority Districts
Health Authority districts were considered, but rejected because of the
difficulties arising from the changes in health authority boundaries over this ten-
year period. Most health authority boundaries were changed once, some twice.
County Boundaries
County boundaries were felt to be the most appropriate geographical boundary,
In the Northern and Yorkshire Region, apart from the creation of unitary
authorities, these have remained relatively unchanged since 1974. It was also
important in this piece of work to ensure that the analysis was relevant to
appropriate administrative boundaries - particularly to those of health
authorities. It is health authorities that would make any investment decision
involving the future of cancer services. Health authorities in the region could be
clearly assigned to county boundaries.
Non administrative boundaries were also rejected (latitude, longitude) because
of the lack of clear relevance to organisations making investment decisions.
Time period
Smaller administrative boundaries could have been utilised had the time period
been extended. A ten-year time period was estimated to provide sufficient
cases to allow meaningful analysis in the region. In spite of this there was
concern from some of the clinicians that the period of the study was extending
over too great a length of time, and would have preferred the study to be more
contemporary than it eventually was.
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6.10 Qualitative Study of the Priorities and Experience of Young People
with Cancer
6.10.1 Background and Introduction
Qualitative research is a frequently used technique in the social sciences.
Unlike quantitative research, qualitative methods do not provide quantified
answers to research questions. The objective of qualitative research is to
identify areas of interest or concern and to give emphasis to the meanings,
experiences and views of the participants.
Holloway and Wheeler describe the following as the main features of qualitative
research. (135)
1. Qualitative research takes the 'emic' perspective, the insider's point of view.
(136)
2. Researchers immerse and involve themselves in the setting and the culture
understudy. Often qualitative research is called 'naturalistic enquiry'. (137)
3. The data have primacy; the theoretical framework is a consequence of the
data and is not derived a priori. Fetterman claims that the researcher enters
the field with an open mind, not an empty head. (138)
4. The method involves 'thick description'. Immersion in the setting may involve
portrayals of the participants' experiences, which is likely to be more than
just a report of their experiences. It may, for example include verbatim
quotations from the individuals under study. Denzin (139) describes thick
description as 'deep, dense, detailed accounts of problematic experience. It
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presents detail, context, emotion and the webs of the social relationship that
join persons to one another.'
5. The relationship between researcher and the subject of study is close, much
more so than in quantitative research.
6. There is an interaction between data collection and analysis. In qualitative
research a hypothesis is rarely established at the outset, therefore
qualitative researchers need to be constantly appraising the data and
reformulating working propositions.
The relationship between qualitative and quantitative research
Traditionally, natural science has employed quantitative methods. It has its
basis in 'positivism' - an approach to natural science based on a belief in
universal laws and insistence on objectivity and neutrality (140). It was in the
1960s that the traditional view of this scientific approach began to be
challenged, and the contrast between this and the sociological perspective
began to be more clearly defined (141). Interestingly, this was linked back to
the work earlier in the twentieth century by Mead (13). A more interpretative
paradigm has a long history, but has begun to develop currency in recent
decades.
Corner (142) warns the researcher not to be simplistic about assumptions of
social science or to overemphasise the difference between the methods. The
two approaches are merely different ways of using research pragmatically.
Sometimes techniques are combined as in a paper published by Dolan (143)
and others in which the basic study design was qualitative, but used some
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quantitative techniques to formally compare results of changes in views of
members of the public over time concerning priority setting in the health
service.
These differences may be used to advantage using a technique called
'triangulation', where several methods may be brought together in the study of
one phenomenon. Two qualitative methods will be employed in this study;
focus groups and interviews, at the same time 'thick description' will be
produced from fieldwork in the clinics. This thesis also employs a nested
strategy, where a qualitative piece of work complements a quantitative study,
both aspects of the study being essential to determine the nature of care of
adolescents with cancer.
One of the concerns in studying the experiences and aspirations of people with
cancer is that the research process could cause potential distress interfere with
the doctor patient relationship. A study undertaken by Davies and colleagues
(144) found that for both patients and carers, the interviews were viewed very
positively and were said to have helped, though in 5% of cases this was not so.
On 3% of occasions the interviewer found additional information which was
communicated to the clinical team, a change in management was said to have
occurred in less than half of these instances. Thus conducting interviews, in
general probably does no harm to the vast majority, it does need to be
*
recognised that in some instances some distress can be caused.
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6.10.2 The nature of the qualitative study with adolescents
In delivering care to young people, it is clearly important to decide what
parameters are important as well as survival. These might include such factors
as educational achievement, access to friends, access for parents, internal
environment. A further factor to consider is how these factors might be valued
differently by different aged adolescents. Parents and/or spouses/partners will
also have views on priorities and need to be taken account of in planning
services.
The published literature gives very few clues about what is important about their
care for young people with cancer. This project aims to delineate those
parameters and to gain understanding of how priorities are assigned by age.
This information will then be crucial for the development of an ongoing
monitoring tool.
The experience of young people who have been managed both inside and
outside the adolescent unit will be assessed.
6.10.3 Methodology and Research Design
The study is divided into two phases. Phase one consisting of a series of focus
groups and phase two comprising a number of structured interviews. All the
material used in the qualitative study is contained in the appendix (data
collection instruments, consent forms, information sheets). A transcript of one
of the interviews is also contained in the appendix.
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6.10.3.1. Phase I - Focus Groups
Four focus groups were held to identify issues amongst patients, young people
and professionals. Two focus groups were held with patients in the
adolescents' and children's oncology unit at St. James' Hospital, Leeds. One
focus group comprised normal healthy adolescents and took place at a
comprehensive school in North Yorkshire. The focus group for professionals not
involved in the care of adolescents with malignant disease in a cancer centre
was undertaken at a small hospital in North Yorkshire.
6.10.3.2 Phase II - In-depth interviews
After the four groups had taken place, in depth interviews were carried out in
the outpatient clinic at St James' with patients and their parents/sponsors to
identify the importance of the previously identified parameters. Interviews were
carried out with patients until themes are repeated. A mix of patients was
obtained ensuring that the views of patients treated in the adolescent oncology
unit and in other setting were included, but was limited by the patients in the
ward at the time and not all felt able to take part because of the effects of their
illness and treatment.
6.10.4 Entry Issues, ethical considerations and recruitment
Ethical approval for the study was obtained from the St. James Hospital Leeds
Ethical Committee. Patients were invited to take part in the study, the details of
which were explained to them by a senior nurse or the candidate. Most patients
approached agreed to take part, but some felt unable to participate because of
102
their illness. The sizes of the focus groups were smaller than originally planned
because of the number of patients available at any one time in the ward.
6.10.4.1 Focus Groups
Professionals: Professionals from a peripheral hospital formed a discussion
group.
Patients: Two groups of patients were recruited with appropriate consent and
took place in the inpatient unit. One patient who was unable to take part
because of her illness provided written material based on the 'prompt' questions
used in the focus groups.
Normal Adolescents: A focus group of young people not affected by serious
disease took place at a site away from the hospital, in a comprehensive school.
6.10.4.2 Phase II Recruitment
Patients and their parents were interviewed in the outpatient oncology unit
clinic. In advance of the clinic, all patients were informed of the study and when
arriving for the clinic appointment were invited to take part. Not all those who
had agreed to take part in this phase of the study were interviewed.
6.10.4.3 Consent
Phase I: The purpose of the focus groups was explained in detail to those
taking part by the use of a number of information sheets. At the outset of each
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focus group, the purpose of the study was explained and those attending were
given the opportunity to withdraw from the study if required.
Phase II: In advance of the clinic, patients were informed that the study was
taking place through an information sheet. All patients attending the clinic were
asked to give consent and the purpose of the study explained.
6.10.4.4 Data Collection and Analysis:
The candidate carried out the focus groups and interviews. Focus group
interviews were recorded using a cassette tape recorded and transcribed.
Independent evaluations of the transcripts were performed. These were
undertaken by a colleague consultant in public health who independently read
the transcripts and listed the main themes. These were then compared with the
themes identified by the thesis author.
6.10.4.5 Payment of Expenses
No payment of expenses was made
6.10.4.6 Information Sheets
Information sheets, describing the study were produced and made available at
the focus groups and at the clinic where in-depth interviews took place. The
results of the qualitative study are to be found in the results section at 7.8
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7 Results
A computerised programme is published in conjunction with the ICCC which
allows conversion of data held in ICD 9 to ICD 10, and subsequently to ICCC
classification. The data were processed using this computer programme. For
Yorkshire, of the 1,482 records which were processed, 621 were successfully
coded electronically to ICD 10, the remaining 861 were coded manually. The
data file was then re-processed to ICD 10, this produced 437 errors, 334 were
unrecognised morphology codes, 143 records were benign of unspecified type,
634 records were coded satisfactorily, and 1 record was recommended for
more specific coding. All these errors were examined individually and ICCC
codes applied individually. The results of the final coding are shown in Figure
7.1 (Yorkshire) and Figure 7.2 (Northern).
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Figure 7.1




DATA - CODING FLOW CHART.
NORTHERN
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The same process was undertaken for the data from the Northern Children's
Tumour Registry and of the 1036 records, 221 were identified as requiring
special checking, no benign codes were identified, and no records required
more specific checking. This meant that 815 records had been successfully
coded by the ICCC software, and 221 records required coding by hand. This
was therefore a noticeable difference between the Northern data set and that
from Yorkshire, and is suggestive of an improved quality in the data set in the
Northern data than compared to Yorkshire, and may suggest that specialist
tumour registries are more accurate than data from cancer registries.
7.11ncidence Rates in Northern and Yorkshire Region compared to
England and Wales
This study was undertaken on all young people between the ages of 10 and 25,
resident within the boundaries of the Northern & Yorkshire Region. During the
study period there have been a number of changes to the configuration of
Regions in the area. South Cumbria, which was formerly part of the Northern
Region, transferred to the North-West Region. South Humber Health Authority,
which had previously been part of the Yorkshire Region, transferred to Trent.
For the purposes of this study, the populations of these two areas have been
included in the study population. The population of the area under study was
6.77 million, of which 3.09 million were resident in the former Northern Region,
and 3.68 million resident in the former Yorkshire Region. The landmass
covered in this study extends from the Scottish border, including the whole of
Cumbria, and extends to the south of the river Humber. It covers an area which
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contains two Regional Centres, Leeds and Newcastle, and also other major
cities, such as Carlisle, Durham, Middlesbrough, York, Hull, Wakefield,
Huddersfield. The area includes extensive rural areas, such as those in the
northern part of Northumberland and in North Yorkshire.
Table 7.1: Population (all ages) of the Northern and Yorkshire Region - Population Estimates
1991





Table 7.2: Cases of Cancer in Adolescents and Young Adults by Region and Age group 1985 -
1994
Age group 10-14 15-19 20-24 Totals
Region
Northern 186 333 517 1036
Yorkshire 255 417 703 1375
Total 441 840 1220 2411
Of the 6.77 million residents of the extended region, 1,346,200. Were aged
between 10 and 25 (19.89%). During the 10-year period, 1985 - 1994, a total -
of 2,411 cancers were recorded (1241 in boys and 1170 in girls). Table 7.2
shows the distribution of cases by former region over this period, illustrating that
approximately 100 cases of cancer in this age group is found in the Northern
Region and around 138 new cases each year in the former Yorkshire Region.
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Table 7.3: Age specific incidence rates for all cancers per million person years (Standardised to
World Standard Populations- truncated to 10-24)
Age group 10-14 15-19 20-24 Age Standardised Totals
Male 133 186 200 173
Female 116 176 208 165
Table 7.3 shows the standardised incidence rates for all cancers in the
extended region per million population. These figures are broadly compatible
with other similar studies. The excess cancer in boys has been noted
previously. The rising trend in cancer rates by age group is also clearly
illustrated by these figures.
7.2 Numbers of Cancers in Young People in the Northern and Yorkshire
Region
Graphical and tabular presentation is given as follows of cancer by age group
as follows:
Cancer in Young People in Northern and Yorkshire Region (numbers) figure
7.3, table 7.4
Cancer in Young People in Northern and Yorkshire Region (percentages) figure
7.4 table 7.4
Cancer in Young People in Northern Region (numbers) - figure 7.5 table 7.5
Cancer in Young People in Northern Region (percentages) - figure 7.6 table 7.5
Cancer in Young People in Yorkshire Region (numbers) - figure 7.7, table 7.6
Cancer in Young People in Yorkshire Region (percentages) - figure 7.8, table
7.6
Cancer in Young People in Northern and Yorkshire Region by individual age


























































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7.4 Number arid Percentages of Malignancies by age - Northern and Yorkshire
Classification 10-14 15-19 20-24
n % n % N %
I - leukaemia 99 22.4 98 13.1 72 5.9
II - lymphoma 79 17.9 211 28.2 292 23.9
III -CNS 107 24.3 98 13.1 135 11.1
IV - sympathetic tumours 8 1.8 11 1.5 11 0.9
V - retinoblastoma 0 0.0 0 0.0 0 0.0
VI - renal 1 0.2 4 0.5 10 0.8
VII - hepatic 1 0.2 2 0.3 1 0.1
VIII - bone 46 10.4 63 8.4 34 2.8
IX - soft tissue sarcoma 34 7.7 52 6.9 52 4.3
X - germ cell 14 3.2 77 10.3 220 18.0
XI - epithelial 47 10.7 127 17.0 368 30.2
XII - other 5 1.1 6 0.8 25 2.0
Total 441 100.0 749 100.0 1220 100.0
Table 7.5 Number and Percentages of Malignancies by age - Northern
Classification 10-14 15-19 20-24
n % n % N %
I - leukaemia 44 23.7 53 16.0 32 6.2
II - lymphoma 33 17.7 83 25.0 135 26.1
III - CNS 41 22.0 43 13.0 58 11.2
IV - sympathetic tumours 4 2.2 4 1.2 6 1.2
V - retinoblastoma 0 0.0 0 0.0 0 0.0
VI - renal 1 0.5 3 0.9 5 1.0
VII - hepatic 0 0.0 1 0.3 0 0.0
VIII - bone 19 10.2 33 9.9 15 2.9
IX - soft tissue sarcoma 13 7.0 24 7.2 22 4.3
X - germ cell 8 4.3 33 9.9 102 19.7
XI - epithelial 23 12.4 53 16.0 140 27.1
XII - other 0 0.0 2 0.6 2 0.4
Total 186 100.0 332 100.0 517 100.0
111
Table 7.6 Number and Percentages of Malignancies by age - Yorkshire
Classification 10-14 15-19 20-24
n % n % N %
I - leukaemia 55 21.6 45 10.8 40 5.7
II - lymphoma 46 18.0 128 30.7 157 22.3
III - CNS 66 25.9 55 13.2 77 11.0
IV - sympathetic tumours 4 1.6 7 1.7 5 0.7
V - retinoblastoma 0 0.0 0 0.0 0 0.0
VI - renal 0 0.0 1 0.2 5 0.7
VII - hepatic 1 0.4 1 0.2 1 0.1
VIII - bone 27 10.6 30 7.2 19 2.7
IX - soft tissue sarcoma 21 8.2 28 6.7 30 4.3
X - germ cell 6 2.4 44 10.6 118 16.8
XI - epithelial 24 9.4 74 17.7 228 32.4
XII - other 5 2.0 4 1.0 23 3.3
Total 255 100.0 417 100.0 703 100.0
The patterns of malignancy in the Northern and Yorkshire Region are
remarkably similar. The increase in incidence of epithelial tumours with age is
particularly noticeable in females and is mainly due to thyroid, skin (melanoma),
breast, and cervix. A more detailed breakdown of these cancers is shown in
tables 7.8 and 7.9. and figures 7.13 and 7.14
Germ cell tumours increase with age and include mainly testicular and ovarian
tumours. The data show a decreasing incidence of CNS tumours and
leukaemias with age in contrast to a rise in incidence of lymphomas with age
group.






CNS (25.2%) Lymphoma (22.0%) Leukaemia (20.3%)
F Leukaemia (25.1%) CNS (22.6%) Lymphoma (12.8%)
15-19 M Lymphoma (30.46%) Leukaemia (14.2%) CNS (12.5%)
F Lymphoma (25.8%) Epithelial (23.3%) CNS (13.5%)
20-24 M Germ Cell (29.8%) Lymphoma (25.1%) Epithelial (15.8%)












































































































The pattern of cancer in each of the selected age-sex bands demonstrably
differs and is further summarised in table 7.7. This shows a predominance of
CNS tumours in boys aged 10-14. In the same age group girls are much more
likely to be affected by the Leukaemias. As the age increases lymphomas are
the predominant malignancy in both male and female in young people aged 15
- 19. By the age of 20 - 24 germ cell malignancies in males have become
dominant, closely followed by the lymphomas, particularly Hodgkin's Disease.
However, the dominant malignancy at that age is found in epithelial cancers,
particularly breast cancers in women. Hodgkin's Disease dominates the
lymphoma group. In males aged 20 - 24 the majority of germ cell tumours are
caused by testicular cancer.
Bone tumours, leukaemias, lymphomas, Hodgkin's Disease, germ cell tumours,
CNS tumours, carcinoma epithelial tumours: in total account for 96.5% of all
cancers (2326 during study period).
If one excludes the 20 - 24 year old age group the number of new malignancies
in the 10 - 19 year old group amounts to 1281 during the study period, making
an average of around 128 per year.
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Table 7.8 Numbers of carcinomas and other epithelial tumours in
adolescents in Northern Region (1985-1994)
10-14 15-19 20-24 all all
F M F M F M F M
adrenocortex 1 1 1 2 1
breast 15 0 15 0
bronchus 2 2 1 3 3 5
cervix 1 27 0 28 0
endocrine 1 0 1 0
genito-urinary 1 5 2 6 2
large bowel 0 0 2 2 4 3 6 5
melanoma 4 2 10 3 30 13 44 18
nasal 1 0 0 0 1
nasopharynx 0 2 2 1 2 2 4 5
salivary glands 4 0 4 0 0 8 0
skin 2 2 4 2 6 4 12 8
thyroid 3 1 8 6 12 2 23 9
tongue 2 1 2 1 4
other 1 2 0 1 1 3
total 14 9 35 19 105 33 154 61
Table 7.9 Numbers of carcinomas and other epithelial tumours in
adolescents in Yorkshire Region (1985-1994)
10-14 15-19 20-24 all all
F M F M F M F M
breast 1 15 0 16 0
bronchus 0 4 0 4
cervix 1 35 0 36 0
disseminated 2 2 5 2 7 4
genito-urinary 2 7 3 7 5
large bowel 1 0 1 1 1 7 3 8
melanoma 5 4 20 5 53 20 78 29
nasal 0 0 0 0
nasopharynx 1 1 4 1 0 2 5
salivary glands 3 0 2 3 2
skin 3 3 8 7 24 13 35 23
thyroid 1 12 -j 24 7 37 8
tongue 0 1 0 1
uppergi 1 1 0 3 0 0 1 4
other 0 1 4 1 2 5 3
total 14 10 50 25 166 61 230 96
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The pattern of malignant melanoma seen in the Northern data is repeated in
the Yorkshire data. The number of melanomas in the Yorkshire series is higher
(or lower in the Northern dataset) than would be expected if similar incidence
rates applied in both of the former regions, but this could be explained by the
different sources of data being used, implying possibly that the cancer registry
data is a more reliable source of non traditional children's tumours than the
specialist register in the former Northern Region.
Tables 7.10 and 7.11 show the complete data set by ICCC code and age.
For more detailed analysis, a number of categories are now considered, and
some smaller categories not considered further (retinoblastoma, renal, hepatic,
sympathetic nervous system and other tumours), table 7.12
Table 7.12 Number of Malignancies recorded in each group 1985-1994 by age group
Age-band Sex Bone Leukaemia Lymphoma Hodgkin's Germ cell CNS Sarcoma Epithelial All
(NHL) (soft
tissue)
10-14 M 31 50 21 29 4 62 18 19 246
10-14 F 16 49 12 11 10 44 16 28 195
15-19 M 32 58 44 76 50 53 27 44 394
15-19 F 31 40 17 74 25 48 25 83 356
20-24 M 22 38 35 109 179 75 28 95 601
20-24 F 14 39 26 112 39 57 25 271 619
10-24 M 85 146 90 214 233 190 73 158 1241
'10-24 F 61 128 55 197 74 149 66 382 1170
10-24 M&F 146 274 145 411 307 339 139 540 2411
Care must be used in interpreting differences between leukaemias and
lymphomas, as in some instances the diagnostic differences between the two




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.3 Incidence Rates of cancer by county in Northern and Yorkshire
Data are now presented, broken down by county in the Northern and Yorkshire
Region. Table 7.13 shows the crude data showing actual number of
malignancies and the % distribution by county. In terms of pure numbers (which
clearly has a bearing on workload), West Yorkshire contributes more to the data
series than any other county in the region, with the smallest contribution coming
from Northumberland.
Table 7.13 (a) Number of Malignancies recorded in each county 1985-1994
County Bone Leukaemia NHL
East Yorkshire 18 33 22
North Yorkshire 15 27 21
West Yorkshire 43 80 53
Tyneside 17 42 34
Cleveland 19 24 13
Northumberland 7 12 5
Cumbria 15 17 9
County Durham 9 34 13
Total 143 269 170
Table 7.13 (b) Number of Malignancies recorded in each county 1985-1994
County Hodgkin's Germ cell CNS
East Yorkshire 58 46 49
North Yorkshire 37 23 36
West Yorkshire 139 99 113
Tyneside 66 65 58
Cleveland 35 27 26
Northumberland 10 12 8
Cumbria 33 21 23
County Durham 33 18 27
Total 411 311 340
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Table 7.13 (c) Number of Malignancies recorded in each county 1985-1994
County Sarcoma Epithelial All
East Yorkshire 18 85 342
North Yorkshire 15 63 250
West Yorkshire 46 178 783
Tyneside 16 89 397
Cleveland 18 49 216
Northumberland 11 14 81
Cumbria 7 31 161
County Durham 7 34 181
Total 138 543 2411
Table 7.14 Age & Sex Standardised Incidence Rates (person years) [ASRs] of Malignancies





Bone 11.3 8.7-14.0 10.5 8.1-12.8
Leukaemia 21.7 18.0-25.3 19.3 16.1-22.5
Lymphoma 40.4 35.4-45.4 45.54 40.6-50.4
Hodgkin's 28.5 24.3-32.7 32.3 28.2-36.4
Germ Cell 22.5 18.7-26.2 23.2 19.7-26.7
CNS 22.8 19.8-26.6 27.3 23.5-31.3
Sarcoma 9.8 7.2-12.2 10.9 8.5-13.3
Epithelial* 34.6 30.0-39.2 45.0 40.1-49.8
All tumours* 167.5 157.3-177.7 189.8 179.7-199.8
*p<0.05
Table 7.14 shows age sex standardised rates for the region and shows an
overall significant difference between all tumours in the Northern Region
compared to Yorkshire. Significant differences are seen in the rates for
epithelial tumours. CNS tumours in the Northern region are also lower than
might be expected and could be due to ascertainment problems rather than
necessarily being a real difference.
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Table 7.15 Age & Sex Standardised Rates (person years) [ASR's] of Malignancies recorded in
each county 1985-1994 per million population for 10-24 year age group
Bone tumours
County/Region ASR 95%CL
East Yorkshire 10.6 5.6-15.4
North Yorkshire 11.2 5.5-16.9










East Yorkshire 19.1 12.6-25.6
North Yorkshire 19.9 12.4-27.4










East Yorkshire 47.6 37.2-58.1
North Yorkshire 42.8 31.8-53.8











East Yorkshire 34.6 25.7-43.6
North Yorkshire 27.6 18.7-36.4










East Yorkshire 28.0 19.7-36.0
North Yorkshire 17.0 10.0-24.0










East Yorkshire 28.6 20.6-36.7
North Yorkshire 26.9 18.1-35.8











East Yorkshire 10.6 5.7-15.5
North Yorkshire 11.2 5.5-16.8










East Yorkshire 50.5 39.8-61.4
North Yorkshire 47.8 36.0-59.6










East Yorkshire 202.7 181.2-224.3
North Yorkshire 186.8 163.7-210.0









Table 7.15 shows age/sex standardised rates by county. There are some
striking differences in the data between counties, although they do not reach
statistical significance. The results for bone tumours in Tyneside and County
Durham are surprisingly lower than might be expected. The reasons for this are
unclear. Similarly some of the data for Northumberland in respect of Hodgkin's
disease, CNS and epithelial tumours seem somewhat low and may represent
some leakage to treatment centres in adjacent Scotland. Although
arrangements do exist to transfer data between Scotland and England, such
arrangements may not be as robust as capturing the data direct in the place of
treatment.
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Tables 7.16 and 7.17 show incidence rates for males and females.
Table 7.16 Incidence Rates in Males by Age Band per million person years
Cancer Yorkshire Northern
10-14 15-19 20-24 10-14 15-19 20-24
Bone 17.8 9.0 9.6 11.3 20.4 7.8
Leukaemia 24.0 20.5 15.5 23.6 32.1 14.8
NHL 13.3 23.0 12.6 6.1 15.5 15.6
Hodgkin's 13.3 32.9 46.5 14.3 35.0 40.0
Germ Cell 1.8 24.6 73.9 2.1 19.4 68.6
CNS 32.9 24.6 29.6 25.6 22.4 30.4
Sarcoma 9.8 13.1 14.0 7.2 10.7 7.8
Epithelial 8.9 20.5 45.1 9.2 18.5 29.5
All 127.8 172.5 249.0 104.4 178.8 229.4
Although similar in most age groups, the incidence of leukaemia in Yorkshire is
lower than expected in 15-19 year age band and again this may be a real
difference or could possibly be due to improved recording of data by a specialist
tumour registry in the Northern region. Haematological malignancies are often
poorly recorded by cancer registries (145).
There are also some observed differences between the reported incidence
rates in the younger age groups in bone tumours, lower incidence in 10-14 year
olds and higher incidence in 15-19 year group.
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Table 7.17 Incidence Rates in Females by Age Band per million person years
Cancer Yorkshire Northern
10-14 15-19 20-24 10-14 15-19 20-24
Bone 6.6 16.3 4.5 9.7 12.3 7.1
Leukaemia 26.3 17.1 14.1 22.7 20.5 17.8
NHL 5.6 9.4 10.4 6.5 6.2 5.3
Hodgkln's 5.6 41.1 46.7 5.4 26.7 43.5
Germ Cell 3.7 12.0 13.4 6.5 11.3 18.6
CNS 27.2 21.4 27.4 16.2 23.6 17.8
Sarcoma 9.4 10.3 8.2 6.5 13.3 12.4
Epithelial 13.1 42.0 123.9 15.2 34.9 92.3
All 104.1 177.4 271.5 90.9 152.7 224.6
Table 7.18 Rate ratio of males to female cancer incidence
Cancer Yorkshire Northern
10-14 15-19 20-24 10-14 15-19 20-24
Bone 2.7 0.6 2.1 1.2 1.7 1.1
Leukaemia 0.9 1.2 1.1 1.0 1.6 0.8
NHL 2.4 2.4 1.2 0.9 2.5 2.9
Hodgkin's 2.4 0.8 1.0 2.6 1.3 0.9
Germ Cell 0.5 2.1 5.5 0.3 1.7 3.7
CNS 1.2 1.1 1.1 1.6 0.9 1.7
Sarcoma 1.0 1.3 1.7 1.1 0.8 0.6
Epithelial 0.7 0.5 0.4 0.6 0.5 0.3
All 1.2 1.0 0.9 1.1 1.2 1.0
Table 7.18 confirms the excess of cancer in young people seen in males,
although the excess then changes to females in the 20-24 year age group.
There is a large excess of germ cell tumours in males (reflecting the incidence
of testicular cancer). Notable differences are also seen in bone tumours.
Differences are also seen with a lower rate ratio of epithelial cancers, reflecting
increased incidence of certain tumours e.g. thyroid and skin in females,
together with the inclusion of some female specific tumours (breast, ovary and
cervix)
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7.4 Trends over time
7.4.1 Overall Trends
Trends over time have been plotted, looking at the number of individual cancers
by year over the ten year period of study. These have been plotted for all
cancers in figure 7.15. To eliminate fluctuations, three year rolling figures have
been plotted and are shown in figure 7.16 (smoothing). The overall trend is
downwards. Ideally, it would have been useful to plot age/sex standardised
rates to take account of fluctuations in population size. However, this is not
possible due to the absence of reliable population statistics for such small age
groups apart from the very accurate figures available in census years
(1981,1991, 2001).
7.4.2 Trends for individual cancers
Figures 7.17 and 7.18 show the trend data for individual cancers, unsmoothed
and smoothed figures respectively. At the end of the ten year study period, the
numbers of lymphoma had fallen. There are small, but perceptible rises in the
















































































Survival results are shown in two ways. Firstly survival curves are shown.
Survival has also been examined using Cox's proportional hazard ratio
technique (this was fully described in section 6.8)
Firstly survival curves figures 7.19 -7.23 will be considered.
7.5.1 Overall Five Year Survival
Overall survival is shown in figure 7.19
In this series, over 28.1% of young people diagnosed with cancer had died
during the ten year period and up to the time of follow up (2 years after the end
of the ten-year period). There were a total of 387 deaths during this period from
malignant causes (table 7.19).
Table 7.19 Analysis of deaths and 5 year survival rate by disease category (ICCC Category)




Leukaemia (I) 140 76 50.4 54.3
Lymphoma (II) 330 64 84.0 19.4
CNS Tumours (III) 198 61 64.1 30.8
Sympathetic system
tumours (IV)
16 12 78.3 75.0
Renal Tumours (VI) 6 2 66.6 33.3
Hepatic Tumours (VII) 3 3 0 100.0
Bone Tumours (VIII) 76 39 55.7 51.3
Soft tissue sarcomas (IX) 79 26 64.2 32.9
Germ cell tumours (X) 168 28 85.0 16.7
Carcinomas (XI) 326 71 87.3 21.8
Unspecified tumours (XII) 33 5 77.2 15.2
Total 1375 387 72.4 28.1
7.5.2 Five year survival by age band
Though not reaching statistical significance (p=.81), greater survival is seen in













be a reflection of case mix, with more of the older group having proportionately
fewer life threatening cancers, (figure 7.20)
7.5.3 Survival by Sex
Figure 7.21 suggests that five year survival in females is greater than males
(76.4% and 74.2% respectively) (on the border of statistical significance,
p=0.29) - this may be related to case mix. This is repeated in the Northern data,
which does reach the level of statistical significance (p=0.02) in the comparison
of the survival curves using the log rank test.
7.5.4 Survival by County ofResidence
Figure 7.22 shows apparently different five year survival in the three main
counties in the region. North Yorkshire (74.3%; county 37), Humberside
(70.4%; county 28) and West Yorkshire (77.4%; county 8). Apparently better
survival is demonstrated in West Yorkshire, followed by North Yorkshire and
Fiumberside. This difference reaches statistical significance (p=0.02). A similar
difference is seen in the Northern region data with an apparently worse survival
rate in one of the counties (county Durham).
7.5.5 Survival by Hospital of Treatment
The categories shown in figure 7.23 are as follows:
Hospital category 1 = large teaching hospital - in practice Leeds or Hull
Hospital category 2 = large district hospital (more than 150 beds)
Hospital category 3 = small hospital (less than 150 beds)














































































































Outcomes in small hospital appear best (five year survival = 81.7%), with
hospitals in categories 3 having best outcome and 4 (five year survival =
69.1%) having poorest outcome, this could be due to casemix. A large
proportion of hospitals in category 4 were London Teaching Hospitals. This
issue is considered in some depth in the discussion. (p=0.42). In the Northern
Region data, survival was notably poorer in those patients treated in the cancer
centres, this is almost certainly explained by casemix which was not accounted
for in the analysis.
7.5.6 Casemix of treatment units in Yorkshire
Figures 7.24 - 7.27 shows the differential casemix in the units of Yorkshire.
Figure 7.25 illustrates the % of malignancies treated in the various units. It
shows, as expected, that a higher % of patients with CNS malignancies are
treated in major centres (neurosurgery does not occur outside major centres).
The figures suggest a disproportionately low level of teaching hospital
involvement in the treatment of lymphomas.
7.5.7 Survival by Year of Diagnosis
Figure 7.28 shows a marginally significant improvement in five year survival
over the decade (p=0.092) 76.4% compared to 74.0%. Such an improvement
over time was not noted in the Northern data.
7.5.8 Survival by diagnostic group







































































































































































































For leukaemia there were 140 cases, and 76 deaths. The vast majority of
these deaths occurred in patients who had received treatment in a teaching








































Table 7.20 Cases of and deaths from leukaemia by setting
Main source of care Deaths Cases % deaths in
each setting
Teaching Hospital 46 101 60.5
Large non-teaching hospital 15 27 19.7
Small non-teaching hospital 4 4 5.3
Non Yorkshire hospital 1 8 1.3
Private hospital 0 0 0
Death certificate registration 0 0 0
Unknown 0 0 0
Total 76 140 100
7.5.8.2 Lymphoma Survival
For lymphoma there were 331 cases and 64 deaths as shown in table 7.21.
In this case more deaths occurred in patients treated in large district hospital,
reflecting the place of treatment of most patients with lymphoma. The survival
curve is shown in figure 7.30
Table 7.21 Cases of and deaths from lymphoma by setting
Main source of care Deaths Cases % deaths
in each
setting
Teaching Hospital 27 127 42.2
Large non-teaching hospital 33 173 51.6
Small non-teaching hospital 1 17 1.6
Non Yorkshire hospital 1 9 1.6
Private hospital 2 5 3.1
Death certificate registration 0 0 0
Unknown 0 0 0
Total 64 331 100
7.5.8.3 CNS Tumours Survival
For CNS tumours there were 198 cases and 61 deaths. Table 7.22 shows how












































Table 7.22 Cases of and deaths from CNS Tumours by setting
Main source of care Deaths Cases % deaths
in each
Teaching Hospital 39 135
setting
63.9
Large non-teaching hospital 18 50 29.5
Small non-teaching hospital 0 0 0
Non Yorkshire hospital 2 11 3.3
Private hospital 0 0 0
Death certificate registration 1 1 1.6
Unknown 1 1 1.6
Total 61 198 100
7.5.8.4 Sympathetic Tumours Survival
For sympathetic nervous system tumours there were
Table 7.23 shows how these deaths were distributed
Survival curves are shown in figure 7.32
Table 7.23 Cases of and deaths from sympathetic tumours by setting
Main source of care Deaths Cases % deaths
in each
institution
Teaching Hospital 7 10 58.3
Large non-teaching hospital 4 5 33.3
Small non-teaching hospital 0 0 0
Non Yorkshire hospital 1 1 8.3
Private hospital 0 0 0
Death certificate registration 0 0 0
Unknown 0 0 0
Total 12 16 100
Table 7.24 shows how
Survival curves are shown
16 cases and 12 deaths,
by place of treatment.
7.5.8.5 Renal Tumours Survival
For renal tumours there were 6 cases and 2 deaths,
these deaths were distributed by place of treatment,
in figure 7.33













































































Main source of care Deaths Cases % deaths
in each
setting
Teaching Hospital 1 4 50
Large non-teaching hospital 1 2 50
Small non-teaching hospital 0 0 0
Non Yorkshire hospital 0 0 0
Private hospital 0 0 0
Death certificate registration 0 0 0
Unknown 0 0 0
Total 2 6 100
7.5.8.6 Hepatic Tumours Survival
For hepatic tumours there were 3 cases and 3 deaths confirming the poor
prognosis for hepatic malignancy in this age group. Table 7.25 shows how
these deaths were distributed by place of treatment. Survival curves are shown
in figure 7.34
Table 7.25 Cases of and deaths from hepatic tumours by setting
Main source of care Deaths Cases % deaths
in each
Teaching Hospital 1 1
setting
33.3
Large non-teaching hospital 1 1 33.3
Small non-teaching hospital 0 0 0
Non Yorkshire hospital 1 1 33.3
Private hospital 0 0 0
Death certificate registration 0 0 0
Unknown 0 0 0
Total
. 3 3 100
7.5.8.7 Bone Tumours Survival
For bone tumours there were 76 cases and 39 deaths. Table 7.26 shows how















Table 7.26 Cases of and deaths from bone tumours by setting
Main source of care Deaths Cases % deaths
in each
setting
Teaching Hospital 16 36 41.0
Large non-teaching hospital 15 23 38.5
Small non-teaching hospital 0 2 0
Non Yorkshire hospital 0 15 0
Private hospital 0 0 0
Death certificate registration 0 0 0
Unknown 0 0 0
Total 31 76 100
7.5.8.8 Soft Tissue Sarcomas Survival
For soft tissue sarcomas there were 79 cases and 26 deaths. Table 7.27 shows
how these deaths were distributed by place of treatment. Survival curves are
shown in figure 7.36
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Table 7.27 Cases of and deaths from soft tissue sarcomas by setting
Main source of care Deaths Cases % deaths
in each
setting
Teaching Hospital 11 36 42.3
Large non-teaching hospital 11 31 42.3
Small non-teaching hospital 2 6 7.7
Non Yorkshire hospital 2 5 7.7
Private hospital 0 1 0
Death certificate registration 0 0 0
Unknown 0 0 0
Total 26 79 100
7.5.8.9 Germ Cell Tumours Survival
For germ cell tumours there were 168 cases and 28 deaths. Table 7.28 shows
how these deaths were distributed by place of treatment. Survival curves are
shown in figure 7.37
Table 7.28 Cases of and deaths from germ cell tumours by setting
Main source of care Deaths Cases % deaths
in each
setting
Teaching Hospital 3 52 10.7
Large non-teaching hospital 21 88 75.0
Small non-teaching hospital 2 16 7.1
Non Yorkshire hospital 2 5 7.1
Private hospital 0 7 0
Death certificate registration 0 0 0
Unknown 0 0 0








































































For carcinomas there were 326 cases and 28 deaths. Table 7.29 shows how
these deaths were distributed by place of treatment. Survival curves are shown
in figure 7.38
Table 7.29 Cases of and deaths from carcinomas by setting
Main source of care Deaths Cases % deaths
in each
setting
Teaching Hospital 22 93 31.0
Large non-teaching hospital 37 173 52.1
Small non-teaching hospital 6 23 8.5
Non Yorkshire hospital 5 9 7.0
Private hospital 1 13 1.4
Death certificate registration 0 0 0
Unknown 0 13 0
Total 71 326 100
7.5.8.11 Other Tumours Survival
For other tumours there were 32 cases and 6 deaths. Table 7.30 shows how
these deaths were distributed by place of treatment. Survival curves are shown
in figure 7.39
Table 7.30 Cases and deaths from other tumours by setting
Main source of care Deaths Cases % deaths
in each
setting
Teaching Hospital 2 12 33.3
Large non-teaching hospital 4 15 66.7
Small non-teaching hospital 0 4 0
Non Yorkshire hospital 0 0 0
Private hospital 0 1 0
Death certificate registration 0 0 0
Unknown 0 0 0














7.5.8.12 Survival by county by main diagnosis
A survival curve has already been shown for all groups of cancers by county
(figure 7.22). The following curves (figures 7.40 - 44) show survival for each
main cancer group. The differences which are demonstrated do not reach
statistical significance (p values are shown on each figure from log rank tests).
[County 8 = West Yorkshire; County 28 = Humberside; County 37 = North
Yorkshire],
The patterns are broadly similar showing best survival in leukaemia in West
Yorkshire, with West Yorkshire showing consistently better survival with the
exception of carcinomas. Humberside shows consistently poor survival,
























































Further examination of the data was performed to determine if it could be
demonstrated whether survival had improved over the ten-year period,
information requested by consultant staff in Humberside. The following survival
curves suggest that survival has if anything got worse, although the changes do
not reach statistical significance. Figure 7.45 shows the overall survival curve
from 1985-1994. Figure 7.46 shows the survival curve for the first five years of
this time period and 7.47 shows the latter (1990-1994). The Flumberside line in
figure 7.47 is further away from those of North and West Yorkshire suggesting
that survival has worsened during this time.
7.5.8.13 Population density
The following table (7.31) shows that population density does not explain the
demonstrated differences between survival across Yorkshire.
Table 7.31 Trends in survival by person-based population density and diagnostic group.
Population density Test of
(1=low, 2=medium, 3=high) trend
% of cases
that died
Diagnostic Group Cases Low Medium High P-value
Ail cancers 1097 23.8 25.9 29.4 0.14
Leukaemias 84 54.6 77.8 57.1 0.35
Hodgkin's disease (HD) 206 12.1 12.9 12.7 0.99
Non-Hodgkin's lymphoma (NHL) 70 28.6 20.0 40.9 0.26
Central nervous system (CNS) tumours 129 29.6 27.9 42.9 0.17
Germ cell tumours 162 13.6 19.3 17.4 0.66
Carcinomas 295 15.9 21.1 23.2 0.44
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Figure 7.45 Overall Survival estimates (1985-1994)
Kaplan-Meier survival estimates, by county
analysis time
Figure 7.46 Survival estimates (1989-1994)
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7.5.9 Survival Results - Hazards Ratio Method
Table 7.32 Frequency of cancers and number of deaths by diagnostic group
Diagnostic group cases deaths %
All cancers 1330 358 26.9
Leukaemias 136 72 52.9
Lymphomas
Hodgkin's Lymphoma 224 27 12.1
Non-Hodgkin's Lymphoma 95 29 30.5
CNS Tumours 192 57 29.7
Germ Cell Tumours 167 28 16.8
Carcinomas 310 64 20.6
Of the 1375 in the original data set, 45 patients were omitted because of the
potential unreliable completion of death data for the years 1996 - 1997. This
represented 0.032% of cases (table 7.29).
Table 7.33 is the summary table of results from multi-variate analysis of survival
with table 7.34 showing the numbers of events in each category (table 7.33a
shows the 95% confidence limits of the figures shown in table 7.33) Within this
series, 358 deaths were recorded. The total number of person years of survival
to censor dates was 8,400.7 years. Length of follow-up arranged from 0 days
to 9.9 years. Kaplan-Meier survival curves are shown for all categories of
tumour, as well as the revised groupings.
7.5.9.1 Results - General observations
*
No significant difference between males and females were identified. Young
female adults with carcinomas, leukaemias, and all cancers, appeared to do

























































































































































































































































































































































































































































































































































































































































































































































































































































































with germ cell tumours, Hodgkin's Disease and non-Hodgkin's Disease. Some
of the differences shown in the hazard ratio calculations are quite large and
plausibility of the size of these differences must be raised. Although technically
statistically significant, some of the numbers in the subgroups are relatively
small and therefore these observations should be interpreted with caution.
7.5.9.2 Age at Diagnosis
The data suggested that the younger the patient with cancer the more likely
they were to survive, although the differences were not significant overall.
Significant improvements in survival were observed in the 10 - 14 year age
group for leukaemia's and CNS tumours, and in the 15 - 19 year olds with germ
cell tumours. It can be seen that the ratio of the incidence of ALLAML changes
from a predominance of ALL in younger age groups to that of AML in 20-24
year olds.
7.5.9.3 Period ofDiagnosis
Significant improvements in survival have been observed during the second 5-
year period of study. The improvements were significant in non-Hodgkin's
Disease.
7.5:9.4 County ofResidence
The most striking feature of the data is the consistent increased risk of death in
Humberside and North Yorkshire compared with West Yorkshire across most
diagnostic groups. This is not explained by socio-economic status or population
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density. The overall significant increase of death of 54% in Humberside and
41% in North Yorkshire is reflected most strongly in adolescents with
leukaemia: here, the risk of death in North Yorkshire and Humberside is almost
twice as great. Some larger differences are seen in ALL.
7.5.9.5 Socio-economic disadvantage
For socio-economic status and survival a non-significant dose response was
present in the carcinoma group and came close to, but did not reach, statistical
significance. Those in the least affluent groups were at least twice as likely to
die compared to the most affluent. Numbers of deaths were insufficient to sub-
categorise this heterogeneous group of malignancies.
The figure below shows the distribution of scores from the Carstairs index for
each of the main county areas. It suggests that there are a greater proportion of
deprived wards in West Yorkshire than in either North or East Yorkshire. This
again suggests that the observed differences are not due to social
disadvantage.
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Figure 7.48 Illustrates histograms showing the frequency Carstairs scores
(measures of disadvantage) in wards in each of the counties under
consideration





















7.5.9.6 Size of treating hospital and Treatment
The picture was mixed. No significant differences were observed. The
difficulties in labelling a particular treatment episode according to hospital size
means interpretation of these data are problematic.
Receiving chemotherapy in leukaemia is an indicator of significant survival
benefit especially in AML. Similarly, treatment of germ cell tumours by surgery
produces a similar effect.
7.5.9.7 Population Density
The data suggests that greater population density is associated with poorer
survival.
7.5.9.8 Analysis with the 10-14 year olds removed
As the service issue is predominantly about the health care of the older age
groups in this study (i.e. 15 - 24), then in order to look in more detail at these
age groups the effect of the age group 10-14 had been removed. These
analyses are shown in tables 7.35 --7.36. (Confidence limits are shown in table
7.35a). This then exacerbates the differences especially in survival of AML and


















































































































































































































































































































































































































































































































































































































































































































































































7.6 Individual cancer requiring special comment
7.6.1 Cancer of the cervix
The distribution of CIN III by age is shown in table 7.37 and illustrated in figure
7.49 and demonstrates the rapid rise in incidence with age.
Table 7.37 Number of Cases of CIN III recorded 1985-1994 in Yorkshire














In the Yorkshire region, between 1985 1994, there were a total of 88
hydatidiform moles, with the majority occurring at the age of 20 years.
Table 7.38 shows the age distribution of patients with the tumour.
Table 7.38 Age distribution of cases of hydatidiform mole in Yorkshire 1985 - 1994
















The following table illustrates where patients aged 10-24 years old, during the
study period were treated in both the Northern and Yorkshire part of the region.




Age band 10-14 15-19 20-24 total 10-14 15-19 20-24 total
Major cancer
centre
n 163 211 266 640 212 244 402 858
% 87.63 63.36 51.45 61.78 83.14 58.51 57.18 62.40
Other cancer
centre
n 16 45 74 135 17 62 110 189
% 8.60 13.51 14.31 13.03 6.67 14.87 15.65 13.75
Other hospital n 7 77 177 261 26 111 191 328
% 3.76 23.12 34.24 25.19 10.20 26.62 27.17 23.85
Total n 186 333 517 1036 255 417 703 1375
% 100 100 100 100 100 100 100 100
7.8 Results of the Qualitative Study
7.8.1 Healthy adolescent focus group
This focus group took place at a school some 50 miles away from the nearest
cancer centre. There were four males and four females in the group. All were
Caucasian. All members of the group had 10 GCSEs, all claimed to be fit and
well. Only two members of the group had never been admitted to hospital. The
commonest reason for hospital admission was trauma. Most of the group was
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from social class HIM and above, only one child in the group was from below
social class III. The discussion lasted 80 minutes, and was fitted into a standard
teaching period. The group displayed a good understanding of cancer, this may
have been helped by the fact that a pupil in the school had recently been
diagnosed with cancer.
When asked to prioritise a list of issues deemed to be important, these were
ranked and are shown in the box below:
Box 7.1 Rankings of criteria deemed to be important in healthy adolescents
1. Getting better
2. Being managed in a specialist centre
3. Being accessible for parents
4. Being accessible for friends
5. Being close to home
6. Keeping up with education
Some of the quotes from pupils are shown below in boxes:
"Well I was stuck in this little room because was the oldest in a children's ward.
It was last year and they wouldn't put me in an adult ward and I had nothing to
do "
There were lots of little kids running round!
"(adult wards)., are just full of old men having hips replaced and stuff"
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There was strong support for being looked after in an adolescent cancer centre,
being in a centre of excellence; being in an appropriate environment was felt to
be very important.
You're with people who've got the same problem as you.
You can discuss it with them
"cancer is more focussed and ifyou've got cancer you're in a specialist centre
anyway, so you're going to have more ofyour own age and then you would be
in a ward with your own age"
Those who had been admitted to hospital felt that being looked after in a
dedicated environment for teenagers was very important. There were examples
of dissatisfaction of care in both paediatric and adult wards.
(Where you would like to be looked after)....Not like a hospital, not like wards
with loads of beds in . Just like the surroundings similar to what you normally
have.
7.8.2 Results of the focus group ofprofessionals in a setting away from the cancer centre
*
A focus group lasting for one hour was held in a unit away from the cancer
centre. The participants were three consultant paediatricians, one of whom had
special experience in the management of cancer. The main conclusions from
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the focus group was that there was strong support for the creation of an
adolescent cancer centre as long as this was not funded at the expense of
peripheral units and would not compromise the current shared care
arrangements which were felt to be working very well.
The other themes were as follows:
Access - distance was not felt to be a problem:
What you tend to find is that the further you get away from this hospital, the less
concerned families become about travelling vast differences. I'm thinking of one
family from K****, who were just as happy to drive to Leeds as they were to
drive here. There isn't a problem with transport unless the family is poverty
stricken and transportless. There are some on Catterick Garrison, and that is a
problem.
Importance of a centre of expertise
. ..these children have three or four drips up, they need a nurse, more than one
nurse, and they need a fully trained nurse. A frightening number of nurses here
have not got the expertise, neither have the SHOs I think it would be
unreasonable to expect our GP trainees to do it.
..and contact with other teenagers;
they get a lot of support from other teenagers and children in the unit and they
grow older with them. OK they die, some of them, but they can discuss that and
they're not suddenly left in limbo when there are other major changes occurring,
like leaving school or going on to college...
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maintaining education and 'being seen to be normal' was felt to be important;
they don't want to miss school at this stage. They don't want to be different
Agreeing an appropriate level of shared care was felt to be important;
I think with teenagers coming up for exams, they can come for a review, have a
finger prick and be back at school by ten. They go down to Leeds and it's the
whole morning and you know we can always negotiate....
...I think whatever can be done, should be done on (this) site, the none expert
stuff, review of blood counts, occasional treating of febrile neutropaenia,
occasional delivery of chemotherapy as laid down by a recipe from the centre
7.8.3 Results of the focus group and interviews among adolescents with cancer
A total of fourteen young patients were interviewed. Two groups of three were
run and eight further adolescents were interviewed individually. The interviews
lasted between 45 minutes and 1 hour each. Interviewing in the outpatient
department proved much the most successful approach. Many adolescents in
the ward were too ill to participate in the focus groups. Individual interviews
proved adequate as in the groups that were run, the small numbers involved in
each meant there was little opportunity to develop themes in the way that can -
normally be expected from focus groups.
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The demographic details of the patients are shown in table 7.40 below, and
where they were treated (table 7.41):
Table 7.40 Demographic profile of focus group participants
Patient Age Sex Diagnosis GCSE Father's Mother's Ethnic
No







2 18 Female Ewing's Sarcoma 8 Metal worker Carer Caucasian
3 19 Male Rhabdomyosarcoma 9 None Hoffman
presser
Caucasian
4 18 Male Rhabdomyosarcoma 7 Mechanic Housewife Asian
5 16 Male Osteosarcoma 0 None None Asian
6 15 Female PNETIJ 0 Opera singer Singing
teacher
Caucasian
7 20 Male Osteosarcoma 11 Lecturer Teacher Caucasian
8 17 Female Osteosarcoma 6 Retired Housewife Caucasian
9 16 Male Hodgkin's Disease 9 Fireman Secretary Caucasian
10 13 Male Soft tissue sarcoma 0 Trainer Nurse Caucasian
11 15 Male ALL 0 Unemployed Unemployed Caucasian
12 16 Male ALL 0 - Unemployed Caucasian
13 16 Female ALL 0 Storeman Care worker Caucasian
14 18 Male Hodgkin's Disease 8 Factory
manager
Staff nurse Caucasian








2 St James, Leeds Airedale
3 Leeds General St James, Leeds
4 Bradford Royal Cookridge St James, Leeds
5 Birmingham St James, Leeds
6 Bradford Royal Leeds General St James, Leeds
7 York Birmingham St James, Leeds
8 St James, Leeds Birmingham
9 Bradford Royal St James, Leeds
10 Hull Royal St James, Leeds
11 St James, Leeds
12 St James, Leeds Leeds General
13 St James, Leeds




The main themes to emerge were as follows:
1. There were recurrent problems of delays in diagnosis. This did not appear to
be the case with the leukaemic patients who by and large experienced
speedy diagnosis and referral for treatment. Some adolescents reported
prolonged delays in diagnosis with a minimum period of three weeks and in
one case up to seven months. Presentations were generally atypical, and in
some instances patients were only admitted after repeated presentation at
an accident and emergency department. There were some significant
delays on occasions within general hospitals as well as in primary care.
There was an underlying feeling that there had been undue delay in their
diagnoses. In some cases this had led to considerable resentment towards
the referring hospitals and their doctors.
I was on children's ward and every single doctor in d****** Hospital saw me,
every one. I had about five trainees as well. I had about seven main doctors,
who came to se me, none of them knew what it was and then they set the
trainees on to me as well!
I saw my doctor at home and he said it was just a swelling. I went again and
they sent me home again.
2. Once the patients were in contact with the adolescent ward, the care was
deemed to be excellent. They felt that they wanted to be told straight as had
always occurred in the specialist unit.
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Its got a lot of facilities and this is the best place to be really. Ifyou had to pick
somewhere, I'd pick here.
The staff in this unit are really nice.
3. Education ranked persistently highly among the patients
4. As well as what was perceived to be high quality treatment, being in close
proximity to other young people with similar conditions was felt to be of great
importance. It was felt to be well worth travelling for specialist treatment
On an adult ward I didn't really like it and I kept jumping from ward to ward. I
was on an adult ward and this patient who was next to me, was like 25 and
then I moved down the ward and I don't think that there was anyone under 50
in the ward
I think this place [adolescent unit] is very good. Its miles better than the
children's ward, because they specialise in your type of thing, so you're not
alone and everybody there has got what you've got so It gives you a bit of
comfort that you can talk to other people who understand, instead of someone
who's got a nasty little cold next to you, you've got such a big
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Box 7.2 Rankings of criteria deemed to be important in adolescents with cancer
1. Getting better
2. Being managed in a specialist centre
3. Keeping up with education
4. Being accessible for parents
5. Being accessible for friends
6. Being close to home
One of the adolescents raised the issue of being punished.
../ have been on the adult ward many times. I didn't like it at all, knowing what
the comparison between the adolescent and adult ward. On the adult ward, it
felt like I was in solitude or being punished for something I haven't done.
7.8.4 Results of the focus group and interviews among adolescents with leukaemias
Clinical advice was given which suggested that some specific interviews
targeted at adolescents with leukaemia would be of value. This indeed proved
to be the case. Different themes did emerge, particularly in respect of the early
management of the patients. In particular, diagnosis and referral appeared
more straightforward and rapid in-patients with leukaemia than with patients
with solid tumours. Of the three patients with leukaemia who were interviewed,
all had been managed in the main regional centre and had been referred there
rapidly.
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7.8.5 Results of discussions with parents ofpatients
Parents were prepared to put up with considerable inconvenience to be close to
their children. In some cases this involved staying away from home for very
long periods of time which had adverse effects on other family members.
Parents were aware that treatment in a number of cases away from the centre
had been sub-optimal. Parents were universally satisfied with the treatment in
the centre. Some patients did comment on extending the concept of an
adolescent inpatient unit to outpatient facilities.
7.8.5 Conclusions
The qualitative work revealed considerable sub-optimal practice within referring
units and in some cases from primary care, this did not appear to apply to
patients with leukaemia. There were delays in initiating treatment and in
identifying the correct diagnosis. There was no criticism of the treatment in the
centre by parents or their children. The perceived expertise in the centre was
felt to be very important and the adolescents themselves felt that the staff were
more attuned to dealing with the needs of adolescents which were different
from children and adults. The facilities (computers, televisions) were an
important adjunct in their care, but the overall benefit was the quality of the staff
in the centralised unit.
Qualitative work does not aim to identify the size of the particular problem or
concern but to identify themes. Care also needs to be given to interpreting
information from desperately ill patients who inevitably will want to have the
maximum faith in what may be their only place of hope. There may also be
inappropriate levels of blame cast against others involved in the young peoples'
care in an effort to find some reason for their predicament.
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The conclusions that can be drawn from the qualitative work are that there were
no real disadvantages of centralised care identified and indeed that there were
felt to be very many advantages in bringing the care together as is currently the
case in the small unit in Leeds. It was only possible to identify some relatively
minor features of the adolescents care that might be improved (food and
temperature of the wards), although one young man thought security should be
increased because computer games kept being stolen.
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8 Service Issues
8.1 The Newcastle Adolescent Cancer Unit
The Newcastle Adolescent cancer centre has been in operation for over one
year. On two separate occasions the unit was asked to provide data on its
experience to date together with a personal approach to the head of the unit.
Unfortunately, no data were made available.
8.2 Treating Consultants
The data from the cancer registry enabled the number of patients in the case
series treated by any one consultant to be analysed.
Table 8.1











An analysis of the number of cases of 10 - 24 cases treated by individual
consultants over the study period was analysed. This showed that a total of
491 consultants were engaged in the case of adolescents in this age range with
cancer (table 8.1). In this ten-year period only 25 consultants (12%) treated
more than ten patients. Over 75% dealt with only one patient in ten years with
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cancer With the exception of one neurosurgeon, all the consultants treating
more than ten patients were based in the cancer centre. This raises the
question of volume related outcomes which have been alluded to in other
studies. It also does need to be emphasised that over this period there have
been considerable changes in clinical practice, and, for example, in
Humberside particularly many of the consultants previously involved with the
clinical care of adolescents have retired.
There are no data available at the present time to make comparisons about the
current service. Should this study be used as evidence for centralisation of all
adolescent cancer care? The arguments that services away from the centre
have changed are powerful ones. However, the difficulty in demonstrating that
the current services have very different outcomes to that previously
demonstrated is that to do so will involve data collection for a further 5-10
years before it is possible to demonstrate any differences. Can services be
allowed to wait that long to change?
What can be demonstrated is the difference in the qualitative aspects of care.
Qualitative work suggests that teenagers gain benefit from being treated with
their peers and are prepared to travel for treatment, so it may be that a more
centralised model of care has benefits which are qualitative as well as
improving survival:
This study challenges the current situation where teenagers are managed in a
range of small units. In the absence of evidence to suggest that treatment in
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small units is beneficial then the only conclusion that can be drawn is one that
supports the development of centralised teenage cancer units.
8.3 The Leeds Adolescent Cancer Unit
The Leeds adolescent unit, operating from a small bay in a ward in St James'
Hospital had found that referrals had increased by 116% since the small
dedicated facility had been established. This had led to an increase in the drug
costs of over £100,000. This is shown in more detail in tables 9.10 -9.11
The proposals for the setting up of an adolescent cancer centre in Leeds




The financial implications of reconfiguring the management of adolescent
cancer services are very significant. A proposal from the Leeds Teaching
Hospitals Trust to establish an adolescent cancer unit includes a cost of
£1,109,180 14. The costs of this development are made up as shown in the
following table:
Table 9.1 Breakdown of proposed costs for Leeds Adolescent Unit
Item Cost (£)
Medical Staff 60,000
Nursing Staff (inpatient) 254,080
Nursing Staff (outpatient) 63,700
Professions Allied to Medicine 42,000
Psychologist 12,900
Administrative costs 18,000
#Other costs (blood, drugs, radiology, 612,500
pathology)
Start up costs (1st Year only beds, equipment) 28,000
Domestic and catering costs 60,000
Total costs 1,109,180
Source: Leeds Teaching Hospitals Trust
#The other costs are further broken down as follows:
14
Leeds Teaching Hospitals NHS Trust. The Business Case for Adolescent Cancer Services. November
1999
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Table 9.2 Other costs (blood, drugs, radiology, pathology)
Item Cost (£)
Blood products 144,000




Source: Leeds Teaching Hospitals Trust
9.2 The experience in Leeds
A small teenage cancer trust unit opened in Leeds on 1st June 1998. The
original aim was to improve the facilities available in Leeds for teenagers
already receiving treatment in the Leeds Cancer Centre. The experience since
the opening of this unit has been that there has been a considerable increase in
referrals from outside Leeds.
9.3 Health Service Data
Data on all hospital episodes are collected. These data extend to the number
of patients, the number of inpatient and day case episodes. These data are
collated routinely by hospital information systems. These data are then
available to health authorities in order for them to perform their commissioning
functions.
Health Service data were collected for adolescents treated between April 1997 -
March 1998 from the six health authorities in Yorkshire. This includes all the
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data on the patients admitted to the various hospitals but only extends to data
on residents from Yorkshire. Thus adolescents treated in the major cancer
centres in Yorkshire who are not Yorkshire residents will not be included in the
data. Conversely, data on residents of Yorkshire treated outside Yorkshire will
be included in the data.
The purpose of examining these data is to assess to what extent there is
potential to further centralising the treatment of adolescents and also to attempt
to suggest what level of resource might be required to effect such a change in
the pattern of clinical activity.
A major weakness in Health Service data is the relative paucity of data on
outpatients. Although numbers of outpatient attendances are recorded, there is
at the present time no systematic attempt to record either presenting symptoms
or presenting diagnosis.
These data do not anonymise hospital of treatment. It is therefore possible to
identify where patients received treatment in the major cancer centre i.e. Leeds.
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9.4 Results of the Analysis ofHealth Service Data
Tables 9.3 - 9.5 show the numbers of patients, the number of day case
episodes and the number of inpatient treatments between April 1997 and
March 1998 in all locations for Yorkshire residents. These data are presented
as percentages in tables 9.4 - 9.6.
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Table 9.3 Total patients treated in Leeds Cancer Centre and non Leeds
locations (April 1997-March 1998)







Leukaemias (C90-95) 64 40 11 2 14 8
Lymphomas (C81-85) 10 3 18 28 21 86
Hodgkin's (C81) 6 2 8 23 8 61
Non-Hodgkin's (C82-85) 4 1 10 5 13 25
CNS Tumours (C71-72) 33 3 3 4 11 8
Skin Tumours (C43-44) 1 1 1 5 4 7
Bone Tumours (C40-41) 38 6 48 2 1 1
All Tumours (C00-97) 186 61 126 45 73 153
Table 9.4 Day case episodes treated in Leeds Cancer Centre and non Leeds
locations (April 1997-March 1998)







Leukaemias (C90-95) 97 20 15 5 48 5
Lymphomas (C81-85) 9 0 13 44 47 61
Hodgkin's (C81) 4 0 3 44 14 47
Non-Hodgkin's (C82-85) 5 0 10 0 33 15
CNS Tumours (C71-72) 17 0 2 0 4 0
Skin Tumours (C43-44) 0 1 1 4 3 3
Bone Tumours (C40-41) 9 1 22 0 0 0
All Tumours (C00-97) 151 25 58 57 107 84
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Table 9.5 In patient episodes treated in Leeds Cancer Centre and non Leeds
locations (April 1997-March 1998)







Leukaemias (C90-95) 68 20 19 2 24 5
Lymphomas (C81-85) 27 3 8 17 21 26
Hodgkin's (C81) 23 2 7 12 12 14
Non-Hodgkin's (C82-85) 4 1 1 5 9 12
CNS Tumours (C71-72) 18 3 2 3 7 8
Skin Tumours (C43-44) 1 0 0 1 1 3
Bone Tumours (C40-41) 42 5 48 3 1 1
All Tumours (C00-97) 220 36 126 34 99 73
Table 9.6 % patients treated in Leeds Cancer Centre and non Leeds
locations (April 1997-March 1998)
Age Group 10-14 15-19 20-24
Leeds Non Leeds Non Leeds Non
Leeds Leeds Leeds
Leukaemias (C90-95) 61.5 38.5 84.6 15.4 63.6 36.4
Lymphomas (C81-85) 76.9 23.1 39.1 60.9 19.6 80.4
Hodgkin's (C81) 75.0 25.0 25.8 74.2 11.6 88.4
Non-Hodgkin's (C82-85) 80.0 20.0 66.7 33.3 34.2 65.8
CNS Tumours (C71-72) 91.7 8.3 42.9 57.1 57.9 42.1
Skin Tumours (C43-44) 50.0 50.0 16.7 83.3 36.4 63.6
Bone Tumours (C40-41) 86.4 13.6 96.0 4.0 50.0 50.0
All Tumours (C00-97) 75.3 24.7 73.7 26.3 32.3 67.7
Table 9.7 Day case episodes treated in Leeds Cancer Centre and non Leeds
locations (April 1997-March 1998)
Age Group 10-14 15-19 20-24




Leukaemias (C90-95) 82.9 17.1 75.0 25.0 90.6 9.4
Lymphomas (C81-85) 100.0 0.0 22.8 77.2 43.5 56.5
Hodgkin's (C81) 100.0 0.0 6.4 93.6 23.0 77.0
Non-Hodgkin's (C82-85) 100.0 0.0 100.0 0.0 68.8 31.3
CNS 'f umours (C71-72) 100.0 0.0 100.0 0.0 100.0 0.0
Skin Tumours (C43-44) 0.0 100.0 20.0 80.0 50.0 50.0
Bone Tumours (C40-41) 90.0 10.0 100.0 0.0 0.0 0.0
All Tumours (C00-97) 85.8 14.2 50.4 49.6 56.0 44.0
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Table 9,8 In patient episodes treated in Leeds Cancer Centre and non Leeds
locations (April 1997-March 1998)
Age Group 10-14 15-19 20-24
Leeds Non Leeds Non Leeds Non
Leeds Leeds Leeds
Leukaemias (C90-95) 77.3 22.7 90.5 9.5 82.8 17.2
Lymphomas (C81-85) 90.0 10.0 32.0 68.0 44.7 55.3
Hodgkin's (C81) 92.0 8.0 36.8 63.2 46.2 53.8
Non-Hodgkin's (C82-85) 80.0 20.0 16.7 83.3 42.9 57.1
CNS Tumours (C71-72) 85.7 14.3 40.0 60.0 46.7 53.3
Skin Tumours (C43-44) 100.0 0.0 0.0 100.0 25.0 75.0
Bone Tumours (C40-41) 89.4 10.6 94.1 5.9 50.0 50.0
All Tumours (C00-97) 85.9 14.1 78.8 21.3 57.6 42.4
Table 9.3 shows that the majority of patients 10-14 years old are treated at
some time in Leeds. This extends to 15-19 year olds but the pattern is
noticeably reversed for 20-24 year olds.
However, the day case day and inpatient data for 20-24 year olds suggest that
most patients do still receive some of their treatment in Leeds. This may well
therefore represent a different referral pattern with these patients being seen
firstly in local hospitals.
Looking at the data in more detail does suggest a differing pattern of treatment
dependent on cancer site. For example, it would seem that a considerable
proportion of leukaemias in the younger age groups are being treated locally.
However, the management of lymphoma in 15-year olds and upwards is mostly
concentrated in local units, a pattern reflected in both inpatient and day case
activity. The small numbers of CNS tumours treated outside Leeds are









































































































































































Data were collected in the year prior to establishing this unit and are compared
with similar data for the subsequent year. These data are shown in table 9.10
Table 9.10 Change in admissions between 1998 and 1999
Year One Year Two (Teenage Comment
(paediatric Cancer Unit)
oncology ward)
Time Period 01/06/97-31/05/98 01/06/98 -31/05/99 Increase
Male 9 26 17 patients
Female 6 15 9 patients
Total 15 41 26 patients
Mean age 14.6 years 16.4 years 1.8 years
Age range 13-19 years 13-23 years 4 years
Source: Leeds Teaching Hospitals Trust
Table 9.10 shows the considerable increase in the number of admissions
between 1997 and 1998. Currently adolescents who are seen in the paediatric
oncology departments attend disease specific clinics. These clinics see patients
between the ages of 0 and 23. Because of the different needs and time
required for these very different age groups, the following table has been
derived which shows the likely work load of a clinic which is solely responsible
for the needs of young people aged 13-23.
Table 9.11
Age range Average no Average no of Total Total
of outpatient outpatient and number per number per
and day care day care week year
episodes per episodes per
week - solid week -
tumours haematological
malignancies
13-23 years 22 7 29 1508
Source: Leeds Teaching Hospitals Trust
The business case makes several suggestions as to why this rise has taken
place, these are as follows:
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• The Caiman - Hine Report
• The Development of the Leeds Cancer Centre
• A high profile opening of the unit by a member of the Royal Family
• Education of professionals within the Leeds cancer centre
• Patient preference
• Increased profile of adolescent care within the NHS
• 'Word of mouth'
The business case contains data that does support the view that an increased
number of patients are being managed in the Teenage Unit who would have
previously been managed elsewhere. This applies particularly to the
management of leukaemia and brain tumours where the biggest increases have
been seen.
Health Authorities in Yorkshire are now being asked to invest in this service.
Broadly speaking, investment in this situation may come from a number of
sources. These are:
1. from within the Trust itself
2. From additional investment by health authorities
*
3. From charitable donations
4. From a transfer of costs from other places of treatment no longer providing
those services.
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Each of these is now considered in some more detail.
1. From within the Trust. A scale of development of the order of £1 Million is
unlikely to be made through internal cost savings through transfer of activity
or efficiency.
2. From additional investment from health authorities. This is the most likely
potential sources of funding. Each year, health authorities consider priorities
for additional investment. A case such as this with evidence of benefit is
likely to find much more likely to find favour with health authorities than other
cases with scanty background information or evidence of effectiveness.
However, health authorities have an ever-increasing number of priorities to
invest in and the need for improving services for adolescents with cancer will
need to be set against other priorities.
3. Charitable donations. Charitable donations within the NHS can be a
valuable source of funding. However, such funding is usually only made
available for capital developments rather than for the ongoing costs of the
facility. Charitable sources may well be a useful source of funding some of
the start up costs for the unit.
4. Transfer of costs from other units. The transfer of costs from units already
providing treatment is always considered when new services are developed.
However, this is only possible when it is possible to release 'stepped costs'
from a contracting unit. In the case of adoioscent cancer, it is unlikely that
the shift of such a small number of patients from any one location will
release any costs as most, if not all of the pre-existing infrastructure (staff,
wards, beds etc.) will need to be retained.
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9.5 Service Issues Conclusions
If health authorities accept the evidence for the development of an adolescent
cancer unit, then it is unlikely that there will be any transference of costs from
other locations or that there will be a significant level of funding from other
sources. However, there will be scope for a more detailed examination of the
costs should the proposal to establish an adolescent cancer unit be agreed.
This service will only be established with a real investment in costs.
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10 Discussion and Recommendations
10.1 General
This study confirms the preliminary examination of previously published data
which suggested that cancer in young people is no more prevalent in the
Northern and Yorkshire Region than other parts of the world, although
comparisons cannot be exact because of the paucity of published studies and
the different age groups involved in the other published analyses. The study
also confirms that there are few differences in the incidence of cancer in
adolescence in the counties of the region. Some small differences do exist e.g.
epithelial cancers in Humberside and these differences merit further
investigation - but these could have occurred by chance simply because of the
number of analyses which were undertaken (even at the normal level of
accepted statistical significance, a chance observation can occur, by definition
one in twenty times).
The analysis of the routine data has shown the wide variety of cancer which
affects young people and that traditional methods of analysing the data using
ICD 9 and 10 may not be the most appropriate way of understanding
malignancy in this age group.
The principal contribution to the debate comes from the survival analyses and
from the qualitative study.
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10.2 Discussion of Hazard Ratio methods survival results
These types of analyses are important from both a clinical and public health
perspective. Population based survival rates are published less frequently than
results of clinical trials.
The purpose of this study was to investigate the alleged effects of the place of
treatment on outcome and other variables.
10.2.1 Place of residence
Significant differences were observed in the place of residence of patients with
cancer. The significantly worse survival in Humberside and North Yorkshire is
not easily explained. The effect is seen in leukaemias and is difficult to explain,
although the differences are large. This suggests that further investigation is
warranted. Data shown in Tables 9.3 - 9.8 suggest that already most of this
treatment is centralised with the exception of treatment for the 20-24 year old
group.
The reasons for the apparent difference in survival are unclear. Similar effect
is seen in North Yorkshire with non-Hodgkin's lymphoma. Again this remains
unexplained. Overall, in individual cancers there was a suggestion that overall
survival is better in West Yorkshire where the teaching hospital is located. The
differences between the geographical areas of Yorkshire are notable. Attempts
were made to examine hospital of treatment in the cancer registry datasets, but
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use of hospital of treatment filed in the dataset was unreliable, and on
discussion with some of the clinicians concerned it was apparent that assigning
a single hospital to a patient was inappropriate, as many of the patients had
been treated in a number of units. Thus it was not possible to be certain where
the patient received the significant part of their treatment. Given that previous
studies have indicated that cancer is both more prevalent and has a poorer
outcome in those areas with lower socio-economic status (146) the findings
presented here are counter intuitive in that West Yorkshire and Humberside are
less socio-economically affluent than North Yorkshire.
The findings of these analyses show that there is a statistically significant
difference in outcome between the three geographical areas. Geographical
differences in survival in Yorkshire could be due to one of 3 explanations.
Could these differences have occurred by chance? This cannot be totally
excluded, although the size of the differences observed would suggest
otherwise. Alternatively, the statistical modelling failed to take account hospital
treatment differences across the region. The observed difference in survival
may then have disappeared in the multivariate analysis.
Within these data, dose response relationships might have been expected
within the individual diagnostic categories. However, the small numbers
involved in each of these groupings, even over a ten-year period, make it
difficult to draw such conclusions. Even extending the study period is unlikely
to be helpful, as the extended study period is likely to encompass considerable
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variation in treatment and management. Other publications in Yorkshire have
previously demonstrated a poorer outcome from treatment in other cancer
areas. This was most recently reported in a poorer outcome for brain tumours
(in Humberside)- which of course is an important group amongst
adolescents.(147)
The second possibility is that the epidemiology of cancer differs significantly
across the North of England and that a systematic pattern of presentation may
have occurred whereby more or less advanced cases appear in one place or
another. There was no evidence to suggest that this might be a possibility, but
clinicians in the area have suggested that more aggressive malignancies are
more common in Humberside than elsewhere (R.Patmore - personal
communication).
Further work needs to be done to explore potential differences in case-mix
particularly in staging data which was, but this is likely to require a new study
rather than utilising existing data collection systems.
The third possibility is that the differences in outcome are related to treatment
and or the organisation of clinical care. All the consultants treating more than
thirty patients (an average of three per year) were based in a cancer centre.
This raises the question of volume related outcomes which have been alluded
to in other studies. It also does need to be emphasised that over this period
there have been considerable changes in clinical practice, and, for example, in
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Humberside particularly, many of the consultants previously involved with the
clinical care of adolescents have retired.
There are no data available at the present time to make comparisons about the
current service. Should this study be used as evidence for centralisation of all
adolescent cancer care? The arguments that services away from the centre
have changed are powerful ones. However, the difficulty in demonstrating that
the current services have very different outcomes to that previously
demonstrated is that to do so will involve data collection for a further 5-10
years before it is possible to demonstrate any differences.
Although it is difficult to resolve the exact reason for these findings, it should be
emphasised that the case data is retrospective in nature, comprising
malignancies diagnosed between 1985- 1994
Population density analysis on the Yorkshire data (not possible for the
Northern data) suggests that those living in more dense areas are more likely to
have a poorer outcome, after accounting for socio-economic status. This may
be explained by ethnicity, because non-whites tend to live in areas of very high
population density (correlation coefficient =0.41 for 16-29 year olds), such as
Bradford and Leeds, and a previous UK study has suggested Asians have
poorer prognosis than native white children. A lack of Asian numbers in the
data prevented further analysis (148).
A further study is needed to determine the reasons for these differences. The
data on hospital of treatment in its current form are less than clear and needs
further study. However it is unlikely that this question can be answered with the
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current data set and that a more sophisticated piece of research will be
required.
10.2.2 Period ofDiagnosis
Significant improvement in survival has been demonstrated in the second
period of the study with an improvement of 27%, most markedly seen in non-
Hodgkin's Disease. This is clearly encouraging and replicates what has been
reported in other studies.
10.2.3 Size of treating hospital
The results of the place of treatment are equivocal, if anything showing some
survival advantage in being treated away from the centre. However, the
difficulties in classifying the treating hospital, together with the potential
inaccuracies in the initial source data mean that no firm conclusion is possible
in relation to place of treatment in this study.
10.2.4 Social Class
No difference could be demonstrated in the county results due to social class
differences. However, it does need to be emphasised that the method used in
this study (as in many others) used a proxy measure based on address to
allocate social class. Clearly this is crude and the approach has been criticised
by some authors (149), (150)
The results of the hazard ratio approach are consistent with the results using
Kaplein Meier techniques, and therefore demonstrate consistency.
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10.3 Discussion of referral data analysis
One of the issues that the study highlights is whether older patients with
lymphoma and leukaemia should be treated centrally. There is a suggestion
from the analysis of outcomes that the outcome is worse in the older age
groups. This may therefore suggest that patients treated in the cancer centre
may have a better outcome, but there is a weakness in the lack of availability of
case mix data. However, it seems improbable that patients with lymphomas
and leukaemia have an inherently poorer prognosis by living outside Leeds.
There is a suggestion therefore that further centralisation of the management of
these two groups of conditions may lead to improved outcomes. However, the
noticeably worse outcome of 10-14 year olds with Hodgkin's disease living in
North Yorkshire and Humberside does not neatly fit this conclusion.
The relatively small numbers of patients each year with cancer in this age group
and therefore in each unit in the region would suggest that it would be difficult to
release resources in the periphery for investment in the development of an
adolescent cancer centre
10.4 Discussion of the qualitative research
The literature review already has identified features of how improvements might
be made to the management of adolescents with cancer. The qualitative
research revealed significant common themes. It was not surprising that the
first priority of those patients who were involved was concentrated on survival.
The support available within the adolescent unit was clearly felt to be important
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and very different to that experienced in other units, either in other hospitals or
in either paediatric or adults wards in other parts of the main cancer centre.
The importance that was placed on being among others with similar problems
was notable and is not unexpected given the way that young adults tend to
share problems and life experiences in groups.
The high priority placed on education reflects a desire to be seen as normal.
This was not appreciated in any sense by the healthy control group, who clearly
thought that any excuse to get away from lessons was paramount.
Outpatient management of patients could be improved by providing a separate
area for adolescents. Some of the experiences reported by the adolescents
were wholly unacceptable and urgent attention now needs to be given to clarify
referral pathways to ensure that speedy diagnoses are made and that
appropriate referral is made as quickly as possible
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10.5 Final Conclusions
The results of both the qualitative research and quantitative work suggest that
the development of an adolescent cancer centre may be beneficial both in
terms of improving survival and by being able to offer a better standard of care
to do more than aid survival -although the results are far from conclusive.
The limitations of the evidence are as follows:
The spatial analysis is crude. However, the ideal analysis based on postcode
data was not possible for confidentiality reasons. Having postcode data would
have allowed more complex analysis using a geographical information system
which would have allowed much more sensitive geographical analysis. It also
needs to be remembered that multiple analyses can produce unexpected
chance findings. The findings described in this study may fall into this category,
but as previously discussed, there is some consistency with other previous
findings.
Qualitative research does not aim to provide conclusive answers to research
questions. Qualitative research inevitably involves a relatively small number of
subjects and findings of qualitative research cannot be extrapolated to wider
populations in the same way as can be done with quantitative research.
The development of a small unit in Leeds, effectively by rearranging the
previous facilities, has provided the opportunity for some of the qualitative
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issues to be tested, it has to be accepted that a randomised control trial in this
situation is impossible and that it is unlikely to be able to gain much better
evidence for the improved management of adolescents with cancer, than has
been demonstrated in this study.
10.6 Recommendations for further work
There is need for further work, this should be centred around two areas in the
first instance:
1. Work to identify the factors associated with the demonstrable differences in
survival. Has this effect continued?
2. The development of a quality of life tool for adolescents looking at
immediate quality of care and of quality of life in the periods following
treatment.
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Box 10.1 Summary of Conclusions from Epidemiological Study
• improvement in survival over ten year period
• Females survival greater than males
• Some unexplained variation in incidence rates
• Survival not demonstrably improved in large cancer centres
• Unexplained greater mortality in Humberside
• Poorer survival in residents of Humberside
• Survival gets worse with age at diagnosis
• No demonstrable differences in epidemiology in former Northern and
Yorkshire Regions
Box 10.2 Summary of Conclusions from Qualitative Studies
• Most important feature of cancer care is deemed to be survival
• Aspects of care are very important - particularly environment
• Adolescents are probably best managed in a special unit
• Education is an important consideration to many individuals
• Shared care is the preferred model of care among consultants in the
peripheral hospitals, with some care being undertaken both in the centre
and the unit.
• Outpatient facilities need to be considered when improvements in care of
adolescents are being considered
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The hypotheses to be tested were set out in paragraph 2.5.2. These were:
1. That place of treatment results in improved survival
2. That the incidence of cancer in 10-24 year olds does not differ across the
Northern and Yorkshire Region
3. That the quality of care which can be offered by specialist teenage units is no
better than that offered by smaller, local hospitals.
Hypothesis 1. Place of treatment. The conclusion concerning treatment is
equivocal, but is suggestive that there may be some relationship between an
improved outcome and being treated in a larger centre. However, the quality of
the data regarding place of treatment meant that a firm conclusion could not be
made. This study has strongly suggested that survival differs by geographical
location and that this is not explained by differences in incidence, casemix,
deprivation or by population density. The possibility that these differences
occurred by chance cannot be excluded.
Hypothesis 2 There is no difference between the incidence of cancer in 10-24
year olds in Yorkshire, with the exception of carcinomas which showed a
slightly higher incidence in East Yorkshire, again the possibility that this was
simply a chance finding as a result of the large numbers of statistical analyses
which were undertaken.
Hypothesis 3 There may be distinct benefit of large centres and specialised
adolescent cancer units being able to provide a better quality of care and more
closely meet the needs of the patients who are treated in such a unit. The
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evidence supporting this comes from both the quantitative work and the
qualitative studies. The qualitative work, though limited is powerful.
10.7 Concluding note
Evidence for policy change in a complex area such as this is difficult to
assemble. Ideally more studies need to be carried out, but the difficulty with this
approach is that answers from further studies, especially where such small
numbers are concerned, will take a long time to materialise. Some of the
evidence in this study (especially the qualitative study suggests that policy
decisions cannot wait). It also needs to be remembered that the evidence
presented here is far stronger than that used in decisions about service
development currently employed.
This work has been published in the European Journal of Cancer (151)
(attached in the appendix). In addition, health authorities in Yorkshire have
agreed to proceed with the proposed adolescent cancer unit in Leeds as
described. The unit will be fully funded from April 2002.
It has been decided to examine many of the unanswered questions in this
thesis by a prospective audit of the experiences and outcome for a cohort of
adolescents with cancer. In the first instance this will be confined to the
Northern and Yorkshire Region. There is a strong possibility, following a
successful pilot that this study will be undertaken at a national (England) level.
Preliminary discussions have taken place with the National Cancer Director to
this effect. It is also envisaged that National Cancer Guidance will be published
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on the management of cancer in adolescents (personal communication
Professor Mike Richards - National Cancer Director [England]).
/
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Annex 1 - The Carstairs and Morris index of deprivation
The Carstairs and Morris index was originally developed in the 1980s using 1981 census data. It is composed of four
indicators which were judged to be representative of material deprivation. (130) It is said to correlate well with a range
of health measures (152).The four indicators are combined to form a composite score. The composite score is divided
into seven separate categories, ranging from very high to very low deprivation. The seven categories were designed to
retain the discriminatory features of the distribution of the deprivation score, rather than to ensure equality of numbers
between each deprivation category. Some very small postcode sectors were excluded and do not have a score. The
index was designed with the expectation that it would be mirrored by direct measurement of household income if that
were possible. The four variables are as follows:
• Overcrowding: persons in private households living at a density of more than one person per room as a proportion
of all persons in private households
• Male unemployment: Proportion of economically active males who are seeking work
• Social class 4 or 5 : Proportion of all persons in private households with head of household in social class 4 or 5
• No car: proportion of all persons in private households with no car
All the proportions are calculated on the households in a given postcode sector.
Problems in the use of area classifications
There are some possible problems in the use of the Carstairs index (which may apply to other similar area
classifications). (153)
• Firstly, the index is based on assumptions about the variables that best represent material deprivation. For
instance the possession of a car may be an essential in some (e.g. rural) areas and not represent the access to
material resources that it appears. Indeed it may be a drain on resources that people cannot avoid. (153)
• Secondly, areas are not internally homogeneous; populations containing a mixture of deprived and less deprived
households are likely to have middle ranking scores (153). Such mixed populations would be more likely to occur
in rural areas. Therefore area based scores are likely to provide a better indication of deprivation in urban than
rural areas.
There are fewer areas of deprivation in categories 1,2,6 and 7 in the smaller areas and more rural areas. This can
be explained in several ways:
There may be less deprivation in such areas
The population may be mixed leading to more postcode sector areas with middle ranking scores, despite
there being similar numbers of deprived individuals across the whole area
Car ownership, being more essential than in more urban areas, may be pushing more people into poverty
A combination of the above
• Thirdly the scores from postcode sectors with small populations (less than 2000) are based on census counts
which are particularly susceptible to random variation (153)
Fourthly the ecological fallacy is an important potential limitation of area based measures. It results from the false
assumption that inferences can be made about individual phenomena based on observations of groups. (154) The
Carstairs deprivation category may be associated with an individual's risk of adverse health outcome through an
individual's personal experience of deprivation, and/or the effect of living in a deprived area. It has been estimated that
the deprivation effect on mortality is entirely explained by the presence of deprived individuals within those areas (155).
It remains possible however that area level effects, in addition to those expected from the concentration of individuals,
may exist for certain health problems. (155)
The process of categorising areas (postcode sectors) by proportion of individuals can lead to difficulties in
interpretation. For instance, Sloggett and Joshi have estimated that 55% of the most deprived individuals in
England and Wales live outside the 20% of areas that are most deprived (155).
• Finally, area based scores such as the Carstairs index use census variables for their creation and can therefore,
only be updated every 10 years. A change in the Carstairs score from 1981 to 1991 census may represent a true
change in the deprivation level in an area, or it may reflect a change in the relative proportions of the component
variables. (153)
In an ideal situation, therefore, the use of reliable individual measure of deprivation, which could be regularly updated
would allow each of these effects to be accounted for at both the individual and the area levels and more reliably
monitored over time. However, at present there is no readily available, validated measure that would be acceptable for
general use.
183
Annex 2 - The SEER Database
Background
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute is the most
authoritative source of information on cancer incidence and survival in the United States. Case ascertainment for SEER
began on January 1, 1973, in the states of Connecticut, Iowa, New Mexico, Utah, and Hawaii and the metropolitan
areas of Detroit and San Francisco-Oakland. In 1974-1975, the metropolitan area of Atlanta and the 13-county Seattle-
Puget Sound area were added. In 1978, 10 predominantly black rural counties in Georgia were added, followed in 1980
by the addition of American Indians residing in Arizona. Three additional geographic areas participated in the SEER
program prior to 1990: New Orleans, Louisiana (1974-1977); four counties in New Jersey (1979-1989); and Puerto Rico
(1973-1989). The National Cancer Institute also began funding a cancer registry that, with technical assistance from
SEER, collects information on cancer cases among Alaska Native populations residing in Alaska. In 1992, the SEER
Program was expanded to increase coverage of minority populations, especially Hispanics, by adding Los Angeles
County and four counties in the San Jose-Monterey area south of San Francisco.
Geographic areas were selected for inclusion in the SEER Program based on their ability to operate and maintain a
high quality population-based cancer reporting system and for their epidemiologically significant population subgroups.
The population covered by SEER is comparable to the general U.S. population with regard to measures of poverty and
education. The SEER population tends to be somewhat more urban and has a higher proportion of foreign-born
persons than the general U.S. population.
SEER Database
The SEER Program currently collects and publishes cancer incidence and survival data from 11 population-based
cancer registries and three supplemental registries covering approximately 14 percent of the U.S. population.
Information on more than 2.5 million in situ and invasive cancer cases is included in the SEER database, and
approximately 160,000 new cases are accessioned each year within the SEER catchment areas. The SEER registries
routinely collect data on patient demographics, primary tumour site, morphology, stage at diagnosis, first course of
treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based
information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each
stage. The mortality data reported by SEER are provided by the National Centre for Health Statistics.
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Appendix
Survival in adolescents and young people with cancer aged
10-24 years in the former Northern Region 1985-1994
Data included in this analysis were obtained from the Northern Children's and Young
Peoples Tumour Registry and relates to data between 1985 and 1994 (with follow up
up to 1996). The methods of data collection and its limitations are considered in
section 5.2 of the main thesis and in a recent publication from the registry (1).
In this appendix 5 year survival rates have been shown calculated using the Kaplein
Meier method (2).
Overall survival (figure A. 1)
Of the 1036 subjects in the case series, 305 had died by the end of the follow up
period. Overall survival at five years was 74%, this was broadly comparable with the
Yorkshire 5 year survival rate for the series of 72%.
Year of diagnosis (figure A.2)
As in the Yorkshire data, comparison was made between two time periods, 1985-1989
and 1990-1994. It can be seen in this figure that unlike in Yorkshire survival does not
appear to have improved over these two time periods.
Age group (figure A.3)
Comparisons have been made between age groups at the time of diagnosis.
Significant differences were noted (p=0.03). However, unlike in Yorkshire the poorest
outcome was experienced in the 15-19 year group. Patients aged 20-24, again had the
best outcome. This is likely to be due to case mix (a predominance of Hodgkins
lymphoma for which there is a relatively good prognosis).
County of Residence (figure A.4)
Differences were observed, but unlike the Yorkshire data these differences did not
reach statistical significance (p=0.114)
Sex (figure A.5)
As is widely reported elsewhere, better outcomes were seen in females compared to
males. This difference was statistically significant (p= 0.0236)
i
Hospital Type (figure A.6)
Treating hospitals were divided into 'centre' and district hospitals. Centres were the
pre-existing cancer centres which have been designated in the Northern Region
(Middlesbrough and Newcastle). Significant difference were noted between centres
and district hospitals, with a worse prognosis in the 'centre' hospitals.
Survival By Cancer site
Figures A.7-A.13 show the survival curves for the main cancers in the 10-24 year age
group. These show similar patterns to those for Yorkshire.
Cox Regression analysis
The Cox regression analysis shows very few significant results. There is a suggestion
that residents in county Durham may fare worst and this is particluartly seen in
carcinomas. However confidence limits are wide, and this difference needs ot be
interpreted with caution. Follow up over a longer period is recommended.
Discussion
Survival in this age group did not appear to differ significantly compared with other
studies and the data presented in this thesis for those patients resident in Yorkshire.
Significant differences in survival have not been demonstrated between counties of
residence unlike in Yorkshire. However, it is interesting to note that, although not
reaching statistical significance, the best outcome is in the residents ofTyne and
Wear, the closest county to the cancer centre and similar to the pattern observed in
Yorkshire.
The differences that were demonstrated between hospital of treatment were to be
expected as it was not possible in these data to take account of case mix. It seems
plausible that more seriously ill adolescents are more likely to be managed in the
cancer centre.
Conclusions
Survival analysis for the former northern region patents in this study appears to be
similar to that observed in Yorkshire, although the inter-county variations have not
been identified to the same extent in the Northern region, though this may be
suggested in the data. More research is clearly required in this area, emphasis should
be given to investigating this issue over a longer time period.
ii

















Figure A.2 Survival by year of diagnosis








year band 0 = 1985 - 1989






Figure A.3 Survival by age group








Figure A.4 Survival by County ofResidence














county 0 = Tyne and Wear
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Figure A5 Survival by Sex
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CONSENT FORM




1. I have read the Information Sheet for patients. Yes/No




I am satisfied with tire answers tomy questions.
I have received enough information about this study.
I have spoken to Dr/Mr/Ms.
Yes/No
Yes/No
6. I understand that I am free to withdraw from the study at any time without
giving a reason and without affectingmy future care.
Yes/No











1. How do you define adolescence?
2. Does it matter?
3. Do you ever look after young people with cancer in this unit, if so what is your
experience of caring for them?
4. What sort of things are important for young people with cancer?
a) Getting better?
b) Being managed in a special centre
c) Close to home
d) Accessible for parents
e) Accessible for friends
f) Keeping up with education
5. Where would you be looked after ifyou had cancer?
6. What facilities do you think are needed for adolescents with cancer
7. What is the role of a hospital away from a large teaching centre in the management of
adolescents with cancer?




1. Can you describe what happened to you when you first became ill?
2. What were the good points, and what were the bad points ofyour treatment?
3. What causes most illness in young people?
4. How common is cancer -
a) In adults
b) In young people?
5. What sort of things are important for you, and how important are they?
a) Getting better
b) Being managed in a special centre
c) Being close to home
d) Being Accessible for parents
e) Being Accessible for friends
f) Keeping up with education
g) Anything else?
6. Where would you have preferred to have been looked after with your illness?
7. What facilities would you like to see provided when adolescents with cancer are
looked after?




1. Who can get cancer?
2. What causes most illness in young people?-
3. How common is cancer -
a) In adults
b) In young people?
4. What sort of things are important ifyou or a close friend has cancer?
a) Getting better?
b) Being managed in a special centre
c) Being close to home
d) Being Accessible for parents
e) Being Accessible for friends
f) Keeping up with education
5. Where would you be looked after ifyou had cancer?
6. What facilities would you like to see provided when adolescents with cancer are
looked after?
focus group topics - healthy adolescents
XX
Study of Cancer in Young people and Adolescents - Questionnaire for Patients
Please could you fill this form in to give us some basic information about people attending these sessions. You will
see that we have not asked for your name, and any information you provide will be held in the strictest confidence.
Aboutyou:
Age: Sex:
Have you passed any public examinations, ifso please can you tell us ifyou have any of the following.
No. ofGCSE's No. ofA Levels
Other qualifications (please say what these are)
Ifyou have left school, please tell us what your job is
Please could you write down the name ofyour diagnosis
Which hospitals have you attended with your current illness? (if so please say when and ■what for)?
Please could you write down the postcode ofwhere you live. Ifyou cannot remember it, just write down the name of




Do you have any brothers or sisters, if so how many?
Brothers Sisters
Thankyou foryour help!
focus group questions - patients
xxi
Stndy of Cancer in Young people and Adolescents - Questionnaire for Healthy Adolescents
Please could you fill this form in to give us some basic information about people attending these discussion groups.




Have you passed any public examinations, if so please can you tell us ifyou have any of the following.
No. ofGCSE's No. ofA Levels
Other qualifications (please say what these are
Are you normally fit and well? yes/no
Have you ever been admitted to hospital (if so please say when, where and what for)?
Please could you write down the postcode ofwhere you live. Ifyou cannot remember it, just write down the name of




Do you have any brothers or sisters, if so how many?
Brothers Sisters
Thankyou for your help!
foots group questions - non patients
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Study of Cancer in Young People and Adolescents
INFORMATION SHEET FOR PATIENTS - INDIVIDUAL INTERVIEWS
This information is about a research project for which we are requesting your
participation. Your decision to take part is entirely voluntary and if you do not wish
to take part this will not affect your care in any way.
We are trying to find out what teenagers and their parents feel are important aspects
of their care and where might be the best place to treat teenagers with cancer in the
future.
We are asking if you would be willing to take part in a discussion with a doctor
talking about your care. This would last up to 30 minutes and be held in the out¬
patient unit in Leeds shortly before or after you have seen your normal doctor. The
conversation would be recorded to allow us to write up in detail, at a later stage, what
was said. Anything that is said will not be connected to any particular individual.
Thank you for taking time to read this.
Ifyou have any questions or queriesplease speak to either
Dr John Wilkinson (telephone number 01904 825238)
Or
Ms Sue Morgan (telephone number 0113 2066205)
information sheet for participants -interviews
xxiii
Study ofCancer in Young People and Adolescents
INFORMATION SHEET FOR PARENTS OF STUDY PARTICIPANTS
This information is about a research project for which we are requesting your child's
participation. Your decision to take part is entirely voluntary and if you do not wish
. to take part this will not affect your child's care in any way.
We are trying to find out what parents and their children feel are important aspects of
their care and where might be the best place to treat teenagers with cancer in the
future.
We are asking if you would be willing to allow your child to take part in a discussion
group talking about their care. This would last up to 1/4 hours and be held in the in¬
patient unit. The conversation would be recorded, to allow us to write up in detail, at
a later stage, what was said. Anything that is said will not be connected to any
particular individual Participants would also be asked to complete a brief
(anonymous) questionnaire about themselves and their family background.
We would like to carry several group discussions groups, one of parents and one of
young people themselves. This would involve a group discussion of up to 8-10
people each. The discussion would be led by a doctor and would last between 1 and
IV2 hours. The discussion would be recorded and later written up. Any comments
made during the course ofthe discussion would be entirely anonymous.
Later in the year we would be interested in talking to some parents in person and if
you would like to be involved, we would be grateful ifyou could let us know.
Thank you for taking time to read this.
Ifyou have any questions or queriesplease speak to either
Dr John Wilkinson (telephone number 01904 825238)
Or
Ms Sue Morgan (telephone number 0113 2066205)
Information sheet for parents - focus groups
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Study ofCancer in Young People and Adolescents
INFORMATION SHEET FOR PATIENTS
This information is about a research project for which we are requesting your
participation. Your decision to take part is entirely voluntary and if you do not wish
to take part this will not affect your care in any way.
We are trying to find out what young adults feel are important aspects of their care
and where might be the best place to treat young people with cancer in the future.
We are asking ifyou would be willing to take part in a discussion group talking about
your care. This would last up to about an hour and be held in the Teenage Cancer
Unit, St James' Hospital, Leeds. The conversation would be recorded to allow us to
write up in detail, at a later stage, what was said. Anything that is said will not be
connected to any particular individual
This would involve a group discussion of up to 5 people each, all current or previous
patients on the ward. The discussion would be led by a doctor not involved in your
care. The discussion would be recorded and later written up. Any comments made
during the course of the discussion would be entirely anonymous. We will also be
asking you to fill in a very short questionnaire about yourself and your family.
Thank you for taking time to read this.
Ifyou have any questions or queriesplease speak to either
Dr John Wilkinson (telephone number 01904 825238)
Or
Ms Sue Morgan (via the ward or telephone 0113 2066205)
information sheet for participants - focus groups 2
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Study ofCancer in Young People and Adolescents
INFORMATION SHEET FOR PATIENTS (OUTPATIENTS)
This information is about a research project for which we are requesting your
participation. Your decision to take part is entirely voluntary and if you do not wish
to take part this will not affect your care in any way.
We are trying to find out what young adults feel are important aspects of their care
and where might be the best place to treat young people with cancer in the future.
We are asking if you would be willing to take part in an interview about your care.
This would last about 30-40 minutes and take place in the clinic. The interviews will
be carried out by a doctor not involved in your care. The conversation would be
recorded to allow us to write up in detail, at a later stage, what was said. Anything
that is said will not be connected to any particular individual.
Any comments made during the course of the discussion would be entirely
anonymous. We will also be asking you to fill in a very short questionnaire about
yourself and your family.
Thank you for taking time to read this.
Ifyou have any questions or queriesplease speak to either
Dr John Wilkinson (telephone number 01904 825238)
Or
Ms Sue Morgan (via the ward or telephone 0113 2066205)
inf sheet - interviews in outpatients
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Extract from focus group discussion held on the 22nd October 2000 at St James
Hospital, Leeds.
Dr W Thank you very much. It's great of you to take part. What I'd like to talk
about first is your experiences of how you were diagnosed. What actually
happened when you were first ill and how that worked? So the early bit in
terms of your early part of your illness and then talk about general things.
So do you want to say how you found that?
PI I had pain when I was sitting down and I went to the doctors. At first they
just gave me some tablets to take the swelling down, then it was still there a
week later, so I went back again and the doctor said you'd better go to the
LGI for some scans and I went to LGI for scans. As soon as I turned up
they decided to keep me in and in total I was in the LGI about 3 weeks
before-they actually knew what was wrong with me. I had a biopsy done
and things like that. It took quite a while.
Dr W In terms ofwhen you were taken ill and getting to hospital; how was that?
Do you think it was OK?
PI At first I didn't know what was wrong with me. When they said we're
going to keep you in hospital and they didn't know what was wrong with
me
DrW How long ago was that?
P1 Beginning ofMay.
Dr W So it happened all very quickly?
PI Yes.
Dr W In terms of getting referred up to the hospital. Did you think that worked
OK, or were there any things that could have been better?
PI I'd seen numerous doctors and the doctor who was going to treat me, his
patients were over at St James', so they transported me over to St James',
where I was on the adult ward at first and then I learned about this ward. I
prefer this ward to other words.
Dr W What happened to you Darren?
P2 One night when I was at home my Dad noticed, we were having some
supper, he noticed a big lump on my neck. I didn't notice it in the past,
because my school shirt covered it up and it was a big, huge lump on my
neck. My Dad started to feel it and as he pressed it I felt really faint and
dizzy and my Dad opened the door and he sat me on the door step. He took
me straight up to the hospital - that Dewsbury hospital. They kept me in
and they decided to do a biopsy on my neck at the hospital.
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Dr W So you didn't go to your GP at all; you went straight up to hospital?
P2 Um - Yeah, I did. That was before it was really big. It was small and I
was complaining of tiredness.
Dr W So how long was it between you seeing your family doctor and that time
you actually went up to hospital? When did you first see your family
doctor?
P2 I saw my doctor and he just sent me home; said it's just a swelling. I went
again and they sent me home again.
Dr W So how long was it roughly, not exactly, from the first time you went to
when you went to hospital and they kept you in?
P2 About a week.
Dr W And how many times in that week had you been to see your GP?
P2 Twice and I was worried about what it was. I couldn't even imagine or
dream that it was this. At first they thought it was glandular fever and it
took them; and Dewsbury hospital -1 thought they were quite slack - it took
them about two weeks to refer me, but they didn't tell me. Dewsbury
hospital knew what I had, but they didn't tell me 'cause they sent all the
scan stuff and my biopsy results up here and then I came here and the first
morning I came here I got told by Dr Lewis that I had
Dr W In Dewsbury had you seen a children's doctor or an adults' doctor? Do you
know?
P2 I was on a children's ward and every single doctor in Dewsbury hospital
saw me - every one! I had about five trainees on me as well. I had about
seven main doctors, who came to see me - none of them knew what it was,
and then they set trainees on me as well.
Dr W OK, thanks for that.
Dr W Akeem. What happened to you? What were your early experiences?
P3 I used to blow my nose, and get bleeding. He give me a spray. He said I
had got an infection, I had a lot of swelling and before that the doctor said it
was sinuses. I used to blow my nose and blood came out. I went 3-4 times
to the doctor. I went to dentist with toothache.
Dr W So how did you eventually get to St James'?
P3 I got a nose bleed this side 5 o'clock, went to BRI and they just told me to
go home and see my GP. So went home. At 6 o'clock it started bleeding
again. Went back to hospital, did some tests. They talked to my mother.
Took 3-4 hours. In afternoon started again.
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Dr W So what happened from that time when you were having all the bleeding?
When you were sent up to the hospital here.
P3 Four weeks, because I was there for two weeks and then they sent me to
?
Dr W So, to get it straight: from having the initial bleeds, you were seeing your
GP before that happened. After the bleeding started what happened then? '
You went up to the hospital?
P3 Four times, and the fourth time they took me in, kept me in the ENT
department. On the following Tuesday they did a scan; on Friday an MRI
scan; Wednesday did a biopsy - all that time I was in hospital. The
following Monday the doctor came to see me and said it is very serious.
He said it is spreading and could go to the brain, he said it was as bad as it
can be.




Dr W So how long was it between you being perfectly well to actually being
here?
P3 A good seven to eight months. Before I was having headaches for 4-5
months.
Dr W So ifwe take the time from when you went to see the doctor about it. What
time would that be? First seeing your GP and getting into St James'?
P3 Six to seven months. Doctor said it was sinuses. My mother had sinuses
before.
DrW So you were all at some stage told about your diagnosis?
Yes, the doctor told me it.
Dr W So how important do you think it was to be told pretty straight about what
was going on?
PI I thought it was important. When the doctor told me same as Akeem, he
laid it out flat, said this is very, very serious. It scared me when he said
that. When they were on about radical surgery. It is serious, but it doesn't
seem as serious as if he'd said I had a year to live or some'at.
P3 When I came here the doctors told
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Dr W So it was painted a lot blacker to you before you came here?
P3 It shocked me.
Dr W But in your case it was painted fairly black to you?
PI It was in the LGI when I found out they told me they had something to tell
me that was very serious. But when I got here ... other treatment.
Dr W So it was here when you saw Dr Lewis?
P1 Dr Picton I saw here.
P3 It's very hard. The treatment works.
Dr W So how do you feel in general about ? What I'm going to ask really is
some general issues about health in people of your age. How common do
you think this is?
What's the most common thing that affects people of your age?
PI Things like meningitis, that's passed easily round schools.
P2 Flus.
PI Things you catch from other people - come into contact with.
Dr W You said cancer affects 1 in 3 which is absolutely right, but in people of
your age any sort of idea?
P2 Haven't got a clue.
Dr W Would you say its common, rare, very rare or extremely rare?
PI I'd say rare. I was the first in my school that got it.
So am I.
There's a thousand in my school small percentage.
P2 It's just so unbelievable that it's you and not the other 900 that have got it.
XXX
Dr W So what we're going to talk about now is some of the things that are
important to you and what actually matters as far as your care is concerned.
We ran a little pilot study to try and identify some of the things that might
be important and I'll just read out some of these. What I'd like to do is just
talk to you about each of these and how important these factors are, and
they're in this order: getting better (that's 1); being managed in a special
centre (that's number 2); being close to home (number 3); being close for
parents to visit; the next is being close for friends to visit; and the last thing
is education and how important is that? For all of these if you want I'll
show you the sheet. What, for you, are the most important out of getting
better; special centre; close to home; parents; friends; education?
P2 I'd say getting better is first priority; then its education.
Well I think it's education, because I feel strongly about keeping up with
school.
PI Parents and visitors, treatment in specialist centres, then probably even.
Dr W You're from Dewsbury and you're from?
PI Between Leeds and Bradford.
Dr W How far away from Bradford?
PI About 15 to 20 minutes drive.
Dr W How far are you?
P2 About 40 minutes.
Dr W You're quite near.
Dr W So how important is being treated near to home as against all those other
things?
P3 The further you are the more hard it is to travel.
Dr W If you put yourself in a situation of being, say, 50 miles away, what would
be more important to you - being looked after in a specialist centre or being
close to home, or being near to your parents?
PI I think being looked after in a specialist centre.





Column Structure ofNorth Yorkshire Adolescents Data 1985-89 and 1990-94
The data is supplied in CSV format in the following structure
Column Explanation
year _ Year of registration
regno pat id Patient Identifier
ward name Ward ofPatient Residence
sex Sex - M or F
age In years between 10 and 24
site ICD9 Site Code
name ICD9 Site Translation
type ICDO Type Code
name ICDO Type Translation
anniv date Anniversary Date
trust 1 Trust Code of 1 st Hospital
trust2 Trust Code of 2nd Hospital
trusts Trust Code of 3rd Hospital
trt op Treatment by Operation - Y orN
trt rt Treatment by R/T - Y orN
trt chem Treatment by Chemotherapy - Y orN
trt horm Treatment by Hormone Therapy - Y or N
death date Death Date
dcausel ICD9 1st Cause ofDeath Code
name ICD9 1st Cause ofDeath Translation
dcause2 ICD9 2nd Cause ofDeath Code
name ICD9 2nd Cause ofDeath Translation
dcause3 ICD9 3rd Cause ofDeath Code
name ICD9 3rd Cause ofDeath Translation
dcause4 ICD9 4th Cause ofDeath Code
name ICD9 4th Cause ofDeath Translation
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I enclose for you, a disc containing the information we have available on database from
the Northern Region Malignant Disease Registry. It differs from that you requested in
the following respects:
1) Ward name is replaced by local authority at diagnosis.
2) First, second and third hospitals of treatment are replaced by referring and treating
hospital.
3) Death cause coding is not on database.
If this information is insufficient for your needs, you are welcome to visit the registry and








Copy to: Professor AW Craft
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Direct Tel: 0191 202 3037
Direct Fax:0191 202 3060
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DLOCAUTH Local Authority at Diagnosis (codes in LOCAUTHXLS)
SEX Gender




REFHOSP Referring Hospital (codes in HOSPITAL.XLS)
EH Treating Hospital
DOFUDATE Date ofLast Follow Up
FOLLOWSTAT Status at Last Follow Up (codes in STATUS.XLS)
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abstract
The aim of this study was to investigate survival rates for adolescents with cancer and identify factors associated with differential
Dng-term prognosis in Yorkshire, UK. A survival analysis of a population-based cohort of young adults aged 15-24 years, diag¬
nosed with a malignancy in the former Yorkshire Regional Health Authority between 1985 and 1994 was carried out. The main
'Utcome was death from all causes. Overall survival for the 1097 adolescents with a malignancy increased by 30% between 1985—
989 and 1990-1994 CP = 0.004). This improvement was reflected in most subgroups of cancer. Large scale geographical differences
-a survival rates were observed across Yorkshire, with an increased risk of death in North Yorkshire and Humberside of 34% and
5%, respectively, compared with West Yorkshire. Small scale analyses showed reduced survival in areas of high population den-
ity, but no consistent trends were associated with socio-economic status. Improved survival from all cancers in young adults over
-he last decade is clearly seen. Reasons for differential survival by geographical area are unclear and warrant further investigation.
5 2001 Elsevier Science Ltd. All rights reserved.
leywords: Survival and cancer; Adolescent; Socio-economic status; Population density
. Introduction
After road traffic accidents and suicide, adolescent
ancer is the third most significant cause of mortality in
•oung people in the United Kingdom. In 1993 in Eng-
^nd and Wales, there were 375 deaths from cancer in
«he age range of 15-24 years [1].
Cancer in adolescence differs from that in adults and
-hildren: cancer in children is usually caused by a range
if developmental tumours, whereas in adults the com-
nonest type of cancer is epithelial in nature (e.g. breast,
ung and prostate). Adolescent cancers tend to be a mix
>f paediatric and adult cancers. Although ICD10 has
ieen used to categorise malignancies in children, this
lassification scheme is not without its problems when
pplied to the adolescent and young adult age groups.
Various studies have looked st adolescence in relation
o cancel, yet the age range examined has differed quite
narkedly. For example, Fritschi [2] looked at the inci-
lence of cancer amongst New South Wales adolescents
* Corresponding author. Tel.: +44-113-233-4842; fax; + 44-113-
33-4877.
E-mail address: p.a.mckiniiey@leeds.ac.uk (PA. McKinney).
and concentrated principally on the appropriate classi¬
fication scheme in a study of adolescents aged 10-19
years with cancer between 1972 and 1991. The authors
concluded that the childhood classification scheme is
appropriate to describe cancer incidence in adolescent
age groups, but perhaps requires minor modifications.
The classification used in this study was therefore the
International Childhood Classification of Cancer
(ICCC) [3], which uses tumour morphology as well as
tumour site.
The biology of malignant disease largely determines
the age groups to be analysed and for the purposes of
this study, adolescence was defined as between 15 and
24 years of age. Over the past 20 years, almost all of the
care of young children with cancer has been centralised
in the regional centres. This has not happened to the
same extent with adolescents. The approach to the;_
treatment of adolescents is not directly' age-related, but'"'"
in Yorkshire varies with hospital and with diagnosis. In
the more common malignancies in this age group,
treatment is more likely to take place at a local level
than in young children.
In 1999, Stiller and colleagues [4] examined patterns
of care and survival in people with acute leukaemia
959-8049/01/$ - see front matter © 2001 Elsevier Science Ltd. All rights reserved.
'II: S0959-8049(01)00012-0
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between the ages of 15 and 29 years. They concluded
hat survival had improved over the 10-year study per-
od in the 15-19 year old group, that survival rates were
imilar at teaching and non-teaching hospitals, and that
;ntry into trials had a significant beneficial effect on
urvival. Apart from this article, there is little in the Iit-
;rature discussing the association of risk factors with
urvival of adolescents and young people from all can-
iers either in the UK or elsewhere. This study therefore
malysed data on all malignancies diagnosed in the age
ange 15-24 years occurring in Yorkshire in the UK, to
-ietermine whether there is a need for a more centralised
.pproach in the management of adolescent cancer ser¬
ines.
Patients and methods
The geographical area of Yorkshire, UK has a total
(opulation of 3.7 million and encompasses a wide vari-
tion of urban and rural environments with accom-
lanying differences in deprivation and population
lensity. A survival analysis was performed on a dataset
ontaining 1097 cases aged 15-24 years, diagnosed in
forkshire (Fig. 1) between 1 January 1985 and 31
December 1994 and followed-up until 1 January 1998.
"here were approximately 0.5 million people living in
Yorkshire aged 15-24 years in 1991 (The 1991 Census,
Crown Copyright, ESRC purchase).
Cases were extracted from a population-based register
of malignancies based at the Northern & Yorkshire
Cancer Registry and Information Service (NYCRIS). In
common with all cancer registries, NYCRIS goes to
extensive lengths to ensure completeness of data cap¬
ture. One of the main strengths of cancer registration is
the multiplicity of sources of notification [5]. In the
Northern and Yorkshire Region, trained peripatetic
clerks from NYCRIS regularly visit all hospitals in the
region. Notifications are usually instigated through
copies of the pathology forms being forwarded to
NYCRIS. Haematological malignancy data are col¬
lected through the haematologists. All cases of cancer
are flagged at the National Health Service Central Reg¬
istry in Southport, so that in. the case.of a non-malig¬
nant cause of death, the registry is notified. Copies of
death certificates are forwarded to the cancer registry,
and therefore we can be confident that details of cases
are accurately captured and that death data is fully
captured by this system.
The national core contract for cancer registration lays,
down standards for completeness, accuracy and time¬
liness in the collection of the minimum dataset [6].
These minimum standards are all being achieved by
NYCRIS.
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Cancers were coded and categorised into the 12 major
-diagnostic groups detailed in Table 1 according to the
CCC [3], which is based on Birch and Marsden's
cheme [7]. The end-point of interest was death from
ny cause, with date of diagnosis acting as the time-ori-
in. For each diagnostic group/subgroup, the following
ariabies were investigated:
• Gender (male or female).
• Age (in years) at diagnosis (15-19, 20-24).
• Period of diagnosis (1985-1989, 1990-1994).
• County of residence at diagnosis (West Yorkshire,
Humberside, North Yorkshire).
• Socio-economic status (Carstairs index [8] from
the 1991 census (1991 Census, ESRC Publication
Crown Copyright) — based on address at diag¬
nosis).
• Person-based population density (ppd) (1991 Cen¬
sus) divided into thirds.
• Chemotherapy treatment (yes/no) for leukaemias
only, was adjusted for in the analysis (result not
shown).
Individuals were assigned a deprivation score as a
roxy for socio-economic status, based on the validated
ostcode of their address at diagnosis using the follow-
ig census variables to calculate the Carstairs index —
ercentages of unemployed male residents over 16 years,
-esidents in social class 4 and 5, non-car ownership and
vercrowding. Each address was linked to its census
• 905
electoral ward (EW) (?z= 532) via the central postcode
directory. The Carstairs index was categorised into five
equal groups of the entire study population, with scores
ranging from —4.95 (most affluent) to 17.63 (least
affluent).
Ppd at EW level was used as a proxy for urban/rural
status: firstly, area-based population density was calcu¬
lated by dividing the population in each enumeration
district (ED) by its area in hectares. Ppd was then
obtained by aggregating the population-weighted aver¬
age of area-based population density in each ED to an
EW. This measure more accurately reflects the density
at which the average person in any geographical area
lives than the classic area-based measure [9]. Ppd was
* categorised into three groups, and was defined as low
(<35.7 persons/ha), medium (35.7-52.6 persons/ha)
and high (>52.6 persons/ha).
Survival rates were calculated using Kaplan-Meier
methods [10], Initially, ppd was investigated separately
using the log-rank test to assess whether survival dif¬
fered for each diagnostic group. The data were then
modelled using Cox's proportional hazards technique
[11]. Hazard ratios (HR) and the level of significance
(5%) were reported. HR are the ratio of the hazards
(probability of dying at time t, having survived to that
time) for two different values of a covariate, and can be
interpreted in a similar way to relative risks. The level of
significance was set at 5%, with a P value of 0.05 or less
indicating a statistically significant effect, for compara-
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ig. 2. Kaplan-Meier survival curve by period of diagnosis for all
mcers diagnosed between 1985 and 1994.
ility with Stiller and colleague's results [4]. HR for each
- ictor were calculated adjusting for all the other factors,
•ithin each diagnostic group. The proportional
-azard's assumption appeared to be valid.
. Results
Table 1 describes the number of cases and deaths for
le diagnostic groups, and those which have a sufficient
umber of deaths to enable a multivariate analysis to be
-erformed. Cases with leukaemia had by far the largest
roportion of deaths (almost two-thirds died), whilst a
xth or less of the cases with germ cell tumours and
lodgkin's disease (HD) died. The carcinomas com-
-rised a mixed group of malignancies including mela-
omas (n= 96, 33%), thyroid (n = 44, 15%), skin
i=52, 18%) and other («= 103, 35%).
Overall survival rates were 87.7, 81.0 and 75.2% at 1
>5% CI: 85.6-89.5), 2 (95% CI: 78.6-83.2) and 5 (95%
■I: 72.6-77.7) years, respectively. There was a sig-
ificant improvement in survival from all cancers com-
ined for adolescents diagnosed in 1990-1994,
-cmpared with those diagnosed in 1985-1989 (Fig. 2),
ith a considerable improvement at 1, 2 and 5 years
-fter diagnosis. This effect was consistent across all
iree counties.
Table 2 lists the proportion of deaths within each ppd
category, by diagnostic group. Although there was no
significant evidence of trend in the.proportion of deaths
across the categories of ppd for any diagnostic group,
there was a suggestion that higher ppd was associated
with a higher rate of death for all malignancies and
carcinoma. (Car cinomas are presented as a single group,
as two-thirds of deaths occurred in the 'Other and
unspecified' category.)
Table 3 gives the number of cases for each variable
and diagnostic group included in the regression analysis.
The results of the multivariate regression are presented
in Table 4. Between 1985-1989 and 1990-1994, survival
improved by 30% overall (P= 0.004), and this effect was
present throughout all diagnostic categories, apart from
leukaemias. However, both acute lymphoblastic (ALL)
and acute myeloid leukaemia (AML) separately con¬
firmed this finding (daia not shown).
The most striking feature of the data is the consistent
increased risk of death in Humberside and North
Yorkshire compared with West Yorkshire across most
of the diagnostic groups. This is not explained by socio¬
economic status or population density. The overall sig¬
nificant increase of death of 45% in Humberside
(F = 0.009) and 34% in North Yorkshire is reflected
most strongly in adolescents with leukaemia: here, the
risk of death in North Yorkshire and Humberside is
almost 2.5 times as great. This pattern was also
observed for germ cell tumours. A survival curve dis¬
playing the significant differences across the three
counties of Yorkshire is given in Fig. 3. No significant
differences could be demonstrated in the case mix
between the three counties in the study.
Further inspection of the data for leukaemia revealed
that 90% of patients living in West Yorkshire and
North Yorkshire at the time of diagnosis had chemo¬
therapy, compared with only 74% of patients living in
Humberside. However, this difference in treatment did
not explain the poorer survival in Humberside, because
we included a binary variable indicating whether or not
chemotherapy was given for leukaemia. Similarly, by
including a variable for chemotherapy for all cancers,
able 2
rends in survival by person-based population density and diagnostic group
ICC group" Diagnostic group Cases Population density Test of trend
P value
Low Medium High
-12 All cancers 1097*-"' 23.8 25.9 29.4 0.1.4
Leukaemias 84 54.6 77.8 57.1 0.35
t Hodgkin's disease (HD) 206 12.1 12.9 12.7 0.99
>-2e Non-Hoagkin's lymphoma (NHL) 70 28.6 20.0 40.9 0.26
Central nervous system (CNS) tumours 129 29.6 27.9 42.9 0.17
) Germ cell tumours 162 13.6 19.3 17.4 0.66
1 Carcinomas 295 15.9 21.1 23.2 0.44
International Classification of Childhood Cancer [3].
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able 3
requency of cancers by diagnostic group for gender, age and period of diagnosis, county, socio-economic status and population density
ariable All cancers Leukaemias Hodgkin's Non-Hodgkin's CNSa Germ cell Carcinoma
disease lymphoma tumours tumours
n (%) n (%) * (%) *(%) * (%) * (%) * (%)-
POnOIIvS (*=84) (* = 206) 'hT II -Jow 1 (*=129) (*=162) (* = 295)
^ender
Male 539 (49) 45 (54) 102 (50) 45 (64) 69 (53) 130 (80) 83 (28)
Female 558 (51) 39 (46) 104 (50) 25 (36) 60 (47) 32 (20) 212 (72)
ge at diagnosis (years)
15-19 408 (37) 44 (52) 85 (41) 39 (56) 53 (41) 44(27) 74(25)
20-24 689 (63) 40 (48) 121 (59) 31 (44) 76 (59) 118 (73) 221 (75)
-eriod of diagnosis
1985-1989 575 (52) 43 (51) 110 (53) 38 (54) 66 (51) 88 (54) 144 (49)
1990-1994 522 (48) 41 (49) 96 (47) 32(46) 63 (49) 74(46) 151 (51)
ounty of residence
West Yorkshire 615 (56) 41 (49) 117(57) 35 (50) 78 (60) 98 (60) - 161 (55)
Humberside 278 (25) 23 (27) 52 (25) 16 (23) 31 (24) 45 (28) 78 (26)
North Yorkshire 204 (19) 20 (24) 37 (18) 19 (27) 20 (16) 19 (12) 56 (19)
arstairs index
1 — most affluent 220 (20) 11 (13) 43 (21) 19 (27) 25(19) 33 (20) 47 (16)
2 216 (20) 16 (19) 40 (19) 12(17) 33 (26) 28 (17) 61 (21)
3 219 (20) 22 (26) 42 (20) 11 (16) 19 (15) 36(22) 68 (23)
4 215 (20) 16 (19) 41 (20) 12(17) 27 (21) 36 (22) 53 (18)
5 — least affluent 227 (21) 19 (23) 40 (19) 16 (23) 25(19) 29 (18) 66 (22)
opulation density
Low 366 (33) 22 (26) 66 (32) 28 (40) 44 (34) 59 (36) 88 (30)
Medium 367 (33) 27 (32) 85 (41) 20 (29) 43 (33) 57 (35) 95 (32)
High 364 (33) 35 (42) 55 (27) 22(31) 42 (33) 46 (28) 112 (38)
1 Centra] nervous system.
rrvivai differences remained between the counties and
opulation densities.
For socio-economic status and survival, a non-sig-
ificant dose response was present in the carcinoma
roup. Those in the least affluent groups were twice as
-kely to die compared with the most affluent. The
umbers of deaths were insufficient to sub-categorise
lis heterogeneous group ofmalignancies.
The significant increased risk of death in areas of
igher population density (P = 0.024) was independent
-f all other factors, including socio-economic status,
"he risk associated with population density appeared
cross all diagnostic groups (apart .from HD and high
;vels of ppd for leukaemia). For leukaemia, including
vLL and AML, germ cell tumours and carcinomas
reas ofmedium levels of ppd conferred the highest risk.
Finally, Table 5 shows the number of patients treated
y each consultant dealing with patients in this age
roup over the period of the study.: A total of 407 con-
ultants were engaged in the care of adolescents in this
.ge range with cancer. In this 10-year period only 40
onsultants (10%) treated 10 or more patients, and
Imost 75% dealt with less than 5 patients. With the
xception of one neurosurgeon, all the consultants
reating more than 10 patients were based in the regio-
al cancer centre in West Yorkshire. The data presented
in Table 5 was derived from aggregate data held by
NYCRIS. We were therefore unable to include a vari¬
able in the Cox regression directly related to patient
accrual. In a separate analysis, we did produce a model
including the size of treating hospital (as registered with
NYCRIS): this had no effect on the risk of death, nor
did it make any difference to the hazard ratio estimates











Fig. 3. Kapian-Meier survival curve by county for all cancers diag¬
nosed between 1985 and 1994.
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able 4
azard ratios of dying using Cox regression analysis by diagnostic group for gender, age and period of diagnosis, county, socio-economic status and
jpulation density1
triable All cancers Leukaemias Hodgkin's Non-Hoagkin's CNSb Germ cell Carcinoma
disease lymphoma tumours tumours
ender
Male 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Female 0.91 0.55 1.00 6.19** 1.14 216 0.57*
*e at diagnosis (years)
15-19 1.01 0.45* 1.04 1.32 0.86 0.48 0.64
20-24 1.00 1.00 1.00 oo 1.00 1.00 1.00
riod of diagnosis
1985-1989 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1990-1994 0.70** 1.06 0.65 0.30* 0.84 0.46 0.67
mnty of residence
West Yorkshire 1.00 1.00 1.00 1.00 1.00 1.00 1.00
dumberside 1.45** 2.43* 0.86 1.49 1.33 5.62**
. 1.39
Corth Yorkshire 1.34 240* 0.30 1.59 0.76 2.88 1.11
rstairs index
— most affluent 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.13 1.75 0.85 1.03 0.77 4.33* 1.62
0.63* 0.74 0.77 0.25 1.09 0.84 1.15
0.79 1.59 0.72 0.36 0.31 3.19 2.28
— least affluent 0.94 2.04 0.82 0.37 0.40 1.49 Z06
pulation density
,ow 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Medium 1.37 2.21 0.83 1.70 1.28 3.30* 1.15
riigh 1.60* 0.83 0.92 7.75* 3.21* ■ 1.34 1.08
Significant at *P < 0.05, **P < 0.01.
Hazard ratios are mutually adjusted for all other factors (i.e. gender, age, period, county, Carstairs index, population density, and chemo-
rapy treatment (Yes/No) for leukaemia).
Central nervous system.
Discussion
Fhere have been , a number of attempts to produce a
ndard definition of adolescence. It is inevitably an
iistinct concept and varies from individual to indivi-
al. There is no universally accepted age limit for
olescents and most would agree that no individual
aid be considered an adolescent outside the age range
10-25 years, but within that age range, piany differ-
: age criteria are used. The World Health Organiza-
n defines adolescents as being aged between 10 and
lie 5
nber of consultants treating individual patients aged 15-24 years in
Yorkshire Region between 1985 and 1994








19 years [12]. Other studies on adolescents, some of
which are described later, consider a different age range.
For example, Jamison [13], in his study of the psycho¬
logical impact of cancer in 1985, used the age range 12-
18 years. Enskar and colleagues [14], in a. study which
looked at 10 adolescents with cancer, used the age range
13—20 years.
The differing types of cancer combined with the spe¬
cific needs of adolescence mean there is currently a
debate on how adolescent cancer should be managed.
This debate centres around whether it 'should be cen¬
tralised in an adolescent cancer unit, as set out in the
Caiman-Hine Report [15], or as a less centralised model
which,, for example, would, avoid the disadvantages for
patients living in rural areas [16]. Currently/there are
around 20 adolescent cancer units in the UK. The pro¬
posal to create an adolescent cancer unit in Yorkshire
was the stimulus for this review.
The strength of this study is that it has examined data
based on an appropriate classification scheme. Making
direct comparisons with other work is difficult because
of the inconsistent use of age groups. However, this
study has concentrated on the 15-24 year olds, a group
on which little has been reported in the past. The
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